Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
LATENT-FLUORIDE CONTAINING POLYMERS FOR TRIGGERED DEGRADATION
Document Type and Number:
WIPO Patent Application WO/2022/256399
Kind Code:
A2
Abstract:
The present disclosure provides copolymers prepared by polymerizing a first monomer comprising at least one C=C and/or at least one C=C; and a second monomer of Formula (B): wherein at least one first monomer and/or at least one second monomer comprises a latent-fluoride moiety (e.g., pentafluorophenyl). Upon contacting the copolymers with a nucleophile (e.g., a thiol) and/or a base, the latent-fluoride moiety may release fluoride ions, which may in turn degrade the copolymers by cleaving the O-Si bonds. The copolymers may be useful for drug delivery, or as degradable (e.g., biodegradable) polymers, adhesives, coatings, or structural materials.

More Like This:
JP3898759Water-soluble polymer and its composition
JP2008031223CHIRAL POLYMERIC COMPOUND, STATIONARY PHASE FOR CHROMATOGRAPHY USING THE SAME, AND CHROMATOGRAPHY FILLER FOR SEPARATING OPTICAL ISOMERS
Inventors:
JOHNSON JEREMIAH (US)
SHIEH PEYTON (US)
BROWN CHRISTOPHER (US)
Application Number:
PCT/US2022/031759
Publication Date:
December 08, 2022
Filing Date:
June 01, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
MASSACHUSETTS INST TECHNOLOGY (US)
International Classes:
C08F26/06
Attorney, Agent or Firm:
ZHANG, William, Wei et al. (US)
Download PDF:
View/Download PDF      PDF Help
Claims:
CLAIMS What is claimed is: 1. A first monomer, wherein the first monomer is of Formula (A1): (A1), or salt thereof, wherein: Z is C(RP)2 or O; each instance of RP is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl; each instance of is independently a single bond or double bond; each instance of RH is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, –ORa, –OCN, –OC(=O)Ra, –OC(=S)Ra, – OC(=O)ORa, –OC(=O)N(Ra)2,–OS(=O)Ra, –OS(=O)ORa, –OS(=O)N(Ra)2, –OS(=O)2Ra, – OS(=O)2ORa, –OS(=O)2N(Ra)2, –OSi(Ra)3, –OSi(Ra)2(ORa), –OSi(Ra)(ORa)2, –OSi(ORa)3, oxo, – N(Ra)2, –N=C(Ra)2, =NRa, –NC, –NCO, –N3, –NO2, –NRaC(=O)Ra, –NRaC(=O)ORa, – NRaC(=O)N(Ra)2, –NRaS(=O)Ra, –NRaS(=O)ORa, –NRaS(=O)N(Ra)2, –NRaS(=O)2Ra, – NRaS(=O)2ORa, –NRaS(=O)2N(Ra)2, –SRa, –SCN, –S(=O)Ra, –S(=O)ORa, –S(=O)N(Ra)2, – S(=O)2Ra, –S(=O)2ORa, –S(=O)2N(Ra)2, –SeRa, –CN, –C(=NRa)Ra, –C(=NRa)ORa, – C(=NRa)N(Ra)2, –C(=O)Ra, –C(=O)ORa, –C(=O)SRa, –C(=S)ORa, –C(=O)N(Ra)2, or a latent- fluoride moiety; or the two instances of RH are joined with the intervening carbon atoms to form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring, optionally wherein at least one substituent of the substituted monocyclic carbocyclic ring, substituted monocyclic heterocyclic ring, substituted monocyclic aryl ring, or substituted monocyclic heteroaryl ring is a latent-fluoride moiety; each instance of Ra is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of Ra are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl; and each instance of the latent-fluoride moiety comprises one or more through covalent bonds a, wherein each covalent bond a is cleavable in the presence of a degradation composition comprising one or more nucleophiles, one or more bases, or a combination thereof; provided that the first monomer comprises at least one instance of the latent-fluoride moiety. 2. A second monomer, wherein the second monomer is of Formula (B1): or a salt thereof, wherein: Y is O or C(RQ)2; each instance of RQ is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl; each instance of RY is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl; each instance of RZ is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl; RK1 is hydrogen, halogen, substituted or unsubstituted, C1-10 alkyl, substituted or unsubstituted, C2-10 alkenyl, substituted or unsubstituted, C2-10 alkynyl, –LK1–(substituted or unsubstituted carbocyclyl), –LK1–(substituted or unsubstituted heterocyclyl), –LK1–(substituted or unsubstituted aryl), –LK1–(substituted or unsubstituted heteroaryl), –ORN1, a latent-fluoride moiety, or –LK1–(a latent-fluoride moiety); LK1 is a single bond, –O–, substituted or unsubstituted, C1-10 alkylene, substituted or unsubstituted, C2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; RN1 is hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; RK2 is hydrogen, halogen, substituted or unsubstituted, C1-10 alkyl, substituted or unsubstituted, C2-10 alkenyl, substituted or unsubstituted, C2-10 alkynyl, –LK2–(substituted or unsubstituted carbocyclyl), –LK2–(substituted or unsubstituted heterocyclyl), –LK2–(substituted or unsubstituted aryl), –LK2–(substituted or unsubstituted heteroaryl), –ORN2, a latent-fluoride moiety, or –LK2–(a latent-fluoride moiety); LK2 is a single bond, –O–, substituted or unsubstituted, C1-10 alkylene, substituted or unsubstituted, C2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; RN2 is hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; or RK1 and RK2 are joined with the intervening atom to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl, optionally wherein at least one substituent of the substituted carbocyclyl or substituted heterocyclyl is a latent-fluoride moiety; j is 1, 2, or 3; k is 0, 1, 2, or 3; and each instance of the latent-fluoride moiety comprises one or more through covalent bonds a, wherein each covalent bond a is cleavable in the presence of a degradation composition comprising one or more nucleophiles, one or more bases, or a combination thereof; provided that the second monomer comprises at least one instance of the latent-fluoride moiety. 3. A copolymer prepared by a method comprising polymerizing: one or more instances of a first monomer, wherein each instance of the first monomer independently comprises at least one C=C and/or at least one C≡C and optionally comprises one or more instances of a latent-fluoride moiety; one or more instances of a second monomer, wherein each instance of the second monomer is of Formula (B): (B), or a salt thereof; and optionally one or more instances of a third monomer; in the presence of a metathesis catalyst; wherein: each instance of Y is independently O or C(RQ)2; each instance of RQ is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl; each instance of RY is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl; each instance of RZ is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl; each instance of RK1 is independently hydrogen, halogen, substituted or unsubstituted, C1- 10 alkyl, substituted or unsubstituted, C2-10 alkenyl, substituted or unsubstituted, C2-10 alkynyl, – LK1–(substituted or unsubstituted carbocyclyl), –LK1–(substituted or unsubstituted heterocyclyl), –LK1–(substituted or unsubstituted aryl), –LK1–(substituted or unsubstituted heteroaryl), –ORN1, a latent-fluoride moiety, or –LK1–(a latent-fluoride moiety); each instance of LK1 is independently a single bond, –O–, substituted or unsubstituted, C1- 10 alkylene, substituted or unsubstituted, C2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; each instance of RN1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; each instance of RK2 is independently hydrogen, halogen, substituted or unsubstituted, C1- 10 alkyl, substituted or unsubstituted, C2-10 alkenyl, substituted or unsubstituted, C2-10 alkynyl, – LK2–(substituted or unsubstituted carbocyclyl), –LK2–(substituted or unsubstituted heterocyclyl), –LK2–(substituted or unsubstituted aryl), –LK2–(substituted or unsubstituted heteroaryl), –ORN2, a latent-fluoride moiety, or –LK2–(a latent-fluoride moiety); each instance of LK2 is independently a single bond, –O–, substituted or unsubstituted, C1- 10 alkylene, substituted or unsubstituted, C2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; each instance of RN2 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; or at least one instance of RK1 and at least one instance of RK2 that are attached to the same instance of Si are joined with the intervening atom to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl, optionally wherein at least one substituent of the substituted carbocyclyl or substituted heterocyclyl is a latent-fluoride moiety; each instance of j is independently 1, 2, or 3; each instance of k is independently 0, 1, 2, or 3; and each instance of the latent-fluoride moiety comprises one or more through covalent bonds a, wherein each covalent bond a is cleavable in the presence of a degradation composition comprising one or more nucleophiles, one or more bases, or a combination thereof; provided that: at least one instance of the first monomer and/or at least one instance of the second monomer comprises at least one instance of the latent-fluoride moiety; and any two instances of the first monomer are the same as or different from each other, any two instances of the second monomer are the same as or different from each other, any two instances of the third monomer are the same as or different from each other, and each instance of the first monomer, the second monomer, and the third monomer if present, is different from each other. 4. A method of preparing a copolymer comprising polymerizing: one or more instances of a first monomer, wherein each instance of the first monomer independently comprises at least one C=C and/or at least one C≡C and optionally comprises one or more instances of a latent-fluoride moiety; one or more instances of a second monomer, wherein each instance of the second monomer is of Formula (B): (B), or a salt thereof; and optionally one or more instances of a third monomer; in the presence of a metathesis catalyst; wherein: each instance of Y is independently O or C(RQ)2; each instance of RQ is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl; each instance of RY is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl; each instance of RZ is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl; each instance of RK1 is independently hydrogen, halogen, substituted or unsubstituted, C1- 10 alkyl, substituted or unsubstituted, C2-10 alkenyl, substituted or unsubstituted, C2-10 alkynyl, – LK1–(substituted or unsubstituted carbocyclyl), –LK1–(substituted or unsubstituted heterocyclyl), –LK1–(substituted or unsubstituted aryl), –LK1–(substituted or unsubstituted heteroaryl), –ORN1, a latent-fluoride moiety, or –LK1–(a latent-fluoride moiety); each instance of LK1 is independently a single bond, –O–, substituted or unsubstituted, C1- 10 alkylene, substituted or unsubstituted, C2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; each instance of RN1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; each instance of RK2 is independently hydrogen, halogen, substituted or unsubstituted, C1- 10 alkyl, substituted or unsubstituted, C2-10 alkenyl, substituted or unsubstituted, C2-10 alkynyl, – LK2–(substituted or unsubstituted carbocyclyl), –LK2–(substituted or unsubstituted heterocyclyl), –LK2–(substituted or unsubstituted aryl), –LK2–(substituted or unsubstituted heteroaryl), –ORN2, a latent-fluoride moiety, or –LK2–(a latent-fluoride moiety); each instance of LK2 is independently a single bond, –O–, substituted or unsubstituted, C1- 10 alkylene, substituted or unsubstituted, C2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; each instance of RN2 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; or at least one instance of RK1 and at least one instance of RK2 that are attached to the same instance of Si are joined with the intervening atom to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl, optionally wherein at least one substituent of the substituted carbocyclyl or substituted heterocyclyl is a latent-fluoride moiety; each instance of j is independently 1, 2, or 3; each instance of k is independently 0, 1, 2, or 3; and each instance of the latent-fluoride moiety comprises one or more through covalent bonds a, wherein each covalent bond a is cleavable in the presence of a degradation composition comprising one or more nucleophiles, one or more bases, or a combination thereof; provided that: at least one instance of the first monomer and/or at least one instance of the second monomer comprises at least one instance of the latent-fluoride moiety; and any two instances of the first monomer are the same as or different from each other, any two instances of the second monomer are the same as or different from each other, any two instances of the third monomer are the same as or different from each other, and each instance of the first monomer, the second monomer, and the third monomer if present, is different from each other. 5. The copolymer or method of any one of the preceding claims, wherein the at least one C=C and/or the at least one C≡C is a non-aromatic bond. 6. The copolymer or method of any one of the preceding claims, wherein at least one instance of the first monomer is of Formula (A): (A), or salt thereof, wherein each instance of Z is independently C(RP)2 or O; each instance of RP is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl; each instance of is independently a single bond or double bond; each instance of RH is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, –ORa, –OCN, –OC(=O)Ra, –OC(=S)Ra, – OC(=O)ORa, –OC(=O)N(Ra)2,–OS(=O)Ra, –OS(=O)ORa, –OS(=O)N(Ra)2, –OS(=O)2Ra, – OS(=O)2ORa, –OS(=O)2N(Ra)2, –OSi(Ra)3, –OSi(Ra)2(ORa), –OSi(Ra)(ORa)2, –OSi(ORa)3, oxo, – N(Ra)2, –N=C(Ra)2, =NRa, –NC, –NCO, –N3, –NO2, –NRaC(=O)Ra, –NRaC(=O)ORa, – NRaC(=O)N(Ra)2, –NRaS(=O)Ra, –NRaS(=O)ORa, –NRaS(=O)N(Ra)2, –NRaS(=O)2Ra, – NRaS(=O)2ORa, –NRaS(=O)2N(Ra)2, –SRa, –SCN, –S(=O)Ra, –S(=O)ORa, –S(=O)N(Ra)2, – S(=O)2Ra, –S(=O)2ORa, –S(=O)2N(Ra)2, –SeRa, –CN, –C(=NRa)Ra, –C(=NRa)ORa, – C(=NRa)N(Ra)2, –C(=O)Ra, –C(=O)ORa, –C(=O)SRa, –C(=S)ORa, –C(=O)N(Ra)2, or a latent- fluoride moiety; or the two instances of RH of one or more instances of are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring, optionally wherein at least one substituent of at least one instance of the substituted monocyclic carbocyclic ring, substituted monocyclic heterocyclic ring, substituted monocyclic aryl ring, or substituted monocyclic heteroaryl ring is a latent-fluoride moiety; each instance of Ra is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of Ra are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl; and each instance of the latent-fluoride moiety comprises one or more through covalent bonds a, wherein each covalent bond a is cleavable in the presence of a degradation composition comprising one or more nucleophiles, one or more bases, or a combination thereof. 7. The first monomer, copolymer, or method of any one of the preceding claims, wherein the two instances of RH of one or more instances of are joined with the intervening carbon atoms to independently form a substituted monocyclic heterocyclic ring, wherein at least one substituent of at least one instance of the substituted monocyclic heterocyclic is a latent- fluoride moiety. 8. The first monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the first monomer is of the formula: late nt-fluoride moiety , or salt thereof, wherein each instance of LX is independently a single bond, substituted or unsubstituted, C1-10 alkylene, substituted or unsubstituted, C2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof. 9. The first monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the first monomer is of the formula: .

10. The first monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the first monomer is of the formula: or salt thereof. 11. The first monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the first monomer is of the formula: , or salt thereof, wherein each instance of g is independently 0, 1, or 2. 12. The first monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the first monomer is of the formula: , or salt thereof. 13. The first monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of LX is a single bond or substituted or unsubstituted, C1-10 alkylene.

14. The copolymer or method of any one of the preceding claims, wherein at least one instance of the first monomer is of the formula: preferably 15. The second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the second monomer is of the formula: latent-fluoride moiety , or a salt thereof. 16. The second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the second monomer is of the formula: , or a salt thereof. 17. The second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the second monomer is of the formula: , or salt thereof. 18. The second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the second monomer is of the formula: , or salt thereof, wherein each instance of g is independently 0, 1, or 2. 19. The second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the second monomer is of the formula: , or salt thereof. 20. The second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the second monomer is of the formula: , or a salt thereof. 21. The second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the second monomer is of the formula: latent-fluoride moiety , or a salt thereof. 22. The second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of LK1 is a single bond or substituted or unsubstituted, C1-10 alkylene. 23. The second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the second monomer is of the formula: , or a salt thereof, wherein: each instance of h is independently an integer between 0 and 10, inclusive; and each instance of RK2 is independently substituted or unsubstituted, C1-10 alkyl; preferably unsubstituted C1-10 alkyl. 24. The second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the second monomer is of the formula:

. 25. The copolymer or method of any one of the preceding claims, wherein at least one instance of the second monomer is of the formula: , 26. The copolymer or method of any one of the preceding claims, wherein at least one instance of the second monomer is of the formula: 27. The copolymer or method of any one of the preceding claims, wherein at least one instance of the second monomer is of the formula: . 28. The copolymer or method of any one of the preceding claims, wherein at least one instance of the third monomer is of Formula (C): or salt thereof, wherein each instance of Z is independently C(RP)2 or O; each instance of RP is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl; each instance of is independently a single bond or double bond; each instance of RG is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, –ORa, –OCN, –OC(=O)Ra, –OC(=S)Ra, – OC(=O)ORa, –OC(=O)N(Ra)2,–OS(=O)Ra, –OS(=O)ORa, –OS(=O)N(Ra)2, –OS(=O)2Ra, – OS(=O)2ORa, –OS(=O)2N(Ra)2, –OSi(Ra)3, –OSi(Ra)2(ORa), –OSi(Ra)(ORa)2, –OSi(ORa)3, oxo, – N(Ra)2, –N=C(Ra)2, =NRa, –NC, –NCO, –N3, –NO2, –NRaC(=O)Ra, –NRaC(=O)ORa, – NRaC(=O)N(Ra)2, –NRaS(=O)Ra, –NRaS(=O)ORa, –NRaS(=O)N(Ra)2, –NRaS(=O)2Ra, – NRaS(=O)2ORa, –NRaS(=O)2N(Ra)2, –SRa, –SCN, –S(=O)Ra, –S(=O)ORa, –S(=O)N(Ra)2, – S(=O)2Ra, –S(=O)2ORa, –S(=O)2N(Ra)2, –SeRa, –CN, –C(=NRa)Ra, –C(=NRa)ORa, – C(=NRa)N(Ra)2, –C(=O)Ra, –C(=O)ORa, –C(=O)SRa, –C(=S)ORa, –C(=O)N(Ra)2, or a latent- fluoride moiety; or the two instances of RG of one or more instances of are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring, optionally wherein at least one substituent on the monocyclic, carbocyclic, heterocyclic, aryl, or heteroaryl ring is substituted or unsubstituted, C1-1000 alkyl, substituted or unsubstituted, C2-1000 alkenyl, substituted or unsubstituted, C2-1000 alkynyl, substituted or unsubstituted, C1-1000 heteroalkyl, substituted or unsubstituted, C2-1000 heteroalkenyl, substituted or unsubstituted, C2- 1000 heteroalkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, – C(=NRa)Ra, –C(=NRa)ORa, –C(=NRa)N(Ra)2, –C(=O)Ra, –C(=O)ORa, –C(=O)N(Ra)2, or a nitrogen protecting group when attached to a nitrogen atom; and each instance of Ra is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of Ra are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl. 29. The copolymer or method of any one of the preceding claims, wherein the two instances of RG of one or more instances of are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring, optionally wherein at least one substituent on the monocyclic, carbocyclic, heterocyclic, aryl, or heteroaryl ring is substituted or unsubstituted, C1-1000 alkyl, substituted or unsubstituted, C2-1000 alkenyl, substituted or unsubstituted, C2-1000 alkynyl, substituted or unsubstituted, C1-1000 heteroalkyl, substituted or unsubstituted, C2-1000 heteroalkenyl, substituted or unsubstituted, C2-1000 heteroalkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, –C(=NRa)Ra, –C(=NRa)ORa, – C(=NRa)N(Ra)2, –C(=O)Ra, –C(=O)ORa, –C(=O)N(Ra)2, or a nitrogen protecting group when attached to a nitrogen atom. 30. The copolymer or method of any one of the preceding claims, wherein the two instances of RG of one or more instances of are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, or substituted or unsubstituted, monocyclic heterocyclic ring, optionally wherein at least one substituent on the monocyclic, carbocyclic or heterocyclic ring is substituted or unsubstituted, C1-1000 alkyl or substituted or unsubstituted, C1-1000 heteroalkyl. 31. The copolymer or method of the preceding claim, wherein at least one instance of the third monomer is of the formula: , or salt thereof, wherein each instance of RX is independently substituted or unsubstituted, C1-1000 alkyl, substituted or unsubstituted, C2-1000 alkenyl, substituted or unsubstituted, C2-1000 alkynyl, substituted or unsubstituted, C1-1000 heteroalkyl, substituted or unsubstituted, C2-1000 heteroalkenyl, substituted or unsubstituted, C2-1000 heteroalkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, –C(=NRa)Ra, –C(=NRa)ORa, –C(=NRa)N(Ra)2, – C(=O)Ra, –C(=O)ORa, –C(=O)N(Ra)2, or a nitrogen protecting group.

32. The copolymer or method of the preceding claim, wherein at least one RX is substituted or unsubstituted, C1-1000 alkyl or substituted or unsubstituted, C1-1000 heteroalkyl. 33. The copolymer or method of any one of the preceding claims, wherein at least one RX is C1-1000 alkyl substituted with one or more fluoro. 34. The copolymer or method of any one of the preceding claims, wherein at least one RX is , wherein: n is an integer from 1 to 300, inclusive; and RF is hydrogen, substituted or unsubstituted, C1-6 alkyl, or an oxygen protecting group. 35. The copolymer or method of any one of the preceding claims, wherein at least one instance of RG is hydrogen. 36. The copolymer or method of any one of the preceding claims, wherein at least one instance of the third monomer is of the formula: . 37. The copolymer or method of any one of the preceding claims, wherein at least one instance of the third monomer is of Formula (D1): or a salt thereof. 38. The copolymer or method of any one of the preceding claims, wherein at least one instance of the third monomer is of Formula (D2): or a salt thereof, wherein: each instance of x is independently 0, 1, or 2; and each instance of y is independently 0, 1, or 2. 39. The copolymer or method of any one of the preceding claims, wherein at least one instance of the third monomer is of the formula: preferably 40. The first monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of Z is CH2. 41. The first monomer, copolymer, or method of any one of the preceding claims, wherein each instance of is a single bond. 42. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one covalent bond a is cleavable in the presence of the degradation composition through an intermolecular substitution reaction. 43. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the latent-fluoride moiety is –L–pentafluorophenyl, wherein each instance of L is independently a single bond, –O–, substituted or unsubstituted, C1- 10 alkylene, substituted or unsubstituted, C2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof. 44. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the latent-fluoride moiety is pentafluorophenyl. 45. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the latent-fluoride moiety is –C(=O)F, –S(=O)F, or – S(=O)2F.

46. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one covalent bond a is cleavable in the presence of the degradation composition through an intramolecular substitution reaction. 47. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the latent-fluoride moiety is of the formula: , wherein g is 0, 1, or 2. 48. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one covalent bond a is cleavable in the presence of the degradation composition through a Hofmann elimination reaction. 49. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the latent-fluoride moiety is –CHF–CH3. 50. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the first monomer comprises at least one instance of the latent-fluoride moiety. 51. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of the second monomer comprises at least one instance of the latent-fluoride moiety. 52. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one instance of RX comprises at least one instance of the latent-fluoride moiety. 53. A method of degrading a copolymer of any one of the preceding claims comprising contacting the copolymer with the degradation composition, wherein at least one covalent bond a is cleaved.

54. The copolymer or method of any one of the preceding claims, wherein the one or more nucleophiles, one or more bases, or combination thereof is the combination. 55. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one nucleophile is a thiol. 56. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one nucleophile is a thiol of the formula: RS–SH, and RS is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cysteine, a peptide, or a protein, wherein the peptide and protein comprise at least one cysteine optionally protected at the C or N terminus. 57. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one nucleophile is C2-12 alkanethiol, e.g., 1-n-octanethiol. 58. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one nucleophile is C12-18 alkanethiol, e.g., 1-n-dodecanethiol. 59. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one nucleophile is cysteine, a peptide, or a protein, wherein the peptide and protein comprise at least one cysteine optionally protected at the C or N terminus. 60. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one base is an alkali metal carbonate, alkali metal bicarbonate, alkaline earth metal carbonate, or alkaline earth metal bicarbonate, e.g., Cs2CO3. 61. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one base is a non-nucleophilic organic base. 62. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one base is a non-aromatic amine or aromatic amine.

63. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one base is 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU); 1,5- diazabicyclo[4.3.0]non-5-ene (DBN); triethylamine, N,N-diisopropylethylamine (DIPEA); or 2,6-di-tert-butylpyridine. 64. The copolymer or method of any one of the preceding claims, wherein the degradation composition further comprises a solvent. 65. The copolymer or method of any one of the preceding claims, wherein the solvent is an aprotic organic solvent comprising at least one heteroatom or a mixture of aprotic organic solvents independently comprising at least one heteroatom. 66. The copolymer or method of any one of the preceding claims, wherein the solvent is tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, cyclopentyl methyl ether, tert-butyl methyl ether, or a mixture thereof. 67. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one covalent bond a is cleavable in the presence of the degradation composition under physiological conditions. 68. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein the half life of at least one covalent bond a in the presence of at least one nucleophile at the concentration of about 1 molar and/or at least one base at the concentration of about 1 molar under physiological conditions is between 1 and 10 minutes, between 10 and 60 minutes, between 1 and 3 hours, between 3 and 8 hours, between 8 and 24 hours, between 1 and 3 days, or between 3 and 7 days, inclusive. 69. The first monomer, second monomer, copolymer, or method of any one of the preceding claims, wherein at least one covalent bond a is cleavable in the presence of the degradation composition at between 20 and 25 °C, inclusive, and 0.5 and 1.1 atm. 70. The copolymer or method of any one of the preceding claims, wherein the molar ratio of the one or more instances of the first monomer to the one or more instances of the second monomer is between 0.1:1 and 0.3:1, between 0.3:1 and 1:1, between 1:1 and 3:1, between 3:1 and 10:1, between 10:1 and 30:1, or between 30:1 and 100:1, inclusive; preferably between 0.3:1 and 10:1, inclusive. 71. The copolymer or method of any one of the preceding claims, wherein the step of polymerizing is ring-opening metathesis polymerization. 72. The copolymer or method of any one of the preceding claims, wherein the metathesis catalyst is a ruthenium metathesis catalyst. 73. The copolymer or method of any one of the preceding claims, wherein the metathesis catalyst is a Grubbs catalyst. 74. The copolymer or method of any one of the preceding claims, wherein the molar ratio of the one or more instances of the third monomer, if present, to the one or more instances of the second monomer is between 0.3:1 and 1:1, between 1:1 and 3:1, between 3:1 and 10:1, between 10:1 and 30:1, between 30:1 and 100:1, or between 100:1 and 300:1, inclusive; preferably between 3:1 and 30:1, inclusive. 75. The copolymer or method of any one of the preceding claims, wherein the molar ratio of the combined amounts of the first monomer, second monomer, and third monomer if present to the amount of the metathesis catalyst is between 3:1 and 10:1, between 10:1 and 100:1, between 100:1 and 1,000:1, between 1,000:1 and 10,000:1, or between 10,000:1 and 100,000:1, inclusive; preferably between 10:1 and 1,000:1, inclusive. 76. The copolymer or method of any one of the preceding claims, wherein the copolymer is crosslinked, and the crosslinking degree is between 0.1% and 0.3%, between 0.3% and 1%, between 1% and 3%, between 3% and 10%, between 10% and 20%, or between 20% and 50%, inclusive, mole:mole; preferably, between 1% and 10%, inclusive, mole:mole. 77. The copolymer or method of any one of the preceding claims, wherein the number- average molecular weight of the copolymer as determined by gel permeation chromatography is between 10 kDa and 100 kDa, between 100 kDa and 1,000 kDa, between 1,000 kDa and 10,000 kDa, or between 10,000 kDa and 100,000 kDa, inclusive.

78. The copolymer or method of any one of the preceding claims, wherein the copolymer is a block copolymer, preferably a block copolymer comprising at least four consecutive blocks, wherein: each of the first consecutive block and the third consecutive block independently comprises one or more repeating units formed from the first monomer or the third monomer if present; and each of the second consecutive block and the fourth consecutive block independently comprises one or more repeating units formed from the second monomer. 79. The copolymer or method of any one of the preceding claims, wherein the copolymer is a random copolymer. 80. The copolymer or method of any one of the preceding claims, wherein the step of polymerizing is substantially free of a chain transfer agent. 81. The copolymer or method of any one of the preceding claims, wherein the copolymer comprises one or more pharmaceutical agents, wherein the pharmaceutical agents are covalently attached to the copolymer. 82. The copolymer or method of claim 81, wherein at least one of the pharmaceutical agents is a therapeutic agent. 83. The copolymer or method of claim 81, wherein at least one of the pharmaceutical agents is an anti-cancer agent. 84. The copolymer or method of claim 81, wherein at least one of the pharmaceutical agents is a prophylactic agent. 85. The copolymer or method of claim 81, wherein at least one of the pharmaceutical agents is a diagnostic agent. 86. The copolymer or method of claim 81, wherein at least one of the pharmaceutical agents is a contrast agent.

87. A composition comprising: the copolymer of any one of the preceding claims; and optionally an excipient. 88. The composition of claim 87, wherein the composition is an adhesive composition. 89. The composition of claim 87, wherein the composition is a coating composition. 90. The composition of claim 87 comprising: the copolymer; and optionally a pharmaceutically acceptable excipient. 91. A kit comprising: the copolymer of any one of the preceding claims; and instructions for using the copolymer. 92. A method of delivering a pharmaceutical agent to a subject in need thereof comprising administering to the subject in need thereof an effective amount of the copolymer of claim 81 or . 93. A method of treating a disease in a subject in need thereof comprising administering to or implanting in the subject in need thereof an effective amount of the copolymer of claim 82 or 83. 94. A method of preventing a disease in a subject in need thereof comprising administering to or implanting in the subject in need thereof an effective amount of the copolymer of claim 84. 95. A method of diagnosing a disease in a subject in need thereof comprising administering to or implanting in the subject in need thereof an effective amount of the copolymer of claim 85 or 86. 96. The method of any one of claims 93-95, wherein the disease is cancer. 97. The method of any one of claims 92-96, wherein the subject is a human.
Description:
LATENT-FLUORIDE CONTAINING POLYMERS FOR TRIGGERED DEGRADATION BACKGROUND Bottlebrush polymers have found widespread applications in fields ranging from drug delivery and molecular imaging to novel materials and stimuli responsive networks (ACS Macro Letters 2012, 1, 1146. Progress in Polymer Science 2008, 33, 759. Progress in Polymer Science 2010, 35, 24.). Graft-through ring-opening metathesis polymerization (ROMP) offers distinct advantages over other bottlebrush synthesis methods (Journal of the American Chemical Society 2009, 131, 18525. Macromolecules 2009, 42, 3761.). The fast-initiating Grubb’s 3 rd generation catalyst has been shown to sustain propagation of polymer chain reactions with exceptionally high tolerance towards a wide range of sterically-hindered multivalent macromonomers, reaching high degrees of polymerization and low dispersity values, even at low millimolar concentrations (Chemical Society Reviews 2015, 44, 2405. Angewandte Chemie International Edition 2012, 51, 11246.). Furthermore, it is possible to control composition, morphology, and size of final macromolecules, allowing the preparation of remarkable polymeric architectures, such as bottlebrush polymers and star polymers (Angewandte Chemie International Edition 2012, 51, 11246. Journal of the American Chemical Society 2016, 138, 12494. Journal of the American Chemical Society 2016, 138, 11501. Chemical Reviews 2016, 116, 6743. Journal of the American Chemical Society 2014, 136, 5896.). Due to the high packing density of their side-chains, the backbones of bottlebrush polymers are very rigid and adopt extended morphologies with minimal side-chain entanglement (Chemical Society Reviews 2015, 44, 2405.). Recently, self-assembly behaviors of bottlebrush block copolymers (BBCPs) have become an active area of research(Chemical Society Reviews 2015, 44, 2405. Proceedings of the National Academy of Sciences 2012, 109, 14332.). Polymeric star nanoarchitectures, on the other hand, offer several different valuable features, such as tunable nanoscale sizes and shapes that mimic globular biomacromolecules, allowing for extended blood circulation and efficient biodistribution and/or tumor accumulation (Accounts of Chemical Research 2009, 42, 1141. Nat Nano 2007, 2, 751. European Journal of Pharmaceutics and Biopharmaceutics 2009, 71, 409.). These properties make star polymers particularly well-suited for biological applications (Chemical Reviews 2016, 116, 6743.). The development of bottlebrush and star polymeric structures (e.g., brush-arm star polymers (BASPs) is a growing field of research as these polymeric structures have broad applications. Previous work has reported preparation of multi-component MMs that can be used in graft-through ROMP; these MMs contain side-chains with a multitude of functions and properties, which can either be on different MMs, or branching off the same MM (Journal of the American Chemical Society 2016, 138, 11501. Journal of the American Chemical Society 2014, 136, 5896. Proceedings of the National Academy of Sciences 2012, 109, 14332. Nat Nano 2007, 2, 751. ACS Macro Letters 2014, 3, 854. Nat Rev Drug Discov 2003, 2, 347.). In particular, the branched platform consists of a ROMP-compatible norbornene group on a molecule that also contains two orthogonally functionalizable sites: an alkyne, for which copper (I)-catalyzed alkyne-azide cycloaddition (CuAAC) can be applied (Coordination Chemistry Reviews 2011, 255, 2933. Chemical Society Reviews 2010, 39, 1302. Science 2013, 340, 457.), and a carboxylic acid group, compatible with carbodiimide coupling chemistry (Tetrahedron 2004, 60, 2447. Chemical Society Reviews 2009, 38, 606. Organic Process Research & Development 2016, 20, 140. Chemical Reviews 2011, 111, 6557. Angewandte Chemie International Edition 978, 17, 522.), both of which are efficient, and known modes of conjugations. The side-chains can be functionalized with two dissimilar polymers that self-assemble into various morphologies or a polymer chain containing an agent (e.g., a therapeutic agent (e.g., drug), a diagnostic agent (e.g., imaging agent), a prophylactic agent, or a biological ligand); resulting polymers are reported to demonstrate interesting characteristics across multiple applications, including self-assembly, drug delivery, and molecular imaging (Journal of the American Chemical Society 2016, 138, 12494. Journal of the American Chemical Society 2016, 138, 11501. Journal of the American Chemical Society 2014, 136, 5896. Photochemistry and Photobiology 2014, 90, 380. Journal of the American Chemical Society 2012, 134, 16337. Nature Communications 2014, 5, 5460.). Even though ROMP has found utility in many applications (Journal of the American Chemical Society, 1998, 120, 10579; Journal of the American Chemical Society, 2014, 136, 15422), one disadvantage of previous polymers synthesized from ROMP is their poor degradability, thus limiting their utility in certain fields. A reported polymer synthesized via ROMP was degradable only at a pH of 4.5 or less (Angewandte Chemie International Edition, 2013, 52, 5061). Another example required multi-step syntheses for each monomer in order to generate a polymer (Journal of the American Chemical Society, 2015, 137, 8038). Therefore, there is a need for degradable brush polymers and degradable BASPs. Tough and highly crosslinked materials are typically associated with a lack of degradability. As an example, poly-dicyclopentadiene (pDCPD) is a produced on industrial scale and valued for its high impact resistance and compatibility with injection molding processes. Owing to its crosslinked all-carbon backbone, however, these materials are considered non- degradable and thus cannot be reused or remolded after formation. Degradable versions of this material, which maintain all of their desirable mechanical properties but enable mild strategies to break down the material, may open the door to myriad applications for both this material and its degraded fragments. SUMMARY OF THE DISCLOSURE There is a need for controlled degradation of thermosets. The present disclosure provides copolymers prepared by polymerizing a first monomer comprising at least one C=C and/or at least one C≡C; and a second monomer of Formula (B): wherein at least one first monomer and/or at least one second monomer comprises a latent- fluoride moiety (e.g., pentafluorophenyl (PFP)). In certain embodiments, the polymerization is ring-opening metathesis polymerization. Upon contacting the copolymers with a nucleophile (e.g., a thiol) and/or a base (e.g., an inorganic base such as Cs 2 CO 3 , or an organic base such as DBU), the latent-fluoride moiety may release fluoride ions, which may in turn degrade the copolymers by cleaving the O–Si bonds. See Figures 1A, 1B, and 2. The copolymers may be useful for drug delivery, or as degradable (e.g., biodegradable) polymers, adhesives, coatings, or structural materials. For example, the provided copolymers may allow for degradation triggered by biological thiols (e.g., the residue of the amino acid cysteine), which may lead to new biodegradable plastics or therapeutics. The copolymers may also be advantageous because they may be degraded under milder conditions (e.g., a nucleophile (e.g., a thiol) and a base), as opposed to harsher conditions (e.g., a strong acid (e.g., HCl) or a fluoride source (e.g., tetrabutylammonium fluoride (TBAF))). The provided copolymers may be prepared by polymerizing the first monomer and the second monomer in the absence or presence of a third monomer. The third monomer may be used to alter the properties of the copolymers. In certain embodiments, a third monomer comprising poly(ethylene glycol) (PEG) may be used to increase the hydrophilicity of the copolymers. In certain embodiments, a third monomer comprising C 1 - 1000 alkyl substituted with one or more fluoro (e.g., perfluoro C 1 - 1000 alkyl) may be used to increase the hydrophobicity of the copolymers. DEFINITIONS For convenience, certain terms employed herein, in the specification, examples and appended claims are collected herein. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The following definitions are more general terms used throughout the present application: The singular terms “a,” “an,” and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” "About" and "approximately" shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5%, 4%, 3%, 2% or 1% of a given value or range of values. Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March March’s Advanced Organic Chemistry, 5 th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3 rd Edition, Cambridge University Press, Cambridge, 1987. Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, e.g., enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw–Hill, NY, 1962); and Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p.268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The invention additionally encompasses compounds as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers. When a range of values (“range”) is listed, it is intended to encompass each value and sub–range within the range. A range is inclusive of the values at the two ends of the range unless otherwise provided. For example, “an integer between 1 and 4” refers to 1, 2, 3, and 4. For example “C 1–6 alkyl” is intended to encompass, C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1–6 , C 1–5 , C 1–4 , C 1–3 , C 1–2 , C 2–6 , C 2–5 , C 2–4 , C 2–3 , C 3–6 , C 3–5 , C 3–4 , C 4–6 , C 4–5 , and C 5–6 alkyl. The term “alkyl” refers to a radical of a C 1 -C 1000 straight–chain or branched saturated hydrocarbon group. In some embodiments, an alkyl group has 1 to 200 carbon atoms (“C 1 -C 200 alkyl”), 1 to 20 carbon atoms (“C 1 -C 20 alkyl”), 1 to 10 carbon atoms (“C 1 -C 10 alkyl”), 1 to 9 carbon atoms (“C 1 -C 9 alkyl”), 1 to 8 carbon atoms (“C 1 -C 8 alkyl”), 1 to 7 carbon atoms (“C 1 -C 7 alkyl”), 1 to 6 carbon atoms (“C 1 -C 6 alkyl”), 1 to 5 carbon atoms (“C 1 -C 5 alkyl”), 1 to 4 carbon atoms (“C 1 -C 4 alkyl”), 1 to 3 carbon atoms (“C 1 -C 3 alkyl”), 1 to 2 carbon atoms (“C 1 -C 2 alkyl”), or 1 carbon atom (“C 1 alkyl”). Examples of C 1 -C 6 alkyl groups include methyl (C 1 ), ethyl (C 2 ), n–propyl (C 3 ), isopropyl (C 3 ), n–butyl (C 4 ), tert–butyl (C 4 ), sec–butyl (C 4 ), iso–butyl (C 4 ), n– pentyl (C 5 ), 3–pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3–methyl–2–butanyl (C 5 ), tertiary amyl (C 5 ), and n–hexyl (C 6 ). Additional examples of alkyl groups include n–heptyl (C 7 ), n–octyl (C 8 ) and the like. C 30 -C 1000 alkyl may be obtained from polymerization. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents. The term “alkenyl” refers to a radical of a straight–chain or branched hydrocarbon group having from 2 to 1000 carbon atoms and one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds). In some embodiments, an alkenyl group has 2 to 200 carbon atoms (“C 2–200 alkenyl”). In some embodiments, an alkenyl group has 2 to 20 carbon atoms (“C 2–20 alkenyl”). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C 2–9 alkenyl”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C 2–8 alkenyl”). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C 2–7 alkenyl”). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C 2–6 alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C 2–5 alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C 2–4 alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C 2–3 alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms (“C 2 alkenyl”). The one or more carbon–carbon double bonds can be internal (such as in 2–butenyl) or terminal (such as in 1–butenyl). Examples of C 2–4 alkenyl groups include ethenyl (C 2 ), 1–propenyl (C 3 ), 2–propenyl (C 3 ), 1–butenyl (C 4 ), 2–butenyl (C 4 ), butadienyl (C 4 ), and the like. Examples of C 2–6 alkenyl groups include the aforementioned C 2–4 alkenyl groups as well as pentenyl (C 5 ), pentadienyl (C 5 ), hexenyl (C 6 ), and the like. C 30 -C 1000 alkenyl may be obtained from polymerization. Unless otherwise specified, each instance of an alkenyl group is independently unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents. In an alkenyl group, a C=C double bond for which the stereochemistry is not specified (e.g., – CH=CHCH 3 , , or ) may be in the (E)- or (Z)-configuration. The term “alkynyl” refers to a radical of a straight–chain or branched hydrocarbon group having from 2 to 1000 carbon atoms and one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds) (“C 2–10 alkynyl”). In some embodiments, an alkynyl group has 2 to 200 carbon atoms (“C 2–200 alkynyl”), 2 to 20 carbon atoms (“C 2–20 alkynyl”), 2 to 9 carbon atoms (“C 2–9 alkynyl”), 2 to 8 carbon atoms (“C 2–8 alkynyl”), 2 to 7 carbon atoms (“C 2–7 alkynyl”), 2 to 6 carbon atoms (“C 2–6 alkynyl”), 2 to 5 carbon atoms (“C 2–5 alkynyl”), 2 to 4 carbon atoms (“C 2–4 alkynyl”), 2 to 3 carbon atoms (“C 2–3 alkynyl”), or 2 carbon atoms (“C 2 alkynyl”). The one or more carbon–carbon triple bonds can be internal (such as in 2–butynyl) or terminal (such as in 1– butynyl). Examples of C2–4 alkynyl groups include, without limitation, ethynyl (C2), 1–propynyl (C 3 ), 2–propynyl (C 3 ), 1–butynyl (C 4 ), 2–butynyl (C 4 ), and the like. Examples of C 2–6 alkenyl groups include the aforementioned C 2–4 alkynyl groups as well as pentynyl (C 5 ), hexynyl (C 6 ), and the like. C 30 -C 1000 alkynyl may be obtained from polymerization. Unless otherwise specified, each instance of an alkynyl group is independently unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents. The term “heteroalkyl” refers to an alkyl group which further includes at least one heteroatom (e.g., 1, 2, 3, 4, or more heteroatoms, as valency permits) selected from oxygen, nitrogen, phosphorus, or sulfur within (i.e., inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkyl group refers to a saturated group having from 1 to 1000 carbon atoms and 1 or more heteroatoms within the parent chain (“C 1– C 1000 heteroalkyl”), 1 to 20 carbon atoms and 1 or more heteroatoms within the parent chain (“C 1– C 20 heteroalkyl”), 1 to 10 carbon atoms and 1 or more heteroatoms within the parent chain (“C 1– C 10 heteroalkyl”), 1 to 9 carbon atoms and 1 or more heteroatoms within the parent chain (“C 1– C 9 heteroalkyl”), 1 to 8 carbon atoms and 1 or more heteroatoms within the parent chain (“C 1– C 8 heteroalkyl”), 1 to 7 carbon atoms and 1 or more heteroatoms within the parent chain (“C 1– C 7 heteroalkyl”), 1 to 6 carbon atoms and 1 or more heteroatoms within the parent chain (“C 1– C 6 heteroalkyl”), 1 to 5 carbon atoms and 1 or more heteroatoms within the parent chain (“C 1– C 5 heteroalkyl”), 1 to 4 carbon atoms and 1or more heteroatoms within the parent chain (“C 1– C 4 heteroalkyl”), 1 to 3 carbon atoms and 1 or more heteroatoms within the parent chain (“C1–C3 heteroalkyl”), 1 to 2 carbon atoms and 1 heteroatom within the parent chain (“C 1– C 2 heteroalkyl”), or 1 carbon atom and 1 heteroatom (“C 1 heteroalkyl”). C 30 -C 1000 heteroalkyl may be obtained from polymerization. Unless otherwise specified, each instance of a heteroalkyl group is independently unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted heteroalkyl”) with one or more substituents. The term “heteroalkenyl” refers to an alkenyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, 4, or more heteroatoms, as valency permits) selected from oxygen, nitrogen, or sulfur within (i.e., inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkenyl group refers to a group having from 2 to 1000 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–1000 alkenyl”). In certain embodiments, a heteroalkenyl group refers to a group having from 2 to 20 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–20 alkenyl”). In certain embodiments, a heteroalkenyl group refers to a group having from 2 to 10 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–10 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 9 carbon atoms at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–9 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 8 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–8 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 7 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–7 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–6 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 5 carbon atoms, at least one double bond, and 1 or 2 heteroatoms within the parent chain (“heteroC 2–5 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 4 carbon atoms, at least one double bond, and 1or 2 heteroatoms within the parent chain (“heteroC 2–4 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 3 carbon atoms, at least one double bond, and 1 heteroatom within the parent chain (“heteroC 2–3 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or 2 heteroatoms within the parent chain (“heteroC 2–6 alkenyl”). C 30 -C 1000 heteroalkenyl may be obtained from polymerization. Unless otherwise specified, each instance of a heteroalkenyl group is independently unsubstituted (an “unsubstituted heteroalkenyl”) or substituted (a “substituted heteroalkenyl”) with one or more substituents. In certain embodiments, the heteroalkenyl group is an unsubstituted heteroC 2–10 alkenyl. In certain embodiments, the heteroalkenyl group is a substituted heteroC 2–10 alkenyl. The term “heteroalkynyl” refers to an alkynyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, 4, or more heteroatoms, as valency permits) selected from oxygen, nitrogen, or sulfur within (i.e., inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 1000 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–1000 alkynyl”). In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 20 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–20 alkynyl”). In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 10 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–10 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 9 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–9 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 8 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–8 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 7 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–7 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC 2–6 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heteroC 2–5 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 4 carbon atoms, at least one triple bond, and 1or 2 heteroatoms within the parent chain (“heteroC 2–4 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 3 carbon atoms, at least one triple bond, and 1 heteroatom within the parent chain (“heteroC 2–3 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heteroC 2–6 alkynyl”). C 30 - C 1000 heteroalkynyl may be obtained from polymerization. Unless otherwise specified, each instance of a heteroalkynyl group is independently unsubstituted (an “unsubstituted heteroalkynyl”) or substituted (a “substituted heteroalkynyl”) with one or more substituents. In certain embodiments, the heteroalkynyl group is an unsubstituted heteroC 2–10 alkynyl. In certain embodiments, the heteroalkynyl group is a substituted heteroC 2–10 alkynyl. The term “carbocyclyl” or “carbocyclic” or “cycloalkyl” refers to a radical of a non– aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C 3–10 carbocyclyl”) and zero heteroatoms in the non–aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (“C 3–8 carbocyclyl”), 3 to 7 ring carbon atoms (“C 3–7 carbocyclyl”), 3 to 6 ring carbon atoms (“C 3–6 carbocyclyl”), 4 to 6 ring carbon atoms (“C 4–6 carbocyclyl”), 5 to 6 ring carbon atoms (“C 5–6 carbocyclyl”), or 5 to 10 ring carbon atoms (“C 5–10 carbocyclyl”). Exemplary C 3–6 carbocyclyl groups include, without limitation, cyclopropyl (C 3 ), cyclopropenyl (C 3 ), cyclobutyl (C 4 ), cyclobutenyl (C 4 ), cyclopentyl (C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ), and the like. Exemplary C 3–8 carbocyclyl groups include, without limitation, the aforementioned C 3–6 carbocyclyl groups as well as cycloheptyl (C 7 ), cycloheptenyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatrienyl (C 7 ), cyclooctyl (C 8 ), cyclooctenyl (C 8 ), bicyclo[2.2.1]heptanyl (C 7 ), bicyclo[2.2.2]octanyl (C 8 ), and the like. Exemplary C 3–10 carbocyclyl groups include, without limitation, the aforementioned C 3–8 carbocyclyl groups as well as cyclononyl (C 9 ), cyclononenyl (C 9 ), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro–1H–indenyl (C 9 ), decahydronaphthalenyl (C 10 ), spiro[4.5]decanyl (C 10 ), and the like. As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or polycyclic (e.g., containing a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) or tricyclic system (“tricyclic carbocyclyl”)) and can be saturated or can contain one or more carbon–carbon double or triple bonds. “Carbocyclyl” also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents. The term “heterocyclyl” or “heterocyclic” refers to a radical of a 3– to 14–membered non–aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorus, and sulfur (“3–14 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or polycyclic (e.g., a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”) or tricyclic system (“tricyclic heterocyclyl”)), and can be saturated or can contain one or more carbon–carbon double or triple bonds. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings. “Heterocyclyl” also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents. In some embodiments, a heterocyclyl group is a 5–10 membered non–aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorus, and sulfur (“5–10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5–8 membered non–aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorus, and sulfur (“5–8 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5–6 membered non–aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorus, and sulfur (“5–6 membered heterocyclyl”). In some embodiments, the 5–6 membered heterocyclyl has 1–3 ring heteroatoms selected from nitrogen, oxygen, phosphorus, and sulfur. In some embodiments, the 5–6 membered heterocyclyl has 1–2 ring heteroatoms selected from nitrogen, oxygen, phosphorus, and sulfur. In some embodiments, the 5–6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, phosphorus, and sulfur. Exemplary 3–membered heterocyclyl groups containing 1 heteroatom include, without limitation, azirdinyl, oxiranyl, and thiiranyl. Exemplary 4–membered heterocyclyl groups containing 1 heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5–membered heterocyclyl groups containing 1 heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl–2,5–dione. Exemplary 5–membered heterocyclyl groups containing 2 heteroatoms include, without limitation, dioxolanyl, oxathiolanyl and dithiolanyl. Exemplary 5–membered heterocyclyl groups containing 3 heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6–membered heterocyclyl groups containing 1 heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6–membered heterocyclyl groups containing 2 heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6–membered heterocyclyl groups containing 3 heteroatoms include, without limitation, triazinanyl. Exemplary 7–membered heterocyclyl groups containing 1 heteroatom include, without limitation, azepanyl, oxepanyl, and thiepanyl. Exemplary 8– membered heterocyclyl groups containing 1 heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro–1,8–naphthyridinyl, octahydropyrrolo[3,2–b]pyrrole, indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, 1H–benzo[e][1,4]diazepinyl, 1,4,5,7–tetrahydropyrano[3,4–b]pyrrolyl, 5,6–dihydro–4H–furo[3,2–b]pyrrolyl, 6,7–dihydro– 5H–furo[3,2–b]pyranyl, 5,7–dihydro–4H–thieno[2,3–c]pyranyl, 2,3–dihydro–1H–pyrrolo[2,3– b]pyridinyl, 2,3–dihydrofuro[2,3–b]pyridinyl, 4,5,6,7–tetrahydro–1H–pyrrolo[2,3–b]pyridinyl, 4,5,6,7–tetrahydrofuro[3,2–c]pyridinyl, 4,5,6,7–tetrahydrothieno[3,2–b]pyridinyl, 1,2,3,4– tetrahydro–1,6–naphthyridinyl, and the like. The term “aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) having 6–14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C 6–14 aryl”). In some embodiments, an aryl group has 6 ring carbon atoms (“C 6 aryl”; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (“C 10 aryl”; e.g., naphthyl such as 1–naphthyl and 2–naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms (“C14 aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Unless otherwise specified, each instance of an aryl group is independently unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents. The term “heteroaryl” refers to a radical of a 5–14 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–14 membered heteroaryl”). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. “Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused polycyclic (aryl/heteroaryl) ring system. Polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2–indolyl) or the ring that does not contain a heteroatom (e.g., 5– indolyl). A heteroaryl group be monovalent or may have more than one point of attachment to another moiety (e.g., it may be divalent, trivalent, etc), although the valency may be specified directly in the name of the group. For example, “triazoldiyl” refers to a divalent triazolyl moiety. In some embodiments, a heteroaryl group is a 5–10 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–10 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5–8 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–8 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5–6 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–6 membered heteroaryl”). In some embodiments, the 5–6 membered heteroaryl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heteroaryl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents. Exemplary 5–membered heteroaryl groups containing 1 heteroatom include, without limitation, pyrrolyl, furanyl, and thiophenyl. Exemplary 5–membered heteroaryl groups containing 2 heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5–membered heteroaryl groups containing 3 heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5–membered heteroaryl groups containing 4 heteroatoms include, without limitation, tetrazolyl. Exemplary 6– membered heteroaryl groups containing 1 heteroatom include, without limitation, pyridinyl. Exemplary 6–membered heteroaryl groups containing 2 heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6–membered heteroaryl groups containing 3 or 4 heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7– membered heteroaryl groups containing 1 heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6–bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6– bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Exemplary tricyclic heteroaryl groups include, without limitation, phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl and phenazinyl. As understood from the above, alkyl, alkenyl, alkynyl, carbocyclyl, aryl, and heteroaryl groups are, in certain embodiments, optionally substituted. Optionally substituted refers to a group which may be substituted or unsubstituted (e.g., “substituted” or “unsubstituted” alkyl). In general, the term “substituted” means that at least one hydrogen present on a group is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term “substituted” is contemplated to include substitution with all permissible substituents of organic compounds, any of the substituents described herein that results in the formation of a stable compound. The present invention contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety. Affixing the suffix “ene” to a group indicates the group is a polyvalent (e.g., bivalent, trivalent, tetravalent, or pentavalent) moiety. In certain embodiments, affixing the suffix “ene” to a group indicates the group is a bivalent moiety. Exemplary carbon atom substituents include, but are not limited to, halogen, −CN, −NO 2 , −N 3 , −SO 2 H, −SO 3 H, −OH, −OR aa , −ON(R bb ) 2 , −N(R bb ) 2 , −N(R bb ) 3 + X − , −N(OR cc )R bb , −SH, −SR aa , −SSR cc , −C(=O)R aa , −CO 2 H, −CHO, −C(OR cc ) 2 , −CO 2 R aa , −OC(=O)R aa , −OCO 2 R aa , −C(=O)N(R bb ) 2 , −OC(=O)N(R bb ) 2 , −NR bb C(=O)R aa , −NR bb CO 2 R aa , −NR bb C(=O)N(R bb ) 2 , −C(=NR bb )R aa , −C(=NR bb )OR aa , −OC(=NR bb )R aa , −OC(=NR bb )OR aa , −C(=NR bb )N(R bb ) 2 , −OC(=NR bb )N(R bb ) 2 , −NR bb C(=NR bb )N(R bb ) 2 , −C(=O)NR bb SO 2 R aa , −NR bb SO 2 R aa , −SO 2 N(R bb ) 2 , −SO 2 R aa , −SO 2 OR aa , −OSO 2 R aa , −S(=O)R aa , −OS(=O)R aa , −Si(R aa ) 3 , −OSi(R aa ) 3 −C(=S)N(R bb ) 2 , −C(=O)SR aa , −C(=S)SR aa , −SC(=S)SR aa , −SC(=O)SR aa , −OC(=O)SR aa , −SC(=O)OR aa , −SC(=O)R aa , −P(=O)(R aa ) 2 , −P(=O)(OR cc ) 2 , −OP(=O)(R aa ) 2 , −OP(=O)(OR cc ) 2 , −P(=O)(N(R bb ) 2 ) 2 , −OP(=O)(N(R bb ) 2 ) 2 , −NR bb P(=O)(R aa ) 2 , −NR bb P(=O)(OR cc ) 2 , −NR bb P(=O)(N(R bb ) 2 ) 2 , −P(R cc ) 2 , −P(OR cc ) 2 , −P(R cc ) 3 + X − , −P(OR cc ) 3 + X − , −P(R cc ) 4 , −P(OR cc ) 4 , −OP(R cc ) 2 , −OP(R cc ) 3 + X − , −OP(OR cc ) 2 , −OP(OR cc ) 3 + X − , −OP(R cc ) 4 , −OP(OR cc ) 4 , −B(R aa ) 2 , −B(OR cc ) 2 , −BR aa (OR cc ), C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups; wherein X − is a counterion; or two geminal hydrogens on a carbon atom are replaced with the group =O, =S, =NN(R bb ) 2 , =NNR bb C(=O)R aa , =NNR bb C(=O)OR aa , =NNR bb S(=O) 2 R aa , =NR bb , or =NOR cc ; each instance of R aa is, independently, selected from C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl, or two R aa groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups; each instance of R bb is, independently, selected from hydrogen, −OH, −OR aa , −N(R cc ) 2 , −CN, −C(=O)R aa , −C(=O)N(R cc ) 2 , −CO 2 R aa , −SO 2 R aa , −C(=NR cc )OR aa , −C(=NR cc )N(R cc ) 2 , −SO 2 N(R cc ) 2 , −SO 2 R cc , −SO 2 OR cc , −SOR aa , −C(=S)N(R cc ) 2 , −C(=O)SR cc , −C(=S)SR cc , −P(=O)(R aa ) 2 , −P(=O)(OR cc ) 2 , −P(=O)(N(R cc ) 2 ) 2 , C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2- 10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl, or two R bb groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups; wherein X − is a counterion; each instance of R cc is, independently, selected from hydrogen, C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl, or two R cc groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups; each instance of R dd is, independently, selected from halogen, −CN, −NO 2 , −N 3 , −SO 2 H, −SO 3 H, −OH, −OR ee , −ON(R ff ) 2 , −N(R ff ) 2 , −N(R ff ) 3 + X − , −N(OR ee )R ff , −SH, −SR ee , −SSR ee , −C(=O)R ee , −CO 2 H, −CO 2 R ee , −OC(=O)R ee , −OCO 2 R ee , −C(=O)N(R ff ) 2 , −OC(=O)N(R ff ) 2 , −NR ff C(=O)R ee , −NR ff CO 2 R ee , −NR ff C(=O)N(R ff ) 2 , −C(=NR ff )OR ee , −OC(=NR ff )R ee , −OC(=NR ff )OR ee , −C(=NR ff )N(R ff ) 2 , −OC(=NR ff )N(R ff ) 2 , −NR ff C(=NR ff )N(R ff ) 2 , −NR ff SO 2 R ee , −SO 2 N(R ff ) 2 , −SO 2 R ee , −SO 2 OR ee , −OSO 2 R ee , −S(=O)R ee , −Si(R ee ) 3 , −OSi(R ee ) 3 , −C(=S)N(R ff ) 2 , −C(=O)SR ee , −C(=S)SR ee , −SC(=S)SR ee , −P(=O)(OR ee ) 2 , −P(=O)(R ee ) 2 , −OP(=O)(R ee ) 2 , −OP(=O)(OR ee ) 2 , C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, heteroC 1-6 alkyl, heteroC 2-6 alkenyl, heteroC 2-6 alkynyl, C 3-10 carbocyclyl, 3-10 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups, or two geminal R dd substituents can be joined to form =O or =S; wherein X − is a counterion; each instance of R ee is, independently, selected from C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, heteroC 1-6 alkyl, heteroC 2-6 alkenyl, heteroC 2-6 alkynyl, C 3-10 carbocyclyl, C 6-10 aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups; each instance of R ff is, independently, selected from hydrogen, C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, heteroC 1-6 alkyl, heteroC 2-6 alkenyl, heteroC 2-6 alkynyl, C 3- 10 carbocyclyl, 3-10 membered heterocyclyl, C 6-10 aryl and 5-10 membered heteroaryl, or two R ff groups are joined to form a 3-10 membered heterocyclyl or 5-10 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups; and each instance of R gg is, independently, halogen, −CN, −NO 2 , −N 3 , −SO 2 H, −SO 3 H, −OH, −OC 1-6 alkyl, −ON(C 1-6 alkyl) 2 , −N(C 1-6 alkyl) 2 , −N(C 1-6 alkyl) 3 + X − , −NH(C 1-6 alkyl) 2 + X − , −NH 2 (C 1-6 alkyl) + X − , −NH 3 + X − , −N(OC 1-6 alkyl)(C 1-6 alkyl), −N(OH)(C 1-6 alkyl), −NH(OH), −SH, −SC 1-6 alkyl, −SS(C 1-6 alkyl), −C(=O)(C 1-6 alkyl), −CO 2 H, −CO 2 (C 1-6 alkyl), −OC(=O)(C 1- 6 alkyl), −OCO 2 (C 1-6 alkyl), −C(=O)NH 2 , −C(=O)N(C 1-6 alkyl) 2 , −OC(=O)NH(C 1-6 alkyl), −NHC(=O)( C 1-6 alkyl), −N(C 1-6 alkyl)C(=O)( C 1-6 alkyl), −NHCO 2 (C 1-6 alkyl), −NHC(=O)N(C 1- 6 alkyl) 2 , −NHC(=O)NH(C 1-6 alkyl), −NHC(=O)NH 2 , −C(=NH)O(C 1-6 alkyl), −OC(=NH)(C 1-6 alkyl), −OC(=NH)OC 1-6 alkyl, −C(=NH)N(C 1-6 alkyl) 2 , −C(=NH)NH(C 1-6 alkyl), −C(=NH)NH 2 , −OC(=NH)N(C 1-6 alkyl) 2 , −OC(NH)NH(C 1-6 alkyl), −OC(NH)NH 2 , −NHC(NH)N(C 1-6 alkyl) 2 , −NHC(=NH)NH 2 , −NHSO 2 (C 1-6 alkyl), −SO 2 N(C 1-6 alkyl) 2 , −SO 2 NH(C 1-6 alkyl), −SO 2 NH 2 , −SO 2 C 1-6 alkyl, −SO 2 OC 1-6 alkyl, −OSO 2 C 1-6 alkyl, −SOC 1-6 alkyl, −Si(C 1-6 alkyl) 3 , −OSi(C 1-6 alkyl) 3 −C(=S)N(C 1-6 alkyl) 2 , C(=S)NH(C 1-6 alkyl), C(=S)NH 2 , −C(=O)S(C 1-6 alkyl), −C(=S)SC 1- 6 alkyl, −SC(=S)SC 1-6 alkyl, −P(=O)(OC 1-6 alkyl) 2 , −P(=O)(C 1-6 alkyl) 2 , −OP(=O)(C 1-6 alkyl) 2 , −OP(=O)(OC 1-6 alkyl) 2 , C 1-6 alkyl, C 1-6 perhaloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, heteroC 1-6 alkyl, heteroC 2-6 alkenyl, heteroC 2-6 alkynyl, C 3-10 carbocyclyl, C 6-10 aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two geminal R gg substituents can be joined to form =O or =S; wherein X − is a counterion. In certain embodiments, the carbon atom substituents are independently halogen, substituted or unsubstituted, C 1-6 alkyl, −OR aa , −SR aa , −N(R bb ) 2 , –CN, –SCN, –NO 2 , −C(=O)R aa , −CO 2 R aa , −C(=O)N(R bb ) 2 , −OC(=O)R aa , −OCO 2 R aa , −OC(=O)N(R bb ) 2 , −NR bb C(=O)R aa , −NR bb CO 2 R aa , or −NR bb C(=O)N(R bb ) 2 . In certain embodiments, the carbon atom substituents are independently halogen, substituted or unsubstituted, C 1-6 alkyl, −OR aa , −SR aa , −N(R bb ) 2 , –CN, – SCN, or –NO 2 . In certain embodiments, a carbon atom substituent is a latent-fluoride moiety. Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, −OH, −OR aa , −N(R cc ) 2 , −CN, −C(=O)R aa , −C(=O)N(R cc ) 2 , −CO 2 R aa , −SO 2 R aa , −C(=NR bb )R aa , −C(=NR cc )OR aa , −C(=NR cc )N(R cc ) 2 , −SO 2 N(R cc ) 2 , −SO 2 R cc , −SO 2 OR cc , −SOR aa , −C(=S)N(R cc ) 2 , −C(=O)SR cc , −C(=S)SR cc , −P(=O)(OR cc ) 2 , −P(=O)(R aa ) 2 , −P(=O)(N(R cc ) 2 ) 2 , C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2- 10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl, or two R cc groups attached to an N atom are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups, and wherein R aa , R bb , R cc and R dd are as defined above. In certain embodiments, the substituent present on the nitrogen atom is an nitrogen protecting group (also referred to herein as an “amino protecting group”). Nitrogen protecting groups include, but are not limited to, −OH, −OR aa , −N(R cc ) 2 , −C(=O)R aa , −C(=O)N(R cc ) 2 , −CO 2 R aa , −SO 2 R aa , −C(=NR cc )R aa , −C(=NR cc )OR aa , −C(=NR cc )N(R cc ) 2 , −SO 2 N(R cc ) 2 , −SO 2 R cc , −SO 2 OR cc , −SOR aa , −C(=S)N(R cc ) 2 , −C(=O)SR cc , −C(=S)SR cc , C 1-10 alkyl (e.g., aralkyl, heteroaralkyl), C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl groups, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups, and wherein R aa , R bb , R cc and R dd are as defined herein. Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference. For example, nitrogen protecting groups such as amide groups (e.g., −C(=O)R aa ) include, but are not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3- pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o- nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N’- dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o- nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o- phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o- nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide and o- (benzoyloxymethyl)benzamide. Nitrogen protecting groups such as carbamate groups (e.g., −C(=O)OR aa ) include, but are not limited to, methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2- sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9- (10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4- methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2- trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1- methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2- dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1- methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2′- and 4′-pyridyl)ethyl carbamate (Pyoc), 2-(N,N- dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC or Boc), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N- hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2- phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), 1,1- dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p- (dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6- chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p- decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl carbamate, o-(N,N- dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p’-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1- methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5- dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1- phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p- (phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzyl carbamate. Nitrogen protecting groups such as sulfonamide groups (e.g., −S(=O) 2 R aa ) include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4- methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4- methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6- dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9- anthracenesulfonamide, 4-(4′,8′-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide. Other nitrogen protecting groups include, but are not limited to, phenothiazinyl-(10)-acyl derivative, N’-p-toluenesulfonylaminoacyl derivative, N’-phenylaminothioacyl derivative, N- benzoylphenylalanyl derivative, N-acetylmethionine derivative, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N- 1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5- triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5- dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4- methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7- dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino N’- oxide, N-1,1-dimethylthiomethyleneamine, N-benzylideneamine, N-p- methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(N’,N’-dimethylaminomethylene)amine, N,N’-isopropylidenediamine, N-p- nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2- hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1- cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N- [phenyl(pentaacylchromium- or tungsten)acyl]amine, N-copper chelate, N-zinc chelate, N- nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o- nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys). In certain embodiments, a nitrogen atom substituent is a latent-fluoride moiety. In certain embodiments, the substituent present on an oxygen atom is an oxygen protecting group (also referred to herein as an “hydroxyl protecting group”). Oxygen protecting groups include, but are not limited to, −R aa , −N(R bb ) 2 , −C(=O)SR aa , −C(=O)R aa , −CO 2 R aa , −C(=O)N(R bb ) 2 , −C(=NR bb )R aa , −C(=NR bb )OR aa , −C(=NR bb )N(R bb ) 2 , −S(=O)R aa , −SO 2 R aa , −Si(R aa ) 3 , −P(R cc ) 2 , −P(R cc ) 3 + X − , −P(OR cc ) 2 , −P(OR cc ) 3 + X − , −P(=O)(R aa ) 2 , −P(=O)(OR cc ) 2 , and −P(=O)(N(R bb ) 2 ) 2 , wherein X − , R aa , R bb , and R cc are as defined herein. Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference. Exemplary oxygen protecting groups include, but are not limited to, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p- methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1- methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4- methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin- 4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a- octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl, o- nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2- picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl, p,p’-dinitrobenzhydryl, 5- dibenzosuberyl, triphenylmethyl, α-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4’- bromophenacyloxyphenyl)diphenylmethyl, 4,4′,4″-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4′,4″-tris(levulinoyloxyphenyl)methyl, 4,4′,4″-tris(benzoyloxyphenyl)methyl, 3-(imidazol-1- yl)bis(4′,4″-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1′-pyrenylmethyl, 9-anthryl, 9- (9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodithiolan-2-yl, benzisothiazolyl S,S- dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t- butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3- phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p- phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), ethyl carbonate, 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2-(triphenylphosphonio) ethyl carbonate (Peoc), isobutyl carbonate, vinyl carbonate, allyl carbonate, t-butyl carbonate (BOC or Boc), p-nitrophenyl carbonate, benzyl carbonate, p-methoxybenzyl carbonate, 3,4- dimethoxybenzyl carbonate, o-nitrobenzyl carbonate, p-nitrobenzyl carbonate, S-benzyl thiocarbonate, 4-ethoxy-1-napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4- azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2- formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2- (methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4- (1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o- (methoxyacyl)benzoate, α-naphthoate, nitrate, alkyl N,N,N’,N’-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts). In certain embodiments, an oxygen atom substituent is a latent-fluoride moiety. In certain embodiments, the substituent present on a sulfur atom is a sulfur protecting group (also referred to as a “thiol protecting group”). Sulfur protecting groups include, but are not limited to, −R aa , −N(R bb ) 2 , −C(=O)SR aa , −C(=O)R aa , −CO 2 R aa , −C(=O)N(R bb ) 2 , −C(=NR bb )R aa , −C(=NR bb )OR aa , −C(=NR bb )N(R bb ) 2 , −S(=O)R aa , −SO 2 R aa , −Si(R aa ) 3 , −P(R cc ) 2 , −P(R cc ) 3 + X − , −P(OR cc ) 2 , −P(OR cc ) 3 + X − , −P(=O)(R aa ) 2 , −P(=O)(OR cc ) 2 , and −P(=O)(N(R bb ) 2 ) 2 , wherein R aa , R bb , and R cc are as defined herein. Sulfur protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference. In certain embodiments, a sulfur atom substituent is a latent-fluoride moiety. The term “halo” or “halogen” refers to fluorine (fluoro, –F), chlorine (chloro, –Cl), bromine (bromo, –Br), or iodine (iodo, –I). The term “hydroxyl” or “hydroxy” refers to the group –OH. The term “thiol” or “thio” refers to the group –SH. The term “amine” or “amino” refers to the group –NH– or –NH 2 . As used herein, the term “polyethylene glycol” or "PEG" refers to an ethylene glycol polymer that contains about 20 to about 2,000,000 linked monomers, typically about 50-1,000 linked monomers, usually about 100-300. Polyethylene glycols include ethylene glycol polymer containing various numbers of linked monomers, e.g., PEG20, PEG30, PEG40, PEG60, PEG80, PEG100, PEG115, PEG200, PEG300, PEG400, PEG500, PEG600, PEG1000, PEG1500, PEG2000, PEG3350, PEG4000, PEG4600, PEG5000, PEG6000, PEG8000, PEG11000, PEG12000, PEG2000000 and any mixtures thereof. A “counterion” or “anionic counterion” is a negatively charged group associated with a positively charged group in order to maintain electronic neutrality. An anionic counterion may be monovalent (i.e., including one formal negative charge). An anionic counterion may also be multivalent (i.e., including more than one formal negative charge), such as divalent or trivalent. Exemplary counterions include halide ions (e.g., F – , Cl – , Br – , I – ), NO 3 – , ClO 4 – , OH – , H 2 PO 4 – , HCO 3 − , HSO 4 – , sulfonate ions (e.g., methansulfonate, trifluoromethanesulfonate (triflate), p– toluenesulfonate, benzenesulfonate, 10–camphor sulfonate, naphthalene–2–sulfonate, naphthalene–1–sulfonic acid–5–sulfonate, ethan–1–sulfonic acid–2–sulfonate, and the like), carboxylate ions (e.g., acetate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, gluconate, and the like), BF 4 − , PF 4 – , PF 6 – , AsF 6 – , SbF 6 – , B[3,5-(CF 3 ) 2 C 6 H 3 ] 4 ] – , B(C 6 F 5 ) 4 − , BPh 4 – , Al(OC(CF 3 ) 3 ) 4 – , and carborane anions (e.g., CB 11 H 12 – or (HCB 11 Me 5 Br 6 ) – ). Exemplary counterions which may be multivalent include CO 3 2− , HPO 4 2− , PO 4 3− , B 4 O 7 2− , SO 4 2− , S 2 O 3 2− , carboxylate anions (e.g., tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelate, sebacate, salicylate, phthalates, aspartate, glutamate, and the like), and carboranes. In certain embodiments, the counterion is triflate. The term “salt” refers to ionic compounds that result from the neutralization reaction of an acid and a base. A salt is composed of one or more cations (positively charged ions) and one or more anions (negative ions) so that the salt is electrically neutral (without a net charge). Salts of the compounds of this invention include those derived from inorganic and organic acids and bases. Examples of acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange. Other salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2– naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3–phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further salts include ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate. A “subject” to which administration is contemplated refers to a human (i.e., male or female of any age group, e.g., pediatric subject (e.g., infant, child, or adolescent) or adult subject (e.g., young adult, middle–aged adult, or senior adult)) or non–human animal. In certain embodiments, the non–human animal is a mammal (e.g., primate (e.g., cynomolgus monkey or rhesus monkey), commercially relevant mammal (e.g., cattle, pig, horse, sheep, goat, cat, or dog), or bird (e.g., commercially relevant bird, such as chicken, duck, goose, or turkey)). In certain embodiments, the non-human animal is a fish, reptile, or amphibian. The non-human animal may be a male or female at any stage of development. The non-human animal may be a transgenic animal or genetically engineered animal. In certain embodiments, the subject is a human. The term “administer,” “administering,” or “administration” refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound described herein, or a composition thereof, in or on a subject. The terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease described herein. In some embodiments, treatment may be administered after one or more signs or symptoms of the disease have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease. For example, treatment may be administered to a susceptible subject prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of exposure to a pathogen). Treatment may also be continued after symptoms have resolved, for example, to delay and/or prevent recurrence. The term “prevent,” “preventing,” or “prevention” refers to a prophylactic treatment of a subject who is not and was not with a disease but is at risk of developing the disease or who was with a disease, is not with the disease, but is at risk of regression of the disease. In certain embodiments, the subject is at a higher risk of developing the disease or at a higher risk of regression of the disease than an average healthy member of a population of subjects. The terms “condition,” “disease,” and “disorder” are used interchangeably. An “effective amount” of a compound described herein refers to an amount sufficient to elicit the desired biological response. An effective amount of a compound described herein may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. In certain embodiments, an effective amount is a therapeutically effective amount. In certain embodiments, an effective amount is a prophylactically effective amount. In certain embodiments, an effective amount is the amount of a compound or pharmaceutical composition described herein in a single dose. In certain embodiments, an effective amount is the combined amounts of a compound or pharmaceutical composition described herein in multiple doses. A “therapeutically effective amount” of a compound described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms, signs, or causes of the condition, and/or enhances the therapeutic efficacy of another therapeutic agent.. A “prophylactically effective amount” of a compound described herein is an amount sufficient to prevent a condition, or one or more symptoms associated with the condition or prevent its recurrence. A prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the condition. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent. The term “agent” means a molecule, group of molecules, complex or substance administered to an organism for diagnostic, therapeutic, preventative medical, or veterinary purposes. In certain embodiments, the agent is an agent (e.g., a therapeutic agent, a diagnostic agent, or a prophylactic agent). In certain embodiments, the monomers, conjugates, or particles disclosed herein comprise an agent(s), e.g., a first therapeutic agent (e.g., at least one (including, e.g., at least two, at least three). The agent(s) can be coupled to the conjugate or particle. In other embodiments, the agent(s) can be associated with a conjugate or particle. In some embodiments, a first agent can be coupled to the conjugate or particle, and a second agent, targeting moiety, and/or diagnostic moiety can be non-covalently associated with the conjugate or particle. Any of the agents disclosed herein can be used in the monomers, conjugates, particles and other compositions and methods disclosed herein. The term “therapeutic agent” includes an agent that is capable of providing a local or systemic biological, physiological, or therapeutic effect in the biological system to which it is applied. For example, a therapeutic agent can act to control tumor growth, control infection or inflammation, act as an analgesic, promote anti-cell attachment, and enhance bone growth, among other functions. Other suitable therapeutic agents can include anti-viral agents, hormones, antibodies, or therapeutic proteins. Other therapeutic agents include prodrugs, which are agents that are not biologically active when administered but, upon administration to a subject are converted to biologically active agents through metabolism or some other mechanism. An agent, e.g., a therapeutic agent, can include a wide variety of different compounds, including chemical compounds and mixtures of chemical compounds, e.g., small organic or inorganic molecules; saccharines; oligosaccharides; polysaccharides; biological macromolecules, e.g., peptides, proteins, and peptide analogs and derivatives; peptidomimetics; antibodies and antigen binding fragments thereof; nucleic acids; nucleic acid analogs and derivatives; an extract made from biological materials such as bacteria, plants, fungi, or animal cells; animal tissues; naturally occurring or synthetic compositions; and any combinations thereof. In some embodiments, the agent is in the form of a prodrug. The term “prodrug” refer to a compound that becomes active, e.g., by solvolysis, reduction, oxidation, or under physiological conditions, to provide a pharmaceutically active compound, e.g., in vivo. A prodrug can include a derivative of a pharmaceutically active compound, such as, for example, to form an ester by reaction of the acid, or acid anhydride, or mixed anhydrides moieties of the prodrug moiety with the hydroxyl moiety of the pharmaceutical active compound, or to form an amide prepared by the acid, or acid anhydride, or mixed anhydrides moieties of the prodrug moiety with a substituted or unsubstituted amine of the pharmaceutically active compound. Simple aliphatic or aromatic esters, amides, and anhydrides derived from acidic groups may comprise prodrugs. In some embodiments, the conjugate or particle described herein incorporates one therapeutic agent or prodrug thereof. In some embodiments, the conjugate or particle described herein incorporates more than one therapeutic agents or prodrugs. Exemplary agents include, but are not limited to, those found in Harrison’s Principles of Internal Medicine , 13th Edition, Eds. T.R. Harrison et al. McGraw-Hill N.Y., NY; Physicians’ Desk Reference, 50th Edition, 1997, Oradell New Jersey, Medical Economics Co.; Pharmacological Basis of Therapeutics, 8th Edition, Goodman and Gilman, 1990; United States Pharmacopeia, The National Formulary, USP XII NF XVII, 1990; current edition of Goodman and Oilman’s The Pharmacological Basis of Therapeutics; and current edition of The Merck Index , the complete contents of all of which are incorporated herein by reference. In some embodiments, exemplary therapeutic agents include, but are not limited to, one or more of the agents listed in Paragraph [0148] of U.S. Patent No.9,381,253, incorporated by reference herein. In other embodiments, exemplary therapeutic agents include, but are not limited to, one or more of the therapeutic agents listed in WO 2013/169739, incorporated herein by reference. Examples of therapeutic agents include, but are not limited to, antimicrobial agents, analgesics, antinflammatory agents, counterirritants, coagulation modifying agents, diuretics, sympathomimetics, anorexics, antacids and other gastrointestinal agents; antiparasitics, antidepressants, anti-hypertensives, anticholinergics, stimulants, antihormones, central and respiratory stimulants, drug antagonists, lipid-regulating agents, uricosurics, cardiac glycosides, electrolytes, ergot and derivatives thereof, expectorants, hypnotics and sedatives, antidiabetic agents, dopaminergic agents, antiemetics, muscle relaxants, para-sympathomimetics, anticonvulsants, antihistamines, beta-blockers, purgatives, antiarrhythmics, contrast materials, radiopharmaceuticals, antiallergic agents, tranquilizers, vasodilators, antiviral agents, and antineoplastic or cytostatic agents or other agents with anti-cancer properties, or a combination thereof. Other suitable therapeutic agents include contraceptives and vitamins as well as micro- and macronutrients. Still other examples include antiinfectives such as antibiotics and antiviral agents; analgesics and analgesic combinations; anorexics; antiheimintics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiuretic agents; antidiarrleals; antihistamines; antiinflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics, antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations including calcium channel blockers and beta-blockers such as pindolol and antiarrhythmics; anti-hypertensives; diuretics; vasodilators including general coronary, peripheral and cerebral; central nervous system stimulants; cough and cold preparations, including decongestants; hormones such as estradiol and other steroids, including corticosteroids; hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; psychostimulants; sedatives; and tranquilizers; and naturally derived or genetically engineered proteins, polysaccharides, glycoproteins, or lipoproteins. In certain embodiments, at least one therapeutic agent is an anti-cancer agent. In certain instances, the diagnostic agent is an imaging agent or contrast agent. The terms “imaging agent” and “contrast agent” refer to a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract in medical imaging. The term “small molecule” refers to molecules, whether naturally-occurring or artificially created (e.g., via chemical synthesis) that have a relatively low molecular weight. Typically, a small molecule is an organic compound (i.e., it contains carbon). The small molecule may contain multiple carbon-carbon bonds, stereocenters, and other functional groups (e.g., amines, hydroxyl, carbonyls, and heterocyclic rings, etc.). In certain embodiments, the molecular weight of a small molecule is not more than 2,000 g/mol. In certain embodiments, the molecular weight of a small molecule is not more than 1,500 g/mol. In certain embodiments, the molecular weight of a small molecule is not more than 1,000 g/mol, not more than 900 g/mol, not more than 800 g/mol, not more than 700 g/mol, not more than 600 g/mol, not more than 500 g/mol, not more than 400 g/mol, not more than 300 g/mol, not more than 200 g/mol, or not more than 100 g/mol. In certain embodiments, the molecular weight of a small molecule is at least 100 g/mol, at least 200 g/mol, at least 300 g/mol, at least 400 g/mol, at least 500 g/mol, at least 600 g/mol, at least 700 g/mol, at least 800 g/mol, or at least 900 g/mol, or at least 1,000 g/mol. Combinations of the above ranges (e.g., at least 200 g/mol and not more than 500 g/mol) are also possible. In certain embodiments, the small molecule is a therapeutically active agent such as a drug (e.g., a molecule approved by the U.S. Food and Drug Administration as provided in the Code of Federal Regulations (C.F.R.)). The small molecule may also be complexed with one or more metal atoms and/or metal ions. In this instance, the small molecule is also referred to as a “small organometallic molecule.” Preferred small molecules are biologically active in that they produce a biological effect in animals, preferably mammals, more preferably humans. Small molecules include radionuclides and imaging agents. In certain embodiments, the small molecule is a drug. Preferably, though not necessarily, the drug is one that has already been deemed safe and effective for use in humans or animals by the appropriate governmental agency or regulatory body. For example, drugs approved for human use are listed by the FDA under 21 C.F.R. §§ 330.5, 331 through 361, and 440 through 460, incorporated herein by reference; drugs for veterinary use are listed by the FDA under 21 C.F.R. §§ 500 through 589, incorporated herein by reference. All listed drugs are considered acceptable for use in accordance with the present invention. A “protein,” “peptide,” or “polypeptide” comprises a polymer of amino acid residues linked together by peptide bonds. The term refers to proteins, polypeptides, and peptides of any size, structure, or function. A protein may refer to an individual protein or a collection of proteins. Proteins preferably contain only natural amino acids, although non-natural amino acids (i.e., compounds that do not occur in nature but that can be incorporated into a polypeptide chain) and/or amino acid analogs as are known in the art may alternatively be employed. In certain embodiments, the amino acid residues of a peptide are alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and/or valine, in D and/or L form. In certain embodiments, the amino acid residues of a peptide are alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and/or valine, in L form. One or more of the amino acids in a protein may be protected. Also, one or more of the amino acids in a protein may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation or functionalization, or other modification. A protein may also be a single molecule or may be a multi-molecular complex. A protein may be a fragment of a naturally occurring protein or peptide. A protein may be naturally occurring, recombinant, synthetic, or any combination of these. In certain embodiments, a protein comprises between 2 and 10, between 10 and 30, between 30 and 100, between 100 and 300, or between 300 and 1,000, inclusive, amino acids. In certain embodiments, a protein comprises between 1,000 and 3,000, or between 3,000 and 10,000, inclusive, amino acids. In certain embodiments, the amino acids in a protein are natural amino acids. In certain embodiments, the amino acids in a protein are unnatural amino acids. In certain embodiments, the amino acids in a protein are a combination of natural amino acids and unnatural amino acids. The term “ring-opening metathesis polymerization (ROMP)” refers to a type of olefin metathesis chain-growth polymerization that is driven by the relief of ring strain in cyclic olefins (e.g. norbornene or cyclopentene). The catalysts used in the ROMP reaction (“metathesis catalyst”) include RuCl 3 /alcohol mixture, bis(cyclopentadienyl)dimethylzirconium(IV), dichloro[1,3-bis(2,6-isopropylphenyl)-2- imidazolidinylidene](benzylidene)(tricyclohexylphosphine)rut henium(II), dichloro[1,3-Bis(2- methylphenyl)-2-imidazolidinylidene](benzylidene)(tricyclohe xylphosphine) ruthenium(II), dichloro[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinyliden e][3-(2- pyridinyl)propylidene]ruthenium(II), dichloro(3-methyl-2-butenylidene)bis (tricyclopentylphosphine)ruthenium(II), dichloro[1,3-bis(2-methylphenyl)-2- imidazolidinylidene](2-isopropoxyphenylmethylene)ruthenium(I I) (Grubbs C571), dichloro(benzylidene)bis(tricyclohexylphosphine)ruthenium(II ) (Grubbs I), dichloro[1,3- bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene](benzyliden e)(tricyclohexylphosphine) ruthenium(II) (Grubbs II), and dichloro[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinyliden e] (benzylidene)bis(3-bromopyridine)ruthenium(II) (Grubbs III). A “proliferative disease” refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology; Cambridge University Press: Cambridge, UK, 1990). A proliferative disease may be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis as in proliferative retinopathy and tumor metastasis. Exemplary proliferative diseases include cancers (i.e., “malignant neoplasms”), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases. The term “angiogenesis” refers to the physiological process through which new blood vessels form from pre-existing vessels. Angiogenesis is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesoderm cell precursors. The first vessels in a developing embryo form through vasculogenesis, after which angiogenesis is responsible for most blood vessel growth during normal or abnormal development. Angiogenesis is a vital process in growth and development, as well as in wound healing and in the formation of granulation tissue. However, angiogenesis is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer. Angiogenesis may be chemically stimulated by angiogenic proteins, such as growth factors (e.g., VEGF). “Pathological angiogenesis” refers to abnormal (e.g., excessive or insufficient) angiogenesis that amounts to and/or is associated with a disease. The terms “neoplasm” and “tumor” are used herein interchangeably and refer to an abnormal mass of tissue wherein the growth of the mass surpasses and is not coordinated with the growth of a normal tissue. A neoplasm or tumor may be “benign” or “malignant,” depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis. A “benign neoplasm” is generally well differentiated, has characteristically slower growth than a malignant neoplasm, and remains localized to the site of origin. In addition, a benign neoplasm does not have the capacity to infiltrate, invade, or metastasize to distant sites. Exemplary benign neoplasms includelipoma, chondroma, adenomas, acrochordon, senile angiomas, seborrheic keratoses, lentigos, and sebaceous hyperplasias. In some cases, certain “benign” tumors may later give rise to malignant neoplasms, which may result from additional genetic changes in a subpopulation of the tumor’s neoplastic cells, and these tumors are referred to as “pre-malignant neoplasms.” An exemplary pre-malignant neoplasm is a teratoma. In contrast, a “malignant neoplasm” is generally poorly differentiated (anaplasia) and has characteristically rapid growth accompanied by progressive infiltration, invasion, and destruction of the surrounding tissue. Furthermore, a malignant neoplasm generally has the capacity to metastasize to distant sites. The term “metastasis,” “metastatic,” or “metastasize” refers to the spread or migration of cancerous cells from a primary or original tumor to another organ or tissue and is typically identifiable by the presence of a “secondary tumor” or “secondary cell mass” of the tissue type of the primary or original tumor and not of that of the organ or tissue in which the secondary (metastatic) tumor is located. For example, a prostate cancer that has migrated to bone is said to be metastasized prostate cancer and includes cancerous prostate cancer cells growing in bone tissue. The term “cancer” refers to a class of diseases characterized by the development of abnormal cells that proliferate uncontrollably and have the ability to infiltrate and destroy normal body tissues. See, e.g., Stedman’s Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990. The cancer may be a solid tumor. The cancer may be a hematological malignancy. Exemplary cancers includeacoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma; chordoma; craniopharyngioma; colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma); connective tissue cancer; epithelial carcinoma; ependymoma; endotheliosarcoma (e.g., Kaposi’s sarcoma, multiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g., uterine cancer, uterine sarcoma); esophageal cancer (e.g., adenocarcinoma of the esophagus, Barrett’s adenocarcinoma); Ewing’s sarcoma; ocular cancer (e.g., intraocular melanoma, retinoblastoma); familiar hypereosinophilia; gall bladder cancer; gastric cancer (e.g., stomach adenocarcinoma); gastrointestinal stromal tumor (GIST); germ cell cancer; head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)); hematopoietic cancers (e.g., leukemia such as acute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL)); lymphoma such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma), follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphomas (e.g., mucosa-associated lymphoid tissue (MALT) lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (i.e., Waldenström’s macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma; and T-cell NHL such as precursor T- lymphoblastic lymphoma/leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and anaplastic large cell lymphoma); a mixture of one or more leukemia/lymphoma as described above; and multiple myeloma (MM)), heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease); hemangioblastoma; hypopharynx cancer; inflammatory myofibroblastic tumors; immunocytic amyloidosis; kidney cancer (e.g., nephroblastoma a.k.a. Wilms’ tumor, renal cell carcinoma); liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma); lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a. myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis); neuroendocrine cancer (e.g., gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor); osteosarcoma (e.g.,bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors); penile cancer (e.g., Paget’s disease of the penis and scrotum); pinealoma; primitive neuroectodermal tumor (PNT); plasma cell neoplasia; paraneoplastic syndromes; intraepithelial neoplasms; prostate cancer (e.g., prostate adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small bowel cancer (e.g., appendix cancer); soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small intestine cancer; sweat gland carcinoma; synovioma; testicular cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer); urethral cancer; vaginal cancer; and vulvar cancer (e.g., Paget’s disease of the vulva). The term “inflammatory disease” refers to a disease caused by, resulting from, or resulting in inflammation. The term “inflammatory disease” may also refer to a dysregulated inflammatory reaction that causes an exaggerated response by macrophages, granulocytes, and/or T-lymphocytes leading to abnormal tissue damage and/or cell death. An inflammatory disease can be either an acute or chronic inflammatory condition and can result from infections or non- infectious causes. Inflammatory diseases include atherosclerosis, arteriosclerosis, autoimmune disorders, multiple sclerosis, systemic lupus erythematosus, polymyalgia rheumatica (PMR), gouty arthritis, degenerative arthritis, tendonitis, bursitis, psoriasis, cystic fibrosis, arthrosteitis, rheumatoid arthritis, inflammatory arthritis, Sjogren’s syndrome, giant cell arteritis, progressive systemic sclerosis (scleroderma), ankylosing spondylitis, polymyositis, dermatomyositis, pemphigus, pemphigoid, diabetes (e.g., Type I), myasthenia gravis, Hashimoto’s thyroiditis, Graves’ disease, Goodpasture’s disease, mixed connective tissue disease, sclerosing cholangitis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, pernicious anemia, usual interstitial pneumonitis (UIP), asbestosis, silicosis, bronchiectasis, berylliosis, talcosis, pneumoconiosis, sarcoidosis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, giant cell interstitial pneumonia, cellular interstitial pneumonia, extrinsic allergic alveolitis, Wegener’s granulomatosis and related forms of angiitis (temporal arteritis and polyarteritis nodosa), inflammatory dermatoses, dermatitis (e.g., stasis dermatitis, allergic contact dermatitis, atopic dermatitis, irritant contact dermatitis, neurodermatitis perioral dermatitis, seborrheic dermatitis), hepatitis, delayed-type hypersensitivity reactions (e.g., poison ivy dermatitis), pneumonia, respiratory tract inflammation, Adult Respiratory Distress Syndrome (ARDS), encephalitis, immediate hypersensitivity reactions, asthma, hayfever, allergies, acute anaphylaxis, rheumatic fever, glomerulonephritis, pyelonephritis, cellulitis, cystitis, chronic cholecystitis, ischemia (ischemic injury), reperfusion injury, allograft rejection, host-versus-graft rejection, appendicitis, arteritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, chorioamnionitis, conjunctivitis, dacryoadenitis, dermatomyositis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, gingivitis, ileitis, iritis, laryngitis, myelitis, myocarditis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, pharyngitis, pleuritis, phlebitis, pneumonitis, proctitis, prostatitis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, testitis, tonsillitis, urethritis, urocystitis, uveitis, vaginitis, vasculitis, vulvitis, vulvovaginitis, angitis, chronic bronchitis, osteomyelitis, optic neuritis, temporal arteritis, transverse myelitis, necrotizing fasciitis, necrotizing enterocolitis, inflammatory rosacea. An ocular inflammatory disease includes post-surgical inflammation. An “autoimmune disease” refers to a disease arising from an inappropriate immune response of the body of a subject against substances and tissues normally present in the body. In other words, the immune system mistakes some part of the body as a pathogen and attacks its own cells. This may be restricted to certain organs (e.g., in autoimmune thyroiditis) or involve a particular tissue in different places (e.g., Goodpasture’s disease which may affect the basement membrane in both the lung and kidney). The treatment of autoimmune diseases is typically with immunosuppression, e.g., medications which decrease the immune response. Exemplary autoimmune diseases includeglomerulonephritis, Goodpasture’s syndrome, necrotizing vasculitis, lymphadenitis, peri-arteritis nodosa, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis/polymyositis, anti-phospholipid antibody syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (e.g., Wegener’s granulomatosis, microscopic polyangiitis), uveitis, Sjogren’s syndrome, Crohn’s disease, Reiter’s syndrome, ankylosing spondylitis, Lyme disease, Guillain-Barré syndrome, Hashimoto’s thyroiditis, and cardiomyopathy. A “hematological disease” includes a disease which affects a hematopoietic cell or tissue. Hematological diseases include diseases associated with aberrant hematological content and/or function. Examples of hematological diseases include diseases resulting from bone marrow irradiation or chemotherapy treatments for cancer, diseases such as pernicious anemia, hemorrhagic anemia, hemolytic anemia, aplastic anemia, sickle cell anemia, sideroblastic anemia, anemia associated with chronic infections such as malaria, trypanosomiasis, HTV, hepatitis virus or other viruses, myelophthisic anemias caused by marrow deficiencies, renal failure resulting from anemia, anemia, polycythemia, infectious mononucleosis (EVI), acute non- lymphocytic leukemia (ANLL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute myelomonocytic leukemia (AMMoL), polycythemia vera, lymphoma, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia, Wilm’s tumor, Ewing’s sarcoma, retinoblastoma, hemophilia, disorders associated with an increased risk of thrombosis, herpes, thalassemia, antibody-mediated disorders such as transfusion reactions and erythroblastosis, mechanical trauma to red blood cells such as micro-angiopathic hemolytic anemias, thrombotic thrombocytopenic purpura and disseminated intravascular coagulation, infections by parasites such as Plasmodium, chemical injuries from, e.g., lead poisoning, and hypersplenism. The term “neurological disease” refers to any disease of the nervous system, including diseases that involve the central nervous system (brain, brainstem and cerebellum), the peripheral nervous system (including cranial nerves), and the autonomic nervous system (parts of which are located in both central and peripheral nervous system). Neurodegenerative diseases refer to a type of neurological disease marked by the loss of nerve cells, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, tauopathies (including frontotemporal dementia), and Huntington’s disease. Examples of neurological diseases includeheadache, stupor and coma, dementia, seizure, sleep disorders, trauma, infections, neoplasms, neuro- ophthalmology, movement disorders, demyelinating diseases, spinal cord disorders, and disorders of peripheral nerves, muscle and neuromuscular junctions. Addiction and mental illness, includebipolar disorder and schizophrenia, are also included in the definition of neurological diseases. Further examples of neurological diseases include acquired epileptiform aphasia; acute disseminated encephalomyelitis; adrenoleukodystrophy; agenesis of the corpus callosum; agnosia; Aicardi syndrome; Alexander disease; Alpers’ disease; alternating hemiplegia; Alzheimer’s disease; amyotrophic lateral sclerosis; anencephaly; Angelman syndrome; angiomatosis; anoxia; aphasia; apraxia; arachnoid cysts; arachnoiditis; Arnold-Chiari malformation; arteriovenous malformation; Asperger syndrome; ataxia telangiectasia; attention deficit hyperactivity disorder; autism; autonomic dysfunction; back pain; Batten disease; Behcet’s disease; Bell’s palsy; benign essential blepharospasm; benign focal; amyotrophy; benign intracranial hypertension; Binswanger’s disease; blepharospasm; Bloch Sulzberger syndrome; brachial plexus injury; brain abscess; bbrain injury; brain tumors (including glioblastoma multiforme); spinal tumor; Brown-Sequard syndrome; Canavan disease; carpal tunnel syndrome (CTS); causalgia; central pain syndrome; central pontine myelinolysis; cephalic disorder; cerebral aneurysm; cerebral arteriosclerosis; cerebral atrophy; cerebral gigantism; cerebral palsy; Charcot-Marie-Tooth disease; chemotherapy-induced neuropathy and neuropathic pain; Chiari malformation; chorea; chronic inflammatory demyelinating polyneuropathy (CIDP); chronic pain; chronic regional pain syndrome; Coffin Lowry syndrome; coma, including persistent vegetative state; congenital facial diplegia; corticobasal degeneration; cranial arteritis; craniosynostosis; Creutzfeldt-Jakob disease; cumulative trauma disorders; Cushing’s syndrome; cytomegalic inclusion body disease (CIBD); cytomegalovirus infection; dancing eyes-dancing feet syndrome; Dandy-Walker syndrome; Dawson disease; De Morsier’s syndrome; Dejerine- Klumpke palsy; dementia; dermatomyositis; diabetic neuropathy; diffuse sclerosis; dysautonomia; dysgraphia; dyslexia; dystonias; early infantile epileptic encephalopathy; empty sella syndrome; encephalitis; encephaloceles; encephalotrigeminal angiomatosis; epilepsy; Erb’s palsy; essential tremor; Fabry’s disease; Fahr’s syndrome; fainting; familial spastic paralysis; febrile seizures; Fisher syndrome; Friedreich’s ataxia; frontotemporal dementia and other “tauopathies”; Gaucher’s disease; Gerstmann’s syndrome; giant cell arteritis; giant cell inclusion disease; globoid cell leukodystrophy; Guillain-Barre syndrome; HTLV-1 associated myelopathy; Hallervorden-Spatz disease; head injury; headache; hemifacial spasm; hereditary spastic paraplegia; heredopathia atactica polyneuritiformis; herpes zoster oticus; herpes zoster; Hirayama syndrome; HIV-associated dementia and neuropathy (see also neurological manifestations of AIDS); holoprosencephaly; Huntington’s disease and other polyglutamine repeat diseases; hydranencephaly; hydrocephalus; hypercortisolism; hypoxia; immune-mediated encephalomyelitis; inclusion body myositis; incontinentia pigmenti; infantile; phytanic acid storage disease; Infantile Refsum disease; infantile spasms; inflammatory myopathy; intracranial cyst; intracranial hypertension; Joubert syndrome; Kearns-Sayre syndrome; Kennedy disease; Kinsbourne syndrome; Klippel Feil syndrome; Krabbe disease; Kugelberg-Welander disease; kuru; Lafora disease; Lambert-Eaton myasthenic syndrome; Landau-Kleffner syndrome; lateral medullary (Wallenberg) syndrome; learning disabilities; Leigh’s disease; Lennox-Gastaut syndrome; Lesch-Nyhan syndrome; leukodystrophy; Lewy body dementia; lissencephaly; locked-in syndrome; Lou Gehrig’s disease (aka motor neuron disease or amyotrophic lateral sclerosis); lumbar disc disease; lyme disease-neurological sequelae; Machado-Joseph disease; macrencephaly; megalencephaly; Melkersson-Rosenthal syndrome; Menieres disease; meningitis; Menkes disease; metachromatic leukodystrophy; microcephaly; migraine; Miller Fisher syndrome; mini-strokes; mitochondrial myopathies; Mobius syndrome; monomelic amyotrophy; motor neurone disease; moyamoya disease; mucopolysaccharidoses; multi-infarct dementia; multifocal motor neuropathy; multiple sclerosis and other demyelinating disorders; multiple system atrophy with postural hypotension; muscular dystrophy; myasthenia gravis; myelinoclastic diffuse sclerosis; myoclonic encephalopathy of infants; myoclonus; myopathy; myotonia congenital; narcolepsy; neurofibromatosis; neuroleptic malignant syndrome; neurological manifestations of AIDS; neurological sequelae of lupus; neuromyotonia; neuronal ceroid lipofuscinosis; neuronal migration disorders; Niemann-Pick disease; O’Sullivan-McLeod syndrome; occipital neuralgia; occult spinal dysraphism sequence; Ohtahara syndrome; olivopontocerebellar atrophy; opsoclonus myoclonus; optic neuritis; orthostatic hypotension; overuse syndrome; paresthesia; Parkinson’s disease; paramyotonia congenita; paraneoplastic diseases; paroxysmal attacks; Parry Romberg syndrome; Pelizaeus-Merzbacher disease; periodic paralyses; peripheral neuropathy; painful neuropathy and neuropathic pain; persistent vegetative state; pervasive developmental disorders; photic sneeze reflex; phytanic acid storage disease; Pick’s disease; pinched nerve; pituitary tumors; polymyositis; porencephaly; Post-Polio syndrome; postherpetic neuralgia (PHN); postinfectious encephalomyelitis; postural hypotension; Prader-Willi syndrome; primary lateral sclerosis; prion diseases; progressive; hemifacial atrophy; progressive multifocal leukoencephalopathy; progressive sclerosing poliodystrophy; progressive supranuclear palsy; pseudotumor cerebri; Ramsay-Hunt syndrome (Type I and Type II); Rasmussen’s Encephalitis; reflex sympathetic dystrophy syndrome; Refsum disease; repetitive motion disorders; repetitive stress injuries; restless legs syndrome; retrovirus-associated myelopathy; Rett syndrome; Reye’s syndrome; Saint Vitus Dance; Sandhoff disease; Schilder’s disease; schizencephaly; septo-optic dysplasia; shaken baby syndrome; shingles; Shy-Drager syndrome; Sjogren’s syndrome; sleep apnea; Soto’s syndrome; spasticity; spina bifida; spinal cord injury; spinal cord tumors; spinal muscular atrophy; stiff-person syndrome; stroke; Sturge- Weber syndrome; subacute sclerosing panencephalitis; subarachnoid hemorrhage; subcortical arteriosclerotic encephalopathy; sydenham chorea; syncope; syringomyelia; tardive dyskinesia; Tay-Sachs disease; temporal arteritis; tethered spinal cord syndrome; Thomsen disease; thoracic outlet syndrome; tic douloureux; Todd’s paralysis; Tourette syndrome; transient ischemic attack; transmissible spongiform encephalopathies; transverse myelitis; traumatic brain injury; tremor; trigeminal neuralgia; tropical spastic paraparesis; tuberous sclerosis; vascular dementia (multi- infarct dementia); vasculitis including temporal arteritis; Von Hippel-Lindau Disease (VHL); Wallenberg’s syndrome; Werdnig-Hoffman disease; West syndrome; whiplash; Williams syndrome; Wilson’s disease; and Zellweger syndrome. A “painful condition” includes neuropathic pain (e.g., peripheral neuropathic pain), central pain, deafferentiation pain, chronic pain (e.g., chronic nociceptive pain, and other forms of chronic pain such as post–operative pain, e.g., pain arising after hip, knee, or other replacement surgery), pre–operative pain, stimulus of nociceptive receptors (nociceptive pain), acute pain (e.g., phantom and transient acute pain), noninflammatory pain, inflammatory pain, pain associated with cancer, wound pain, burn pain, postoperative pain, pain associated with medical procedures, pain resulting from pruritus, painful bladder syndrome, pain associated with premenstrual dysphoric disorder and/or premenstrual syndrome, pain associated with chronic fatigue syndrome, pain associated with pre–term labor, pain associated with withdrawl symptoms from drug addiction, joint pain, arthritic pain (e.g., pain associated with crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis, reactive arthritis, rheumatoid arthritis or Reiter’s arthritis), lumbosacral pain, musculo–skeletal pain, headache, migraine, muscle ache, lower back pain, neck pain, toothache, dental/maxillofacial pain, visceral pain and the like. One or more of the painful conditions contemplated herein can comprise mixtures of various types of pain provided above and herein (e.g. nociceptive pain, inflammatory pain, neuropathic pain, etc.). In some embodiments, a particular pain can dominate. In other embodiments, the painful condition comprises two or more types of pains without one dominating. A skilled clinician can determine the dosage to achieve a therapeutically effective amount for a particular subject based on the painful condition. The term “psychiatric disorder” refers to a disease of the mind and includes diseases and disorders listed in the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV), published by the American Psychiatric Association, Washington D. C. (1994). Psychiatric disorders includeanxiety disorders (e.g., acute stress disorder agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, separation anxiety disorder, social phobia, and specific phobia), childhood disorders, (e.g., attention-deficit/hyperactivity disorder, conduct disorder, and oppositional defiant disorder), eating disorders (e.g., anorexia nervosa and bulimia nervosa), mood disorders (e.g., depression, bipolar disorder, cyclothymic disorder, dysthymic disorder, and major depressive disorder), personality disorders (e.g., antisocial personality disorder, avoidant personality disorder, borderline personality disorder, dependent personality disorder, histrionic personality disorder, narcissistic personality disorder, obsessive-compulsive personality disorder, paranoid personality disorder, schizoid personality disorder, and schizotypal personality disorder), psychotic disorders (e.g., brief psychotic disorder, delusional disorder, schizoaffective disorder, schizophreniform disorder, schizophrenia, and shared psychotic disorder), substance-related disorders (e.g., alcohol dependence, amphetamine dependence, cannabis dependence, cocaine dependence, hallucinogen dependence, inhalant dependence, nicotine dependence, opioid dependence, phencyclidine dependence, and sedative dependence), adjustment disorder, autism, delirium, dementia, multi-infarct dementia, learning and memory disorders (e.g., amnesia and age-related memory loss), and Tourette’s disorder. The term "metabolic disorder" refers to any disorder that involves an alteration in the normal metabolism of carbohydrates, lipids, proteins, nucleic acids, or a combination thereof. A metabolic disorder is associated with either a deficiency or excess in a metabolic pathway resulting in an imbalance in metabolism of nucleic acids, proteins, lipids, and/or carbohydrates. Factors affecting metabolism include the endocrine (hormonal) control system (e.g., the insulin pathway, the enteroendocrine hormones including GLP-1, PYY or the like), the neural control system (e.g., GLP-1 in the brain), or the like. Examples of metabolic disorders includediabetes (e.g., Type I diabetes, Type II diabetes, gestational diabetes), hyperglycemia, hyperinsulinemia, insulin resistance, and obesity. The disclosure is not intended to be limited in any manner by the above exemplary listing of substituents. Additional terms may be defined in other sections of this disclosure. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1A shows that a nucleophilic aromatic substitution at the pentafluorophenyl group with a thiol results in degradation of the copolymer. Figure 1B shows gel permeation chromatography (GPC) traces showing the initial copolymer (black) and the degradation products (green). Figure 2 shows additional reactions resulting in degradation of the copolymer. Figure 3 shows GC-MS spectra showing the cleavage of Si-PFP in the presence of thiol and base. Figures 4A and 4B show the degradation of doped pDCPD thermoset materials. Figure 4A: Control gels (prepared by ROMP of DCPD and iPrSi ( , 10% v/v)) in a solution of: tetrahydrofuran (THF); THF and 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU); THF and 1-dodecanethiol (thiol); THF, thiol, and DBU; or THF and TBAF; at 25 °C, after 0 and 3 h. Figure 4B: Nb-PFP-doped gels (prepared by ROMP of DCPD, iPrSi (10% v/v), and Nb-PFP ( , 2.0 equiv with respect to iPrSi)) in a solution of: THF; THF and DBU; THF and 1-dodecanethiol (thiol); THF, thiol, and DBU; or THF and TBAF; at 25 °C, after 0 and 3 h. DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE DISCLOSURE In one aspect, the present disclosure provides a first monomer, wherein the first monomer is of Formula (A1): (A1), or salt thereof, wherein: Z is C(R P ) 2 or O; each instance of R P is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; each instance of is independently a single bond or double bond; each instance of R H is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, –OR a , –OCN, –OC(=O)R a , –OC(=S)R a , – OC(=O)OR a , –OC(=O)N(R a ) 2 ,–OS(=O)R a , –OS(=O)OR a , –OS(=O)N(R a ) 2 , –OS(=O) 2 R a , – OS(=O) 2 OR a , –OS(=O) 2 N(R a ) 2 , –OSi(R a ) 3 , –OSi(R a ) 2 (OR a ), –OSi(R a )(OR a ) 2 , –OSi(OR a ) 3 , oxo, – N(R a ) 2 , –N=C(R a ) 2 , =NR a , –NC, –NCO, –N 3 , –NO 2 , –NR a C(=O)R a , –NR a C(=O)OR a , – NR a C(=O)N(R a ) 2 , –NR a S(=O)R a , –NR a S(=O)OR a , –NR a S(=O)N(R a ) 2 , –NR a S(=O) 2 R a , – NR a S(=O) 2 OR a , –NR a S(=O) 2 N(R a ) 2 , –SR a , –SCN, –S(=O)R a , –S(=O)OR a , –S(=O)N(R a ) 2 , – S(=O) 2 R a , –S(=O) 2 OR a , –S(=O) 2 N(R a ) 2 , –SeR a , –CN, –C(=NR a )R a , –C(=NR a )OR a , – C(=NR a )N(R a ) 2 , –C(=O)R a , –C(=O)OR a , –C(=O)SR a , –C(=S)OR a , –C(=O)N(R a ) 2 , or a latent- fluoride moiety; or the two instances of R H are joined with the intervening carbon atoms to form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring, optionally wherein at least one substituent of the substituted monocyclic carbocyclic ring, substituted monocyclic heterocyclic ring, substituted monocyclic aryl ring, or substituted monocyclic heteroaryl ring is a latent-fluoride moiety; each instance of R a is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R a are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl; and each instance of the latent-fluoride moiety comprises one or more through covalent bonds a, wherein each covalent bond a is cleavable in the presence of a degradation composition comprising one or more nucleophiles, one or more bases, or a combination thereof; provided that the first monomer comprises at least one instance of the latent-fluoride moiety. In another aspect, the present disclosure provides a second monomer, wherein the second monomer is of Formula (B1): or a salt thereof, wherein: Y is O or C(R Q ) 2 ; each instance of R Q is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; each instance of R Y is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; each instance of R Z is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; R K1 is hydrogen, halogen, substituted or unsubstituted, C 1-10 alkyl, substituted or unsubstituted, C 2-10 alkenyl, substituted or unsubstituted, C 2-10 alkynyl,–L K1 –(substituted or unsubstituted carbocyclyl), –L K1 –(substituted or unsubstituted heterocyclyl), –L K1 –(substituted or unsubstituted aryl), –L K1 –(substituted or unsubstituted heteroaryl), –OR N1 , a latent-fluoride moiety, or –L K1 –(a latent-fluoride moiety); L K1 is a single bond, –O–, substituted or unsubstituted, C 1-10 alkylene, substituted or unsubstituted, C 2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; R N1 is hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C 1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; R K2 is hydrogen, halogen, substituted or unsubstituted, C 1-10 alkyl, substituted or unsubstituted, C 2-10 alkenyl, substituted or unsubstituted, C 2-10 alkynyl, –L K2 –(substituted or unsubstituted carbocyclyl), –L K2 –(substituted or unsubstituted heterocyclyl), –L K2 –(substituted or unsubstituted aryl), –L K2 –(substituted or unsubstituted heteroaryl), –OR N2 , a latent-fluoride moiety, or –L K2 –(a latent-fluoride moiety); L K2 is a single bond, –O–, substituted or unsubstituted, C 1-10 alkylene, substituted or unsubstituted, C 2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; R N2 is hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C 1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; or R K1 and R K2 are joined with the intervening atom to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl, optionally wherein at least one substituent of the substituted carbocyclyl or substituted heterocyclyl is a latent-fluoride moiety; j is 1, 2, or 3; k is 0, 1, 2, or 3; and each instance of the latent-fluoride moiety comprises one or more through covalent bonds a, wherein each covalent bond a is cleavable in the presence of a degradation composition comprising one or more nucleophiles, one or more bases, or a combination thereof; provided that the second monomer comprises at least one instance of the latent-fluoride moiety. In another aspect, the present disclosure provides a copolymer prepared by a method comprising polymerizing: one or more instances of a first monomer, wherein each instance of the first monomer independently comprises at least one C=C and/or at least one C≡C and optionally comprises one or more instances of a latent-fluoride moiety; one or more instances of a second monomer, wherein each instance of the second monomer is of Formula (B): or a salt thereof; and optionally one or more instances of a third monomer; in the presence of a metathesis catalyst; wherein: each instance of Y is independently O or C(R Q ) 2 ; each instance of R Q is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; each instance of R Y is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; each instance of R Z is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; each instance of R K1 is independently hydrogen, halogen, substituted or unsubstituted, C 1- 10 alkyl, substituted or unsubstituted, C 2-10 alkenyl, substituted or unsubstituted, C 2-10 alkynyl, – L K1 –(substituted or unsubstituted carbocyclyl), –L K1 –(substituted or unsubstituted heterocyclyl), –L K1 –(substituted or unsubstituted aryl), –L K1 –(substituted or unsubstituted heteroaryl), –OR N1 , a latent-fluoride moiety, or –L K1 –(a latent-fluoride moiety); each instance of L K1 is independently a single bond, –O–, substituted or unsubstituted, C 1- 10 alkylene, substituted or unsubstituted, C 2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; each instance of R N1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C 1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; each instance of R K2 is independently hydrogen, halogen, substituted or unsubstituted, C 1- 10 alkyl, substituted or unsubstituted, C 2-10 alkenyl, substituted or unsubstituted, C 2-10 alkynyl, – L K2 –(substituted or unsubstituted carbocyclyl), –L K2 –(substituted or unsubstituted heterocyclyl), –L K2 –(substituted or unsubstituted aryl), –L K2 –(substituted or unsubstituted heteroaryl), –OR N2 , a latent-fluoride moiety, or –L K2 –(a latent-fluoride moiety); each instance of L K2 is independently a single bond, –O–, substituted or unsubstituted, C 1- 10 alkylene, substituted or unsubstituted, C 2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; each instance of R N2 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C 1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; or at least one instance of R K1 and at least one instance of R K2 that are attached to the same instance of Si are joined with the intervening atom to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl, optionally wherein at least one substituent of the substituted carbocyclyl or substituted heterocyclyl is a latent-fluoride moiety; each instance of j is independently 1, 2, or 3; each instance of k is independently 0, 1, 2, or 3; and each instance of the latent-fluoride moiety comprises one or more through covalent bonds a, wherein each covalent bond a is cleavable in the presence of a degradation composition comprising one or more nucleophiles, one or more bases, or a combination thereof; provided that: at least one instance of the first monomer and/or at least one instance of the second monomer comprises at least one instance of the latent-fluoride moiety; and any two instances of the first monomer are the same as or different from each other, any two instances of the second monomer are the same as or different from each other, any two instances of the third monomer are the same as or different from each other, and each instance of the first monomer, the second monomer, and the third monomer if present, is different from each other. In another aspect, the present disclosure provides a method of preparing a copolymer comprising polymerizing: one or more instances of a first monomer, wherein each instance of the first monomer independently comprises at least one C=C and/or at least one C≡C and optionally comprises one or more instances of a latent-fluoride moiety; one or more instances of a second monomer, wherein each instance of the second monomer is of Formula (B): or a salt thereof; and optionally one or more instances of a third monomer; in the presence of a metathesis catalyst; wherein: each instance of Y is independently O or C(R Q ) 2 ; each instance of R Q is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; each instance of R Y is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; each instance of R Z is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; each instance of R K1 is independently hydrogen, halogen, substituted or unsubstituted, C 1- 10 alkyl, substituted or unsubstituted, C 2-10 alkenyl, substituted or unsubstituted, C 2-10 alkynyl, – L K1 –(substituted or unsubstituted carbocyclyl), –L K1 –(substituted or unsubstituted heterocyclyl), –L K1 –(substituted or unsubstituted aryl), –L K1 –(substituted or unsubstituted heteroaryl), –OR N1 , a latent-fluoride moiety, or –L K1 –(a latent-fluoride moiety); each instance of L K1 is independently a single bond, –O–, substituted or unsubstituted, C 1- 10 alkylene, substituted or unsubstituted, C 2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; each instance of R N1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C 1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; each instance of R K2 is independently hydrogen, halogen, substituted or unsubstituted, C 1- 10 alkyl, substituted or unsubstituted, C 2-10 alkenyl, substituted or unsubstituted, C 2-10 alkynyl, – L K2 –(substituted or unsubstituted carbocyclyl), –L K2 –(substituted or unsubstituted heterocyclyl), –L K2 –(substituted or unsubstituted aryl), –L K2 –(substituted or unsubstituted heteroaryl), –OR N2 , a latent-fluoride moiety, or –L K2 –(a latent-fluoride moiety); each instance of L K2 is independently a single bond, –O–, substituted or unsubstituted, C 1- 10 alkylene, substituted or unsubstituted, C 2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; each instance of R N2 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C 1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; or at least one instance of R K1 and at least one instance of R K2 that are attached to the same instance of Si are joined with the intervening atom to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl, optionally wherein at least one substituent of the substituted carbocyclyl or substituted heterocyclyl is a latent-fluoride moiety; each instance of j is independently 1, 2, or 3; each instance of k is independently 0, 1, 2, or 3; and each instance of the latent-fluoride moiety comprises one or more through covalent bonds a, wherein each covalent bond a is cleavable in the presence of a degradation composition comprising one or more nucleophiles, one or more bases, or a combination thereof; provided that: at least one instance of the first monomer and/or at least one instance of the second monomer comprises at least one instance of the latent-fluoride moiety; and any two instances of the first monomer are the same as or different from each other, any two instances of the second monomer are the same as or different from each other, any two instances of the third monomer are the same as or different from each other, and each instance of the first monomer, the second monomer, and the third monomer if present, is different from each other. In certain embodiments, “at least one instance” is each instance. In certain embodiments, at least one instance of the first monomer is of Formula (A): or salt thereof, wherein each instance of Z is independently C(R P ) 2 or O; each instance of R P is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; each instance of is independently a single bond or double bond; each instance of R H is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, –OR a , –OCN, –OC(=O)R a , –OC(=S)R a , – OC(=O)OR a , –OC(=O)N(R a ) 2 ,–OS(=O)R a , –OS(=O)OR a , –OS(=O)N(R a ) 2 , –OS(=O) 2 R a , – OS(=O) 2 OR a , –OS(=O) 2 N(R a ) 2 , –OSi(R a ) 3 , –OSi(R a ) 2 (OR a ), –OSi(R a )(OR a ) 2 , –OSi(OR a ) 3 , oxo, – N(R a ) 2 , –N=C(R a ) 2 , =NR a , –NC, –NCO, –N 3 , –NO 2 , –NR a C(=O)R a , –NR a C(=O)OR a , – NR a C(=O)N(R a ) 2 , –NR a S(=O)R a , –NR a S(=O)OR a , –NR a S(=O)N(R a ) 2 , –NR a S(=O) 2 R a , – NR a S(=O) 2 OR a , –NR a S(=O) 2 N(R a ) 2 , –SR a , –SCN, –S(=O)R a , –S(=O)OR a , –S(=O)N(R a ) 2 , – S(=O) 2 R a , –S(=O) 2 OR a , –S(=O) 2 N(R a ) 2 , –SeR a , –CN, –C(=NR a )R a , –C(=NR a )OR a , – C(=NR a )N(R a ) 2 , –C(=O)R a , –C(=O)OR a , –C(=O)SR a , –C(=S)OR a , –C(=O)N(R a ) 2 , or a latent- fluoride moiety; or the two instances of R H of one or more instances of are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring, optionally wherein at least one substituent of at least one instance of the substituted monocyclic carbocyclic ring, substituted monocyclic heterocyclic ring, substituted monocyclic aryl ring, or substituted monocyclic heteroaryl ring is a latent-fluoride moiety; each instance of R a is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R a are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl; and each instance of the latent-fluoride moiety comprises one or more through covalent bonds a, wherein each covalent bond a is cleavable in the presence of a degradation composition comprising one or more nucleophiles, one or more bases, or a combination thereof. In certain embodiments, the two instances of R H of one or more instances of are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic heterocyclic ring, wherein at least one substituent of at least one instance of the substituted monocyclic carbocyclic ring, substituted monocyclic heterocyclic ring, substituted monocyclic aryl ring, or substituted monocyclic heteroaryl ring is a latent-fluoride moiety. In certain embodiments, the two instances of R H of one or more instances of are joined with the intervening carbon atoms to independently form a substituted monocyclic heterocyclic ring, wherein at least one substituent of at least one instance of the substituted monocyclic heterocyclic is a latent-fluoride moiety. In certain embodiments, at least one instance of R H is H. In certain embodiments, at least one instance of R H is substituted or unsubstituted alkyl (e.g., –CF 3 ). In certain embodiments, at least one instance of R H is –CN. In certain embodiments, at least one instance of R H is – C(=O)OR a (e.g., –C(=O)OCH3). In certain embodiments, at least one instance of R H is – C(=O)R a . In certain embodiments, at least one instance of R H is –C(=O)N(R a ) 2 . In certain embodiments, at least one instance of the first monomer is of the formula: late n t-fluoride moiety , or salt thereof, wherein each instance of L X is independently a single bond, substituted or unsubstituted, C 1-10 alkylene, substituted or unsubstituted, C 2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof. In certain embodiments, at least one instance of the first monomer is of the formula: , or a salt thereof. In certain embodiments, at least one instance of the first monomer is of the formula: . In certain embodiments, at least one instance of the first monomer is of the formula: or salt thereof. In certain embodiments, at least one instance of the first monomer is of the formula: , or salt thereof, wherein each instance of g is independently 0, 1, or 2. In certain embodiments, at least one instance of In certain embodiments, at least one instance of the first monomer is of the formula: or salt thereof. In certain embodiments, at least one is . In certain embodiments, at least one In certain embodiments, at least one instance of L X is a single bond or substituted or unsubstituted, C 1-10 alkylene. In certain embodiments, at least one instance of L X is a single bond. In certain embodiments, at least one instance of L X is substituted or unsubstituted, C 2-10 heteroalkylene. In certain embodiments, at least one instance of the first monomer is of the formula: In certain embodiments, at least one instance of the first monomer is of the formula: or salt thereof. In certain embodiments, at least one instance of the first monomer is of Formula (D1): (D1), or a salt thereof. In certain embodiments, each instance of the first monomer is of Formula (D1), or a salt thereof. In certain embodiments, at least one instance of the first monomer is of the formula: . In certain embodiments, each instance of the first monomer is of the formula: . In certain embodiments, each instance of the first monomer is of the formula: . In certain embodiments, at least one instance of the first monomer is of Formula (D2): or a salt thereof, wherein: each instance of x is independently 0, 1, or 2; and each instance of y is independently 0, 1, or 2. In certain embodiments, each instance of the first monomer is of Formula (D2), or a salt thereof. In certain embodiments, each instance of x is 0. In certain embodiments, each instance of x is 1. In certain embodiments, each instance of x is 2. In certain embodiments, each instance of y is 1. In certain embodiments, each instance of y is 0. In certain embodiments, each instance of y is 2. In certain embodiments, each instance of x is 1, and each instance of y is 1. In certain embodiments, each instance of x is 1, and each instance of y is 0. In certain embodiments, each instance of x is 0, and each instance of y is 1. In certain embodiments, at least one instance of the first monomer is of the formula: preferably In certain embodiments, each instance of the first monomer is of the formula: . In certain embodiments, each instance of the first monomer is of the formula: . In certain embodiments, each instance of the first monomer is of the formula: . In certain embodiments, at least one instance of the first monomer comprises one non- aromatic C=C or non-aromatic C≡C bond. In certain embodiments, at least one instance of the first monomer comprises two, three, or four non-aromatic C=C and/or non-aromatic C≡C bonds. In certain embodiments, at least one instance of the first monomer comprises two (i.e., only two) non-aromatic C=C and/or non-aromatic C≡C bonds. In certain embodiments, at least one instance of the first monomer comprises only three non-aromatic C=C and/or non-aromatic C≡C bonds (i.e., the combined number of non-aromatic C=C bonds and non-aromatic C≡C bonds is three). In certain embodiments, at least one instance of the first monomer comprises no C≡C bonds. In certain embodiments, at least one instance of the second monomer is of the formula: or a salt thereof. In certain embodiments, at least one instance of the second monomer is of the formula: , or a salt thereof. In certain embodiments, at least one instance of the second monomer is of the formula: or salt thereof. In certain embodiments, at least one instance of the second monomer is of the formula:

, or salt thereof, wherein each instance of g is independently 0, 1, or 2. In certain embodiments, at least one instance of the second monomer is of the formula: , or salt thereof. In certain embodiments, at least one instance of the second monomer is of the formula: , or a salt thereof. In certain embodiments, at least one instance of the second monomer is of the formula: latent-fluoride moiety , or a salt thereof. In certain embodiments, at least one instance of L K1 is a single bond or substituted or unsubstituted, C 1-10 alkylene. In certain embodiments, at least one instance of L K1 is a single bond. In certain embodiments, at least one instance of L K1 is substituted or unsubstituted, C 2-10 heteroalkylene. In certain embodiments, at least one instance of L K1 is –O– or substituted or unsubstituted, C 1-10 alkylene. In certain embodiments, at least one instance of L K1 is substituted or unsubstituted phenylene. In certain embodiments, Y is O. In certain embodiments, Y is CH 2 . In certain embodiments, at least one instance of R Y is hydrogen. In certain embodiments, at least one instance of R Y is unsubstituted C 1-6 alkyl (e.g., Me). In certain embodiments, at least one instance of R Z is hydrogen. In certain embodiments, at least one instance of R Z is unsubstituted C 1-6 alkyl (e.g., Me). In certain embodiments, the at least one C=C and/or the at least one C≡C is a non- aromatic bond. In certain embodiments, at least one instance of R K1 is substituted or unsubstituted, C 1-10 alkyl. In certain embodiments, at least one instance of R K1 is unsubstituted methyl, unsubstituted ethyl, unsubstituted propyl (e.g., unsubstituted n-propyl or unsubstituted isopropyl), or unsubstituted butyl (e.g., unsubstituted n-butyl). In certain embodiments, at least one instance of R K1 is substituted or unsubstituted, saturated carbocyclyl. In certain embodiments, at least one instance of R K1 is unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or unsubstituted cycloheptyl. In certain embodiments, at least one instance of R K1 is substituted or unsubstituted, partially unsaturated carbocyclyl. In certain embodiments, at least one instance of R K1 is substituted or unsubstituted carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system. In certain embodiments, at least one instance of R K1 is unsubstituted cyclobutenyl, unsubstituted cyclopentenyl, unsubstituted cyclohexenyl, or unsubstituted cycloheptenyl. In certain embodiments, at least one instance of R K1 is substituted or unsubstituted carbocyclyl that comprises only two unsaturated bonds in the carbocyclic ring system. In certain embodiments, at least one instance of R K1 is substituted or unsubstituted carbocyclyl that comprises no C≡C bonds in the carbocyclic ring system. In certain embodiments, at least one instance of R K1 is: wherein: Ring B’, wherein Ring B’ is a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring; Z’ is C(R P’ ) 2 or O; each instance of R P’ is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; is a single bond or double bond; each instance of R H’ is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, –OR a , –OCN, –OC(=O)R a , –OC(=S)R a , – OC(=O)OR a , –OC(=O)N(R a ) 2 ,–OS(=O)R a , –OS(=O)OR a , –OS(=O)N(R a ) 2 , –OS(=O) 2 R a , – OS(=O) 2 OR a , –OS(=O) 2 N(R a ) 2 , –OSi(R a ) 3 , –OSi(R a ) 2 (OR a ), –OSi(R a )(OR a ) 2 , –OSi(OR a ) 3 , oxo, – N(R a ) 2 , –N=C(R a ) 2 , =NR a , –NC, –NCO, –N 3 , –NO 2 , –NR a C(=O)R a , –NR a C(=O)OR a , – NR a C(=O)N(R a ) 2 , –NR a S(=O)R a , –NR a S(=O)OR a , –NR a S(=O)N(R a ) 2 , –NR a S(=O) 2 R a , – NR a S(=O) 2 OR a , –NR a S(=O) 2 N(R a ) 2 , –SR a , –SCN, –S(=O)R a , –S(=O)OR a , –S(=O)N(R a ) 2 , – S(=O) 2 R a , –S(=O) 2 OR a , –S(=O) 2 N(R a ) 2 , ,–SeR a , halogen, –CN, –C(=NR a )R a , –C(=NR a )OR a , – C(=NR a )N(R a ) 2 , –C(=O)R a , –C(=O)OR a , –C(=O)SR a , –C(=S)OR a , or –C(=O)N(R a ) 2 ; or the two instances of R H’ are joined with the intervening carbon atoms to form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring; and each instance of R a is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R a are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl. In certain embodiments, at least one instance of R K1 is: In certain embodiments, Ring B’ is substituted or unsubstituted, monocyclic carbocyclic ring. In certain embodiments, Ring B’ is substituted or unsubstituted, monocyclic, saturated carbocyclyl. In certain embodiments, Ring B’ is unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or unsubstituted cycloheptyl. In certain embodiments, Ring B’ is substituted or unsubstituted, monocyclic, partially unsaturated carbocyclyl. In certain embodiments, Ring B’ is substituted or unsubstituted, monocyclic carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system. In certain embodiments, Ring B’ is unsubstituted cyclobutenyl, unsubstituted cyclopentenyl, unsubstituted cyclohexenyl, or unsubstituted cycloheptenyl. In certain embodiments, Ring B’ is substituted or unsubstituted, monocyclic carbocyclyl that comprises only two unsaturated bonds in the carbocyclic ring system. In certain embodiments, Ring B’ is substituted or unsubstituted, monocyclic carbocyclyl that comprises no C≡C bonds in the carbocyclic ring system. In certain embodiments, Z’ is CH 2 . In certain embodiments, each R H’ is hydrogen. In certain embodiments, two instances of R H’ are joined with the intervening carbon atoms to form an unsubstituted monocyclic carbocyclic ring. In certain embodiments, two instances of R H’ are joined with the intervening carbon atoms to form an unsubstituted monocylic heterocyclic ring. In certain embodiments, at least one instance of R K1 is . In certain embodiments, at least one instance of R K1 is –(substituted or unsubstituted, C 1- 10 alkylene)–(substituted or unsubstituted, partially unsaturated carbocyclyl). In certain embodiments, at least one instance of R K1 is –(unsubstituted C 1-10 alkylene)–(substituted or unsubstituted carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system). In certain embodiments, at least one instance of R K1 is substituted or unsubstituted heterocyclyl or –L K1 –(substituted or unsubstituted heterocyclyl). In certain embodiments, at least one instance of R K1 is substituted or unsubstituted heterocyclyl that comprises O–Si in the heterocyclic ring system or –L K1 –(substituted or unsubstituted heterocyclyl that comprises O–Si in the heterocyclic ring system). In certain embodiments, at least one instance of R K1 is – (substituted or unsubstituted, C 1-10 alkylene)–(substituted or unsubstituted heterocyclyl). In certain embodiments, at least one instance of R K1 is –(substituted or unsubstituted, C 1-10 alkylene)–(substituted or unsubstituted heterocyclyl that comprises O–Si in the heterocyclic ring system). In certain embodiments, at least one instance of R K1 is –(substituted or unsubstituted phenylene)–(substituted or unsubstituted, partially unsaturated heterocyclyl). In certain embodiments, at least one instance of R K1 is –(substituted or unsubstituted phenylene)– (substituted or unsubstituted heterocyclyl that comprises only one unsaturated bond in the heterocyclic ring system). In certain embodiments, at least one instance of R K1 is –(substituted or unsubstituted phenylene)–(substituted or unsubstituted, partially unsaturated heterocyclyl that comprises O–Si in the heterocyclic ring system). In certain embodiments, at least one instance of R K1 is –(substituted or unsubstituted phenylene)–(substituted or unsubstituted heterocyclyl that comprises O–Si and only one unsaturated bond in the heterocyclic ring system). In certain embodiments, at least one instance of R K1 is In certain embodiments, at least one instance of R K1 is In certain embodiments, at least one instance of R K1 is hydrogen. In certain embodiments, at least one instance of R K1 is –OR N1 (e.g., –O(substituted or unsubstituted, C 1-10 alkyl)). In certain embodiments, at least one first instance of R K of a second monomer is –OR N (e.g., –O(substituted or unsubstituted, C 1-10 alkyl)). In certain embodiments, at least one instance of R N1 is substituted or unsubstituted, C 1-10 alkyl. In certain embodiments, at least one instance of R N1 is unsubstituted C 1-6 alkyl. In certain embodiments, at least one instance of R K2 is substituted or unsubstituted, saturated carbocyclyl. In certain embodiments, at least one instance of R K2 is unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or unsubstituted cycloheptyl. In certain embodiments, at least one instance of R K2 is substituted or unsubstituted, partially unsaturated carbocyclyl. In certain embodiments, at least one instance of R K2 is substituted or unsubstituted carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system. In certain embodiments, at least one instance of R K2 is unsubstituted cyclobutenyl, unsubstituted cyclopentenyl, unsubstituted cyclohexenyl, or unsubstituted cycloheptenyl. In certain embodiments, at least one instance of R K2 is substituted or unsubstituted carbocyclyl that comprises only two unsaturated bonds in the carbocyclic ring system. In certain embodiments, at least one instance of R K2 is substituted or unsubstituted carbocyclyl that comprises no C≡C bonds in the carbocyclic ring system. In certain embodiments, at least one instance of R K2 is: wherein: is Ring B”, wherein Ring B” is a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring; Z” is C(R P” ) 2 or O; each instance of R P” is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; is a single bond or double bond; each instance of R H” is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, –OR a , –OCN, –OC(=O)R a , –OC(=S)R a , – OC(=O)OR a , –OC(=O)N(R a ) 2 ,–OS(=O)R a , –OS(=O)OR a , –OS(=O)N(R a ) 2 , –OS(=O) 2 R a , – OS(=O) 2 OR a , –OS(=O) 2 N(R a ) 2 , –OSi(R a ) 3 , –OSi(R a ) 2 (OR a ), –OSi(R a )(OR a ) 2 , –OSi(OR a ) 3 , oxo, – N(R a ) 2 , –N=C(R a ) 2 , =NR a , –NC, –NCO, –N 3 , –NO 2 , –NR a C(=O)R a , –NR a C(=O)OR a , – NR a C(=O)N(R a ) 2 , –NR a S(=O)R a , –NR a S(=O)OR a , –NR a S(=O)N(R a ) 2 , –NR a S(=O) 2 R a , – NR a S(=O) 2 OR a , –NR a S(=O) 2 N(R a ) 2 , –SR a , –SCN, –S(=O)R a , –S(=O)OR a , –S(=O)N(R a ) 2 , – S(=O) 2 R a , –S(=O) 2 OR a , –S(=O) 2 N(R a ) 2 , ,–SeR a , halogen, –CN, –C(=NR a )R a , –C(=NR a )OR a , – C(=NR a )N(R a ) 2 , –C(=O)R a , –C(=O)OR a , –C(=O)SR a , –C(=S)OR a , or –C(=O)N(R a ) 2 ; or the two instances of R H” are joined with the intervening carbon atoms to form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring; and each instance of R a is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R a are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl. In certain embodiments, at least one instance of R K2 is: In certain embodiments, Ring B” is substituted or unsubstituted, monocyclic carbocyclic ring. In certain embodiments, Ring B” is substituted or unsubstituted, monocyclic, saturated carbocyclyl. In certain embodiments, Ring B” is unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or unsubstituted cycloheptyl. In certain embodiments, Ring B” is substituted or unsubstituted, monocyclic, partially unsaturated carbocyclyl. In certain embodiments, Ring B” is substituted or unsubstituted, monocyclic carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system. In certain embodiments, Ring B” is unsubstituted cyclobutenyl, unsubstituted cyclopentenyl, unsubstituted cyclohexenyl, or unsubstituted cycloheptenyl. In certain embodiments, Ring B” is substituted or unsubstituted, monocyclic carbocyclyl that comprises only two unsaturated bonds in the carbocyclic ring system. In certain embodiments, Ring B” is substituted or unsubstituted, monocyclic carbocyclyl that comprises no C≡C bonds in the carbocyclic ring system. In certain embodiments, Z” is CH 2 . In certain embodiments, each R H” is hydrogen. In certain embodiments, two instances of R H” are joined with the intervening carbon atoms to form an unsubstituted monocyclic carbocyclic ring. In certain embodiments, two instances of R H” are joined with the intervening carbon atoms to form an unsubstituted monocylic heterocyclic ring. In certain embodiments, at least one instance of R K2 is In certain embodiments, at least one instance of R K2 is –(substituted or unsubstituted, C 1- 10 alkylene)–(substituted or unsubstituted, partially unsaturated carbocyclyl). In certain embodiments, at least one instance of R K2 is –(unsubstituted C 1-10 alkylene)–(substituted or unsubstituted carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system). In certain embodiments, at least one instance of R K2 is substituted or unsubstituted heterocyclyl or –L K2 –(substituted or unsubstituted heterocyclyl). In certain embodiments, at least one instance of R K2 is substituted or unsubstituted heterocyclyl that comprises O–Si in the heterocyclic ring system or –L K2 –(substituted or unsubstituted heterocyclyl that comprises O–Si in the heterocyclic ring system). In certain embodiments, at least one instance of R K2 is – (substituted or unsubstituted, C 1-10 alkylene)–(substituted or unsubstituted heterocyclyl). In certain embodiments, at least one instance of R K2 is –(substituted or unsubstituted, C 1-10 alkylene)–(substituted or unsubstituted heterocyclyl that comprises O–Si in the heterocyclic ring system). In certain embodiments, at least one instance of R K2 is –(substituted or unsubstituted phenylene)–(substituted or unsubstituted, partially unsaturated heterocyclyl). In certain embodiments, at least one instance of R K2 is –(substituted or unsubstituted phenylene)– (substituted or unsubstituted heterocyclyl that comprises only one unsaturated bond in the heterocyclic ring system). In certain embodiments, at least one instance of R K2 is –(substituted or unsubstituted phenylene)–(substituted or unsubstituted, partially unsaturated heterocyclyl that comprises O–Si in the heterocyclic ring system). In certain embodiments, at least one instance of R K2 is –(substituted or unsubstituted phenylene)–(substituted or unsubstituted heterocyclyl that comprises O–Si and only one unsaturated bond in the heterocyclic ring system). In certain embodiments, at least one instance of R K2 is In certain embodiments, at least one instance of R K2 is , , , In certain embodiments, at least one instance of R K2 is hydrogen. In certain embodiments, at least one instance of R K2 is –OR N2 (e.g., –O(substituted or unsubstituted, C 1-10 alkyl)). In certain embodiments, at least one instance of R N2 is substituted or unsubstituted, C 1-10 alkyl. In certain embodiments, at least one instance of R N2 is unsubstituted C 1-6 alkyl. In certain embodiments, at least one instance of L K2 is –O– or substituted or unsubstituted, C 1-10 alkylene. In certain embodiments, at least one instance of L K2 is unsubstituted C 1-6 alkylene. In certain embodiments, at least one instance of L K2 is substituted or unsubstituted phenylene. In certain embodiments, at least one second instance of R K of the second monomer is substituted or unsubstituted, C 1-10 alkyl. In certain embodiments, at least one second instance of R K of the second monomer is unsubstituted methyl, unsubstituted ethyl, unsubstituted propyl (e.g., unsubstituted n-propyl or unsubstituted isopropyl), or unsubstituted butyl (e.g., unsubstituted n-butyl). In certain embodiments, at least one second instance of R K of the second monomer is substituted or unsubstituted phenyl. In certain embodiments, at least one second instance of R K of the second monomer is –OR N (e.g., –O(substituted or unsubstituted, C 1-10 alkyl)). In certain embodiments, R K1 and R K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted, partially unsaturated carbocyclyl. In certain embodiments, R K1 and R K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted, monocyclic carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system. In certain embodiments, R K1 and R K2 of at least one instance of the second monomer are joined with the intervening atom to form unsubstituted cyclobutenyl, unsubstituted cyclopentenyl, unsubstituted cyclohexenyl, or unsubstituted cycloheptenyl. In certain embodiments, R K1 and R K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted, monocyclic carbocyclyl that comprises only two unsaturated bonds in the carbocyclic ring system. In certain embodiments, R K1 and R K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted carbocyclyl that comprises no C≡C bonds in the carbocyclic ring system. In certain embodiments, R K1 and R K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted, partially unsaturated heterocyclyl. In certain embodiments, R K1 and R K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted, monocyclic heterocyclyl that comprises only one unsaturated bond in the heterocyclic ring system. In certain embodiments, R K1 and R K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted, monocyclic heterocyclyl that comprises only two unsaturated bonds in the heterocyclic ring system. In certain embodiments, R K1 and R K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted heterocyclyl that comprises no C≡C bonds in the heterocyclic ring system. In certain embodiments, at least one instance of the second monomer comprises only one non-aromatic unsaturated bond. In certain embodiments, each instance of the second monomer comprises only one non-aromatic unsaturated bond. In certain embodiments, at least one instance of the second monomer comprises only two non-aromatic unsaturated bonds. In certain embodiments, the C=C bond in the heterocyclic ring that comprises O–Si–Y is of the (Z)-configuration. In certain embodiments, the C=C bond in the heterocyclic ring that comprises O–Si–Y is of the (E)-configuration. In certain embodiments, j is 1. In certain embodiments, j is 2. In certain embodiments, j is 3. In certain embodiments, k is 1. In certain embodiments, k is 2. In certain embodiments, k is 3. In certain embodiments, k is 0. In certain embodiments, j is 1, and k is 1. In certain embodiments, j is 1, and k is 2. In certain embodiments, j is 1, and k is 2 or 3. In certain embodiments, j is 2, and k is 1. In certain embodiments, at least one instance of the second monomer is of the formula: , or a salt thereof, wherein: each instance of h is independently an integer between 0 and 10, inclusive; and each instance of R K2 is independently substituted or unsubstituted, C 1-10 alkyl; preferably unsubstituted C 1-10 alkyl. In certain embodiments, at least one instance of the second monomer is of the formula: . In certain embodiments, at least one instance of the second monomer is of the formula: O , In certain embodiments, at least one instance of the second monomer is of the formula: In certain embodiments, at least one instance of the second monomer is of the formula: . In certain embodiments, at least one instance of the third monomer is of Formula (C): or salt thereof, wherein each instance of Z is independently C(R P ) 2 or O; each instance of R P is independently hydrogen, halogen, or substituted or unsubstituted, C 1-6 alkyl; each instance of is independently a single bond or double bond; each instance of R G is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, –OR a , –OCN, –OC(=O)R a , –OC(=S)R a , – OC(=O)OR a , –OC(=O)N(R a ) 2 ,–OS(=O)R a , –OS(=O)OR a , –OS(=O)N(R a ) 2 , –OS(=O) 2 R a , – OS(=O) 2 OR a , –OS(=O) 2 N(R a ) 2 , –OSi(R a ) 3 , –OSi(R a ) 2 (OR a ), –OSi(R a )(OR a ) 2 , –OSi(OR a ) 3 , oxo, – N(R a ) 2 , –N=C(R a ) 2 , =NR a , –NC, –NCO, –N 3 , –NO 2 , –NR a C(=O)R a , –NR a C(=O)OR a , – NR a C(=O)N(R a ) 2 , –NR a S(=O)R a , –NR a S(=O)OR a , –NR a S(=O)N(R a ) 2 , –NR a S(=O) 2 R a , – NR a S(=O)2OR a , –NR a S(=O)2N(R a )2, –SR a , –SCN, –S(=O)R a , –S(=O)OR a , –S(=O)N(R a )2, – S(=O) 2 R a , –S(=O) 2 OR a , –S(=O) 2 N(R a ) 2 , –SeR a , –CN, –C(=NR a )R a , –C(=NR a )OR a , – C(=NR a )N(R a ) 2 , –C(=O)R a , –C(=O)OR a , –C(=O)SR a , –C(=S)OR a , –C(=O)N(R a ) 2 , or a latent- fluoride moiety; or the two instances of R G of one or more instances of are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring, optionally wherein at least one substituent on the monocyclic, carbocyclic, heterocyclic, aryl, or heteroaryl ring is substituted or unsubstituted, C 1 - 1000 alkyl, substituted or unsubstituted, C 2 - 1000 alkenyl, substituted or unsubstituted, C 2 - 1000 alkynyl, substituted or unsubstituted, C 1 - 1000 heteroalkyl, substituted or unsubstituted, C 2 - 1000 heteroalkenyl, substituted or unsubstituted, C 2 - 1000 heteroalkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, – C(=NR a )R a , –C(=NR a )OR a , –C(=NR a )N(R a ) 2 , –C(=O)R a , –C(=O)OR a , –C(=O)N(R a ) 2 , or a nitrogen protecting group when attached to a nitrogen atom; and each instance of R a is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R a are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl. In certain embodiments, the two instances of R G of one or more instances of are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring, optionally wherein at least one substituent on the monocyclic, carbocyclic, heterocyclic, aryl, or heteroaryl ring is substituted or unsubstituted, C 1 - 1000 alkyl, substituted or unsubstituted, C 2 - 1000 alkenyl, substituted or unsubstituted, C 2 - 1000 alkynyl, substituted or unsubstituted, C 1 - 1000 heteroalkyl, substituted or unsubstituted, C 2 - 1000 heteroalkenyl, substituted or unsubstituted, C 2 - 1000 heteroalkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, –C(=NR a )R a , –C(=NR a )OR a , –C(=NR a )N(R a ) 2 , – C(=O)R a , –C(=O)OR a , –C(=O)N(R a ) 2 , or a nitrogen protecting group when attached to a nitrogen atom. In certain embodiments, the two instances of R G of one or more instances of are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, or substituted or unsubstituted, monocyclic heterocyclic ring, optionally wherein at least one substituent on the monocyclic, carbocyclic or heterocyclic ring is substituted or unsubstituted, C 1 - 1000 alkyl or substituted or unsubstituted, C 1 - 1000 heteroalkyl. In certain embodiments, at least one instance of the third monomer is of the formula: , or salt thereof, wherein each instance of R X is independently substituted or unsubstituted, C 1 - 1000 alkyl, substituted or unsubstituted, C 2 - 1000 alkenyl, substituted or unsubstituted, C 2 - 1000 alkynyl, substituted or unsubstituted, C 1 - 1000 heteroalkyl, substituted or unsubstituted, C 2 - 1000 heteroalkenyl, substituted or unsubstituted, C 2 - 1000 heteroalkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, –C(=NR a )R a , –C(=NR a )OR a , –C(=NR a )N(R a ) 2 , – C(=O)R a , –C(=O)OR a , –C(=O)N(R a ) 2 , or a nitrogen protecting group. In certain embodiments, at least one R X is substituted or unsubstituted, C 1 - 1000 alkyl or substituted or unsubstituted, C 1 - 1000 heteroalkyl. In certain embodiments, at least one R X is substituted or unsubstituted, C 1 - 10 alkyl. In certain embodiments, at least one R X is substituted or unsubstituted, C 11 - 18 alkyl. In certain embodiments, at least one R X is substituted or unsubstituted, C 19 - 100 alkyl. In certain embodiments, at least one R X is substituted or unsubstituted, C 101 - 1000 alkyl. In certain embodiments, at least one R X is substituted or unsubstituted, C 1 - 10 heteroalkyl. In certain embodiments, at least one R X is substituted or unsubstituted, C 2 - 10 heteroalkyl. In certain embodiments, at least one R X is substituted or unsubstituted, C 11 - 18 heteroalkyl. In certain embodiments, at least one R X is substituted or unsubstituted, C 19 - 100 heteroalkyl. In certain embodiments, at least one R X is substituted or unsubstituted, C 101 - 1000 heteroalkyl. In certain embodiments, at least one R X is C 1 - 1000 alkyl substituted with one or more fluoro. In certain embodiments, at least one R X is C 1 - 10 , C 11 - 18 , C 19 - 100 , or C 101 - 1000 , alkyl substituted with one or more fluoro. In certain embodiments, at least one R X is , wherein: n is an integer from 1 to 300, inclusive; and R F is hydrogen, substituted or unsubstituted, C 1-6 alkyl, or an oxygen protecting group. In certain embodiments, n is an integer between 1 and 3, between 3 and 10, between 10 and 30, between 30 and 100, or between 100 and 300, inclusive. In certain embodiments, R F is unsubstituted C 1-6 alkyl (e.g., Me). In certain embodiments, at least one instance of R G is hydrogen. In certain embodiments, at least one instance of R G is substituted or unsubstituted alkyl (e.g., –CF 3 ). In certain embodiments, at least one instance of R G is –CN. In certain embodiments, at least one instance of R G is –C(=O)OR a (e.g., –C(=O)OCH 3 ). In certain embodiments, at least one instance of R G is – C(=O)R a . In certain embodiments, at least one instance of R G is –C(=O)N(R a ) 2 . In certain embodiments, at least one instance of the third monomer is of the formula: Z Z R G G G G R or R R . In certain embodiments, at least one instance of the third monomer is of the formula: Z R G RG , or salt thereof. In certain embodiments, at least one instance of the third monomer is of Formula (D1): (D1), or a salt thereof. In certain embodiments, each instance of the third monomer is of Formula (D1), or a salt thereof. In certain embodiments, at least one instance of the third monomer is of the formula: . In certain embodiments, each instance of the third monomer is of the formula: . In certain embodiments, each instance of the third monomer is of the formula: . In certain embodiments, at least one instance of the third monomer is of Formula (D2): or a salt thereof, wherein: each instance of x is independently 0, 1, or 2; and each instance of y is independently 0, 1, or 2. In certain embodiments, each instance of the third monomer is of Formula (D2), or a salt thereof. In certain embodiments, at least one instance of the third monomer is of the formula: preferably In certain embodiments, each instance of the third monomer is of the formula: . In certain embodiments, each instance of the third monomer is of the formula: . In certain embodiments, each instance of the third monomer is of the formula: . In certain embodiments, at least one instance of the third monomer comprises one non- aromatic C=C or non-aromatic C≡C bond. In certain embodiments, at least one instance of the third monomer comprises two, three, or four non-aromatic C=C and/or non-aromatic C≡C bonds. In certain embodiments, at least one instance of the third monomer comprises two (i.e., only two) non-aromatic C=C and/or non-aromatic C≡C bonds. In certain embodiments, at least one instance of the third monomer comprises only three non-aromatic C=C and/or non-aromatic C≡C bonds (i.e., the combined number of non-aromatic C=C bonds and non-aromatic C≡C bonds is three). In certain embodiments, at least one instance of the third monomer comprises no C≡C bonds. In certain embodiments, at least one instance of Z is C(R P ) 2 . In certain embodiments, at least one instance of Z is CH 2 . In certain embodiments, at least one covalent bond a is cleavable in the presence of the degradation composition through an intermolecular substitution reaction. In certain embodiments, each instance of is a single bond. In another aspect, the present disclosure provides a method of degrading a copolymer of any one of the preceding claims comprising contacting the copolymer with the degradation composition, wherein at least one covalent bond a is cleaved. In certain embodiments, the one or more nucleophiles, one or more bases, or combination thereof is the combination. In certain embodiments, at least one instance of the latent-fluoride moiety is –L– pentafluorophenyl, wherein each instance of L is independently a single bond, –O–, substituted or unsubstituted, C 1-10 alkylene, substituted or unsubstituted, C 2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof. In certain embodiments, at least one instance of L is a single bond. In certain embodiments, at least one instance of L is substituted or unsubstituted, C 1-10 alkylene. In certain embodiments, at least one instance of L is substituted or unsubstituted, C 2-10 heteroalkylene. In certain embodiments, at least one instance of the latent-fluoride moiety is pentafluorophenyl. In certain embodiments, at least one instance of the latent-fluoride moiety is –C(=O)F, – S(=O)F, or –S(=O) 2 F. In certain embodiments, at least one covalent bond a is cleavable in the presence of the degradation composition through an intramolecular substitution reaction. In certain embodiments, at least one instance of the latent-fluoride moiety is of the formula: , wherein g is 0, 1, or 2. In certain embodiments, at least one instance of is . In certain embodiments, at least one instance of is In certain embodiments, at least one covalent bond a is cleavable in the presence of the degradation composition through a Hofmann elimination reaction. In certain embodiments, at least one instance of the latent-fluoride moiety is –CHF–CH 3 . In certain embodiments, at least one instance of the first monomer comprises at least one instance of the latent-fluoride moiety. In certain embodiments, no instance of the first monomer comprises at least one instance of the latent-fluoride moiety. In certain embodiments, at least one instance of the second monomer comprises at least one instance of the latent-fluoride moiety. In certain embodiments, no instance of the second monomer comprises at least one instance of the latent-fluoride moiety. In certain embodiments, no instance of the third monomer comprises at least one instance of the latent-fluoride moiety. In certain embodiments, at least one instance of R X comprises at least one instance of the latent-fluoride moiety. In certain embodiments, at least one nucleophile is a thiol. In certain embodiments, at least one nucleophile is a thiol of the formula: R S –SH, and R S is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cysteine, a peptide, or a protein, wherein the peptide and protein comprise at least one cysteine optionally protected at the C or N terminus. In certain embodiments, at least one nucleophile is a thiol of the formula: R S –(substituted or unsubstituted alkyl). In certain embodiments, at least one nucleophile is C 2-12 alkanethiol, e.g., 1-n-octanethiol. In certain embodiments, at least one nucleophile is C 12-18 alkanethiol, e.g., 1-n- dodecanethiol. In certain embodiments, at least one nucleophile is C 2-4 n-alkanethiol. In certain embodiments, at least one nucleophile is C 5-7 n-alkanethiol. In certain embodiments, at least one nucleophile is C 8-12 n-alkanethiol. In certain embodiments, at least one nucleophile is C 13-18 n- alkanethiol. In certain embodiments, at least one nucleophile is cysteine, a peptide, or a protein, wherein the peptide and protein comprise at least one cysteine optionally protected at the C or N terminus. In certain embodiments, at least one base is an alkali metal carbonate, alkali metal bicarbonate, alkaline earth metal carbonate, or alkaline earth metal bicarbonate, e.g., Cs 2 CO 3 . In certain embodiments, at least one base is Li 2 CO 3 , Na 2 CO 3 , K 2 CO 3 , (NH 4 ) 2 CO 3 , MgCO 3 , CaCO 3 , LiHCO 3 , NaHCO 3 , KHCO 3 , CsHCO 3 , (NH 4 )HCO 3 , Mg(HCO 3 ) 2 , or Ca(HCO 3 ) 2 . In certain embodiments, at least one base is a non-aromatic amine or aromatic amine. In certain embodiments, at least one base comprises no primary or secondary nitrogen atoms. In certain embodiments, at least one base is a non-aromatic tertiary amine comprising no primary or secondary nitrogen atoms. In certain embodiments, at least one base is of the formula: N(unsubstituted alkyl) 3 . In certain embodiments, at least one base is a non-aromatic tertiary amine comprising no primary or secondary nitrogen atoms, wherein at least one tertiary nitrogen atom is a ring atom of a monocyclic or polycyclic cycloalkyl ring. In certain embodiments, at least one base is a non-nucleophilic organic base. In certain embodiments, at least one base is 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU); 1,5-diazabicyclo[4.3.0]non-5-ene (DBN); triethylamine, N,N-diisopropylethylamine (DIPEA); or 2,6-di-tert-butylpyridine. In certain embodiments, at least one base is 1,5,7- triazabicyclo(4.4.0)dec-5-ene (TBD), 7-methyl-1,5,7-triazabicyclo(4.4.0)dec-5-ene (MTBD), 1,1,3,3-tetramethylguanidine (TMG), quinuclidine, 2,2,6,6-tetramethylpiperidine (TMP), pempidine, tri-n-butlyamine, 1,4-diazabicyclo[2.2.2]octan (TED), collidine, or 2,6-lutidine. In certain embodiments, the degradation composition further comprises a solvent. In certain embodiments, the solvent is substantially one single solvent. In certain embodiments, the solvent is a mixture of two or more (e.g., three) solvents (e.g., solvents described in this paragraph). In certain embodiments, the solvent is an organic solvent. In certain embodiments, the solvent is a non-aromatic organic solvent. In certain embodiments, the solvent is an aprotic organic solvent comprising at least one heteroatom or a mixture of aprotic organic solvents independently comprising at least one heteroatom. In certain embodiments, the solvent is tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, cyclopentyl methyl ether, tert-butyl methyl ether, or a mixture thereof. In certain embodiments, the solvent is acetone, methyl ethyl ketone, methyl isopropyl ketone, 2-pentanone, 3-pentanone, or a mixture thereof. In certain embodiments, the solvent is acetonitrile. In certain embodiments, the solvent is N,N- dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, or a mixture thereof. In certain embodiments, the boiling point of the solvent at 1 atm is between 50 and 60, between 60 and 80, between 80 and 100, between 100 and 130, between 130 and 160, or between 160 and 200 °C, inclusive. In certain embodiments, the copolymer swells in the solvent at between 20 and 25 °C, inclusive, and 0.5 and 1.1 atm. In certain embodiments, the copolymer is substantively insoluble in the solvent at between 20 and 25 °C, inclusive, and 0.5 and 1.1 atm. In certain embodiments, at least one covalent bond a is cleavable in the presence of the degradation composition under physiological conditions. In certain embodiments, at least one covalent bond a is cleavable in the presence of the degradation composition at between 20 and 25 °C, inclusive, and 0.5 and 1.1 atm. In certain embodiments, the half life of at least one covalent bond a in the presence of at least one nucleophile at the concentration of about 1 molar and/or at least one base at the concentration of about 1 molar under physiological conditions is between 1 and 10 minutes, between 10 and 60 minutes, between 1 and 3 hours, between 3 and 8 hours, between 8 and 24 hours, between 1 and 3 days, or between 3 and 7 days, inclusive. In certain embodiments, the half life of at least one covalent bond a in the presence of at least one nucleophile at the concentration of about 1 molar and at least one base at the concentration of about 1 molar under physiological conditions is between 10 minutes and 8 hours, inclusive. In certain embodiments, the half life of at least one covalent bond a in the presence of at least one nucleophile at the concentration of about 1 molar and/or at least one base at the concentration of about 1 molar at between 20 and 25 °C, inclusive, and 0.5 and 1.1 atm is between 1 and 10 minutes, between 10 and 60 minutes, between 1 and 3 hours, between 3 and 8 hours, between 8 and 24 hours, between 1 and 3 days, or between 3 and 7 days, inclusive. In certain embodiments, the half life of at least one covalent bond a in the presence of at least one nucleophile at the concentration of about 1 molar and at least one base at the concentration of about 1 molar at between 20 and 25 °C, inclusive, and 0.5 and 1.1 atm is between 10 minutes and 8 hours, inclusive. In certain embodiments, the molar ratio of the one or more instances of the first monomer to the one or more instances of the second monomer is between 0.1:1 and 0.3:1, between 0.3:1 and 1:1, between 1:1 and 3:1, between 3:1 and 10:1, between 10:1 and 30:1, or between 30:1 and 100:1, inclusive; preferably between 0.3:1 and 10:1, inclusive. In certain embodiments, the molar ratio of the one or more instances of the first monomer to the one or more instances of the second monomer is between 0.6:1 and 6:1, inclusive. In certain embodiments, the molar ratio of the one or more instances of the first monomer to the one or more instances of the second monomer is between 1:1 and 4:1, inclusive. In certain embodiments, the step of polymerizing is ring-opening metathesis polymerization (ROMP). Metathesis catalysts include catalysts as described herein and as described in Grubbs et al., Acc. Chem. Res.1995, 28, 446–452; U.S. Pat. No.5,811,515; Schrock et al., Organometallics (1982) 11645; Gallivan et al., Tetrahedron Letters (2005) 46:2577–2580; Furstner et al., J. Am. Chem. Soc. (1999) 121:9453; and Chem. Eur. J. (2001) 7:5299; the entire contents of each of which are incorporated herein by reference. In certain embodiments, the metathesis catalyst is ring-opening metathesis catalyst. In certain embodiments, the metathesis catalyst is a tungsten metathesis catalyst, molybdenum metathesis catalyst, or ruthenium metathesis catalyst. In certain embodiments, the metathesis catalyst is a ruthenium metathesis catalyst. In certain embodiments, the metathesis catalyst is a Grubbs catalyst. In certain embodiments, the Grubbs catalyst is selected from the group consisting of: X = Cl; Br; I C y = cyclohexyl ; Benzylidenebis– (tricyclohexylphosphine)–dichlororuthenium (X = Cl); Benzylidenebis– (tricyclohexylphosphine)–dibromoruthenium (X = Br); Benzylidenebis– (tricyclohexylphosphine)–diiodoruthenium (X = I); X = Cl; Br; I R = cyclohexyl (Cy); phenyl (Ph); benzyl (Bn) ; 1,3–(Bis(mesityl)–2–imidazolidinylidene)dichloro–(ph enylmethylene) (tricyclohexyl– phosphine)ruthenium (X = Cl; R = cyclohexyl); 1,3–(Bis(mesityl)–2– imidazolidinylidene)dibromo–(phenylmethylene) (tricyclohexyl–phosphine)ruthenium (X = Br; R = cyclohexyl); 1,3–(Bis(mesityl)–2–imidazolidinylidene)diiodo–(phen ylmethylene) (tricyclohexyl–phosphine)ruthenium (X = I; R = cyclohexyl); 1,3–(Bis(mesityl)–2– imidazolidinylidene)dichloro–(phenylmethylene) (triphenylphosphine)ruthenium (X = Cl; R = phenyl); 1,3–(Bis(mesityl)–2–imidazolidinylidene)dichloro–(ph enylmethylene) (tribenzylphosphine)ruthenium (X = Cl; R = benzyl);

In certain embodiments, the metathesis catalyst is a Grubbs-Hoveyda catalyst. In certain embodiments, the Grubbs-Hoveyda catalyst is selected from the group consisting of: In certain embodiments, the metathesis catalyst is selected from the group consisting of: Blechart Catalyst; Neolyst TM M1; and Furstner Catalyst. In certain embodiments, the metathesis catalyst is of the formula: . The ROMP can be conducted in one or more aprotic solvents. The term “aprotic solvent” means a non-nucleophilic solvent having a boiling point range above ambient temperature, preferably from about 25 ºC to about 190 ºC at atmospheric pressure. In certain embodiments, the aprotic solvent has a boiling point from about 80 ºC to about 160 ºC at atmospheric pressure. In certain embodiments, the aprotic solvent has a boiling point from about 80 ºC to about 150 ºC at atmospheric pressure. Examples of such solvents are methylene chloride, acetonitrile, toluene, DMF, diglyme, THF, and DMSO. The ROMP can be quenched with a vinyl ether of the formula . Each of R V1 , R V2 , R V3 , and R V4 is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted phenyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl. In certain embodiments, R V1 is optionally substituted alkyl, and R V2 , R V3 , and R V4 are hydrogen. In certain embodiments, R V1 is unsubstituted alkyl, and R V2 , R V3 , and R V4 are hydrogen. In certain embodiments, R V1 is substituted alkyl, and R V2 , R V3 , and R V4 are hydrogen. In certain embodiments, R V1 is methyl, and R V2 , R V3 , and R V4 are hydrogen. In certain embodiments, R V1 is ethyl, and R V2 , R V3 , and R V4 are hydrogen. In certain embodiments, R V1 is propyl, and R V2 , R V3 , and R V4 are hydrogen. In certain embodiments, R V1 is optionally substituted alkenyl, and R V2 , R V3 , and R V4 are hydrogen. In certain embodiments, R V1 is unsubstituted alkenyl, and R V2 , R V3 , and R V4 are hydrogen. In certain embodiments, R V1 is vinyl, and R V2 , R V3 , and R V4 are hydrogen. In certain embodiments, at least one of R V1 , R V2 , R V3 , and R V4 is conjugated with a diagnostic agent as defined above. In certain embodiments, the ROMP is quenched by ethyl vinyl ether. Excess ethyl vinyl ether can be removed from the copolymer by vacuum. In certain embodiments, the molar ratio of the one or more instances of the third monomer, if present, to the one or more instances of the second monomer is between 0.3:1 and 1:1, between 1:1 and 3:1, between 3:1 and 10:1, between 10:1 and 30:1, between 30:1 and 100:1, or between 100:1 and 300:1, inclusive; preferably between 3:1 and 30:1, inclusive. In certain embodiments, the molar ratio of the one or more instances of the third monomer, if present, to the one or more instances of the second monomer is between 5:1 and 20:1, inclusive. In certain embodiments, the molar ratio of the combined amounts of the first monomer, second monomer, and third monomer if present to the amount of the metathesis catalyst is between 3:1 and 10:1, between 10:1 and 100:1, between 100:1 and 1,000:1, between 1,000:1 and 10,000:1, or between 10,000:1 and 100,000:1, inclusive; preferably between 10:1 and 1,000:1, inclusive. In certain embodiments, the molar ratio of the combined amounts of the first monomer, second monomer, and third monomer if present to the amount of the metathesis catalyst is between 30:1 and 100:1, between 100:1 and 300:1, between 300:1 and 1000:1, or between 1000:1 and 3000:1, inclusive. In certain embodiments, the copolymer is crosslinked, and the crosslinking degree is between 0.1% and 0.3%, between 0.3% and 1%, between 1% and 3%, between 3% and 10%, between 10% and 20%, or between 20% and 50%, inclusive, mole:mole; preferably, between 1% and 10%, inclusive, mole:mole. In certain embodiments, the copolymer is crosslinked, and the crosslinking degree is between 20% and 30%, between 30% and 40%, or between 40% and 50%, inclusive. In certain embodiments, the crosslinking degree is an average crosslinking degree determined by swelling measurements. In certain embodiments, the number-average molecular weight of the copolymer as determined by gel permeation chromatography is between 10 kDa and 100 kDa, between 100 kDa and 1,000 kDa, between 1,000 kDa and 10,000 kDa, or between 10,000 kDa and 100,000 kDa, inclusive. In certain embodiments, the copolymer is a block copolymer, preferably a block copolymer comprising at least four consecutive blocks, wherein: each of the first consecutive block and the third consecutive block independently comprises one or more repeating units formed from the first monomer or the third monomer if present; and each of the second consecutive block and the fourth consecutive block independently comprises one or more repeating units formed from the second monomer. In certain embodiments, the copolymer is a random copolymer. In certain embodiments, the step of polymerizing is substantially free of a chain transfer agent. In certain embodiments, the copolymer comprises one or more pharmaceutical agents, wherein the pharmaceutical agents are covalently attached to the copolymer. When the copolymer comprises one or more pharmaceutical agents, wherein the pharmaceutical agents are covalently attached to the copolymer, the copolymer, including the one or more pharmaceutical agents, may be referred to as a conjugate. The pharmaceutical agents include chemical compounds and mixtures of chemical compounds, e.g., small organic or inorganic molecules; saccharines; oligosaccharides; polysaccharides; biological macromolecules, e.g., peptides, proteins, and peptide analogs and derivatives; peptidomimetics; antibodies and antigen binding fragments thereof; nucleic acids; nucleic acid analogs and derivatives; an extract made from biological materials such as bacteria, plants, fungi, or animal cells; animal tissues; naturally occurring or synthetic compositions; and any combinations thereof. In certain embodiments, at least one of the pharmaceutical agents is a small molecule. In certain embodiments, at least one of the pharmaceutical agents is a protein or peptide. Exemplary pharmaceutical agents include, but are not limited to, those found in Harrison’s Principles of Internal Medicine , 13th Edition, Eds. T.R. Harrison et al. McGraw-Hill N.Y., NY; Physicians’ Desk Reference, 50th Edition, 1997, Oradell New Jersey, Medical Economics Co.; Pharmacological Basis of Therapeutics, 8th Edition, Goodman and Gilman, 1990; United States Pharmacopeia, The National Formulary, USP XII NF XVII, 1990; current edition of Goodman and Oilman’s The Pharmacological Basis of Therapeutics ; and current edition of The Merck Index , the complete contents of all of which are incorporated herein by reference. In certain embodiments, at least one of the pharmaceutical agents is a therapeutic agent. In certain embodiments, each instance of the pharmaceutical agent is a therapeutic agent. In some embodiments, exemplary therapeutic agents include, but are not limited to, one or more of the agents listed in Paragraph 0148 of U.S. Patent No.9,381,253, incorporated by reference herein. In other embodiments, exemplary therapeutic agents include, but are not limited to, one or more of the therapeutic agents listed in WO 2013/169739, including the anti-hypertensive and/or a collagen modifying agents (AHCM) disclosed, e.g., in Paragraphs 40-49, 283, 286-295; the microenviroment modulators disclosed, e.g., in Paragraphs 113-121, of WO 2013/169739, incorporated herein by reference. Examples of therapeutic agents also include, but are not limited to, antimicrobial agents, analgesics, antinflammatory agents, counterirritants, coagulation modifying agents, diuretics, sympathomimetics, anorexics, antacids and other gastrointestinal agents; antiparasitics, antidepressants, antihypertensives, anticholinergics, stimulants, antihormones, central and respiratory stimulants, drug antagonists, lipid-regulating agents, uricosurics, cardiac glycosides, electrolytes, ergot and derivatives thereof, expectorants, hypnotics and sedatives, antidiabetic agents, dopaminergic agents, antiemetics, muscle relaxants, para-sympathomimetics, anticonvulsants, antihistamines, beta-blockers, purgatives, antiarrhythmics, contrast materials, radiopharmaceuticals, antiallergic agents, tranquilizers, vasodilators, antiviral agents, and antineoplastic or cytostatic agents or other agents with anticancer properties, or a combination thereof. Other suitable therapeutic agents include contraceptives and vitamins as well as micro- and macronutrients. Still other examples include antiinfectives such as antibiotics and antiviral agents; analgesics and analgesic combinations; anorexics; antiheimintics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiuretic agents; antidiarrleals; antihistamines; antiinflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics, antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations including calcium channel blockers and beta-blockers such as pindolol and antiarrhythmics; antihypertensives; diuretics; vasodilators including general coronary, peripheral and cerebral; central nervous system stimulants; cough and cold preparations, including decongestants; hormones such as estradiol and other steroids, including corticosteroids; hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; psychostimulants; sedatives; and tranquilizers; and naturally derived or genetically engineered proteins, polysaccharides, glycoproteins, or lipoproteins. In certain embodiments, at least one of the pharmaceutical agents is an anti-cancer agent. Anti-cancer agents encompass biotherapeutic anti-cancer agents as well as chemotherapeutic agents. Exemplary biotherapeutic anti-cancer agents include, but are not limited to, interferons, cytokines (e.g., tumor necrosis factor, interferon α, interferon γ), vaccines, hematopoietic growth factors, monoclonal serotherapy, immunostimulants and/or immunodulatory agents (e.g., IL-1, 2, 4, 6, or 12), immune cell growth factors (e.g., GM-CSF) and antibodies (e.g., Herceptin (trastuzumab), T-DM1, AVASTIN (bevacizumab), ERBITUX (cetuximab), Vectibix (panitumumab), Rituxan (rituximab), Bexxar (tositumomab)). Exemplary chemotherapeutic agents include, but are not limited to, anti-estrogens (e.g., tamoxifen, raloxifene, and megestrol), LHRH agonists (e.g., goscrclin and leuprolide), anti-androgens (e.g., flutamide and bicalutamide), photodynamic therapies (e.g., vertoporfin (BPD-MA), phthalocyanine, photosensitizer Pc4, and demethoxy-hypocrellin A (2BA-2-DMHA)), nitrogen mustards (e.g., cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, estramustine, and melphalan), nitrosoureas (e.g., carmustine (BCNU) and lomustine (CCNU)), alkylsulphonates (e.g., busulfan and treosulfan), triazenes (e.g., dacarbazine, temozolomide), platinum containing compounds (e.g., cisplatin, carboplatin, oxaliplatin), vinca alkaloids (e.g., vincristine, vinblastine, vindesine, and vinorelbine), taxoids (e.g., paclitaxel or a paclitaxel equivalent) docosahexaenoic acid bound-paclitaxel (DHA-paclitaxel, Taxoprexin), polyglutamate bound-paclitaxel (PG-paclitaxel, paclitaxel poliglumex, CT-2103, XYOTAX), the tumor-activated prodrug (TAP) ANG1005 (Angiopep-2 bound to three molecules of paclitaxel), paclitaxel-EC-1 (paclitaxel bound to the erbB2-recognizing peptide EC-1), and glucose-conjugated paclitaxel, e.g., 2'-paclitaxel methyl 2- glucopyranosyl succinate; docetaxel, taxol), epipodophyllins (e.g., etoposide, etoposide phosphate, teniposide, topotecan, 9-aminocamptothecin, camptoirinotecan, irinotecan, crisnatol, mytomycin C), anti-metabolites, DHFR inhibitors (e.g., methotrexate, dichloromethotrexate, trimetrexate, edatrexate), IMP dehydrogenase inhibitors (e.g., mycophenolic acid, tiazofurin, ribavirin, and EICAR), ribonuclotide reductase inhibitors (e.g., hydroxyurea and deferoxamine), uracil analogs (e.g., 5-fluorouracil (5-FU), floxuridine, doxifluridine, ratitrexed, tegafur-uracil, capecitabine), cytosine analogs (e.g., cytarabine (ara C), cytosine arabinoside, and fludarabine), purine analogs (e.g., mercaptopurine and Thioguanine), Vitamin D3 analogs (e.g., EB 1089, CB 1093, and KH 1060), isoprenylation inhibitors (e.g., lovastatin), dopaminergic neurotoxins (e.g., 1-methyl-4-phenylpyridinium ion), cell cycle inhibitors (e.g., staurosporine), actinomycin (e.g., actinomycin D, dactinomycin), bleomycin (e.g., bleomycin A2, bleomycin B2, peplomycin), anthracycline (e.g., daunorubicin, doxorubicin, pegylated liposomal doxorubicin, idarubicin, epirubicin, pirarubicin, zorubicin, mitoxantrone), MDR inhibitors (e.g., verapamil), Ca 2+ ATPase inhibitors (e.g., thapsigargin), imatinib, thalidomide, lenalidomide, tyrosine kinase inhibitors (e.g., axitinib (AG013736), bosutinib (SKI-606), cediranib (RECENTIN TM , AZD2171), dasatinib (SPRYCEL ® , BMS-354825), erlotinib (TARCEVA ® ), gefitinib (IRESSA ® ), imatinib (Gleevec ® , CGP57148B, STI-571), lapatinib (TYKERB ® , TYVERB ® ), lestaurtinib (CEP-701), neratinib (HKI-272), nilotinib (TASIGNA ® ), semaxanib (semaxinib, SU5416), sunitinib (SUTENT ® , SU11248), toceranib (PALLADIA ® ), vandetanib (ZACTIMA ® , ZD6474), vatalanib (PTK787, PTK/ZK), trastuzumab (HERCEPTIN ® ), bevacizumab (AVASTIN ® ), rituximab (RITUXAN ® ), cetuximab (ERBITUX ® ), panitumumab (VECTIBIX ® ), ranibizumab (Lucentis ® ), nilotinib (TASIGNA ® ), sorafenib (NEXAVAR ® ), everolimus (AFINITOR ® ), alemtuzumab (CAMPATH ® ), gemtuzumab ozogamicin (MYLOTARG ® ), temsirolimus (TORISEL ® ), ENMD- 2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992 (TOVOK TM ), SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF 1120 (VARGATEF ® ), AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, and/or XL228), proteasome inhibitors (e.g., bortezomib (Velcade)), mTOR inhibitors (e.g., rapamycin, temsirolimus (CCI-779), everolimus (RAD-001), ridaforolimus, AP23573 (Ariad), AZD8055 (AstraZeneca), BEZ235 (Novartis), BGT226 (Norvartis), XL765 (Sanofi Aventis), PF-4691502 (Pfizer), GDC0980 (Genetech), SF1126 (Semafoe), and OSI-027 (OSI)), oblimersen, gemcitabine, carminomycin, leucovorin, pemetrexed, cyclophosphamide, dacarbazine, procarbizine, prednisolone, dexamethasone, campathecin, plicamycin, asparaginase, aminopterin, methopterin, porfiromycin, melphalan, leurosidine, leurosine, chlorambucil, trabectedin, procarbazine, discodermolide, carminomycin, aminopterin, and hexamethyl melamine. In certain embodiments, the anti-cancer agent is JQ1, AZD5153, vincristine, abiraterone acetate (e.g., ZYTIGA), ABVD, ABVE, ABVE- PC, AC, AC-T, ADE, ado-trastuzumab emtansine (e.g., KADCYLA), afatinib dimaleate (e.g., GILOTRIF), aldesleukin (e.g., PROLEUKIN), alemtuzumab (e.g., CAMPATH), anastrozole (e.g., ARIMIDEX), arsenic trioxide (e.g., TRISENOX), asparaginase erwinia chrysanthemi (e.g., ERWINAZE), axitinib (e.g., INLYTA), azacitidine (e.g., MYLOSAR, VIDAZA), BEACOPP, belinostat (e.g., BELEODAQ), bendamustine hydrochloride (e.g., TREANDA), BEP, bevacizumab (e.g., AVASTIN), bicalutamide (e.g., CASODEX), bleomycin (e.g., BLENOXANE), blinatumomab (e.g., BLINCYTO), bortezomib (e.g., VELCADE), bosutinib (e.g., BOSULIF), brentuximab vedotin (e.g., ADCETRIS), busulfan (e.g., BUSULFEX, MYLERAN), cabazitaxel (e.g., JEVTANA), cabozantinib-s-malate (e.g., COMETRIQ), CAF, capecitabine (e.g., XELODA), CAPOX, carboplatin (e.g., PARAPLAT, PARAPLATIN), carboplatin-taxol, carfilzomib (e.g., KYPROLIS), carmustine (e.g., BECENUM, BICNU, CARMUBRIS), carmustine implant (e.g., GLIADEL WAFER, GLIADEL), ceritinib (e.g., ZYKADIA), cetuximab (e.g., ERBITUX), chlorambucil (e.g., AMBOCHLORIN, AMBOCLORIN, LEUKERAN, LINFOLIZIN), chlorambucil-prednisone, CHOP, cisplatin (e.g., PLATINOL, PLATINOL-AQ), clofarabine (e.g., CLOFAREX, CLOLAR), CMF, COPP, COPP- ABV, crizotinib (e.g., XALKORI), CVP, cyclophosphamide (e.g., CLAFEN, CYTOXAN, NEOSAR), cytarabine (e.g., CYTOSAR-U, TARABINE PFS), dabrafenib (e.g., TAFINLAR), dacarbazine (e.g., DTIC-DOME), dactinomycin (e.g., COSMEGEN), dasatinib (e.g., SPRYCEL), daunorubicin hydrochloride (e.g., CERUBIDINE), decitabine (e.g., DACOGEN), degarelix, denileukin diftitox (e.g., ONTAK), denosumab (e.g., PROLIA, XGEVA), Dinutuximab (e.g., UNITUXIN), docetaxel (e.g., TAXOTERE), doxorubicin hydrochloride (e.g., ADRIAMYCIN PFS, ADRIAMYCIN RDF), doxorubicin hydrochloride liposome (e.g., DOXIL, DOX-SL, EVACET, LIPODOX), enzalutamide (e.g., XTANDI), epirubicin hydrochloride (e.g., ELLENCE), EPOCH, erlotinib hydrochloride (e.g., TARCEVA), etoposide (e.g., TOPOSAR, VEPESID), etoposide phosphate (e.g., ETOPOPHOS), everolimus (e.g., AFINITOR DISPERZ, AFINITOR), exemestane (e.g., AROMASIN), FEC, fludarabine phosphate (e.g., FLUDARA), fluorouracil (e.g., ADRUCIL, EFUDEX, FLUOROPLEX), FOLFIRI , FOLFIRI- BEVACIZUMAB, FOLFIRI-CETUXIMAB, FOLFIRINOX, FOLFOX, FU-LV, fulvestrant (e.g., FASLODEX), gefitinib (e.g., IRESSA), gemcitabine hydrochloride (e.g., GEMZAR), gemcitabine-cisplatin, gemcitabine-oxaliplatin, goserelin acetate (e.g., ZOLADEX), Hyper- CVAD, ibritumomab tiuxetan (e.g., ZEVALIN), ibrutinib (e.g., IMBRUVICA), ICE, idelalisib (e.g., ZYDELIG), ifosfamide (e.g., CYFOS, IFEX, IFOSFAMIDUM), imatinib mesylate (e.g., GLEEVEC), imiquimod (e.g., ALDARA), ipilimumab (e.g., YERVOY), irinotecan hydrochloride (e.g., CAMPTOSAR), ixabepilone (e.g., IXEMPRA), lanreotide acetate (e.g., SOMATULINE DEPOT), lapatinib ditosylate (e.g., TYKERB), lenalidomide (e.g., REVLIMID), lenvatinib (e.g., LENVIMA), letrozole (e.g., FEMARA), leucovorin calcium (e.g., WELLCOVORIN), leuprolide acetate (e.g., LUPRON DEPOT, LUPRON DEPOT-3 MONTH, LUPRON DEPOT-4 MONTH, LUPRON DEPOT-PED, LUPRON, VIADUR), liposomal cytarabine (e.g., DEPOCYT), lomustine (e.g., CEENU), mechlorethamine hydrochloride (e.g., MUSTARGEN), megestrol acetate (e.g., MEGACE), mercaptopurine (e.g., PURINETHOL, PURIXAN), methotrexate (e.g., ABITREXATE, FOLEX PFS, FOLEX, METHOTREXATE LPF, MEXATE, MEXATE-AQ), mitomycin c (e.g., MITOZYTREX, MUTAMYCIN), mitoxantrone hydrochloride, MOPP, nelarabine (e.g., ARRANON), nilotinib (e.g., TASIGNA), nivolumab (e.g., OPDIVO), obinutuzumab (e.g., GAZYVA), OEPA, ofatumumab (e.g., ARZERRA), OFF, olaparib (e.g., LYNPARZA), omacetaxine mepesuccinate (e.g., SYNRIBO), OPPA, OTX-015, oxaliplatin (e.g., ELOXATIN), paclitaxel (e.g., TAXOL), paclitaxel albumin- stabilized nanoparticle formulation (e.g., ABRAXANE), PAD, palbociclib (e.g., IBRANCE), pamidronate disodium (e.g., AREDIA), panitumumab (e.g., VECTIBIX), panobinostat (e.g., FARYDAK), pazopanib hydrochloride (e.g., VOTRIENT), pegaspargase (e.g., ONCASPAR), peginterferon alfa-2b (e.g., PEG-INTRON), peginterferon alfa-2b (e.g., SYLATRON), pembrolizumab (e.g., KEYTRUDA), pemetrexed disodium (e.g., ALIMTA), pertuzumab (e.g., PERJETA), plerixafor (e.g., MOZOBIL), pomalidomide (e.g., POMALYST), ponatinib hydrochloride (e.g., ICLUSIG), pralatrexate (e.g., FOLOTYN), prednisone, procarbazine hydrochloride (e.g., MATULANE), radium 223 dichloride (e.g., XOFIGO), raloxifene hydrochloride (e.g., EVISTA, KEOXIFENE), ramucirumab (e.g., CYRAMZA), R-CHOP, recombinant HPV bivalent vaccine (e.g., CERVARIX), recombinant human papillomavirus (e.g., HPV) nonavalent vaccine (e.g., GARDASIL 9), recombinant human papillomavirus (e.g., HPV) quadrivalent vaccine (e.g., GARDASIL), recombinant interferon alfa-2b (e.g., INTRON A), regorafenib (e.g., STIVARGA), rituximab (e.g., RITUXAN), romidepsin (e.g., ISTODAX), ruxolitinib phosphate (e.g., JAKAFI), siltuximab (e.g., SYLVANT), sipuleucel-t (e.g., PROVENGE), sorafenib tosylate (e.g., NEXAVAR), STANFORD V, sunitinib malate (e.g., SUTENT), TAC, tamoxifen citrate (e.g., NOLVADEX, NOVALDEX), temozolomide (e.g., METHAZOLASTONE, TEMODAR), temsirolimus (e.g., TORISEL), thalidomide (e.g., SYNOVIR, THALOMID), thiotepa, topotecan hydrochloride (e.g., HYCAMTIN), toremifene (e.g., FARESTON), tositumomab and iodine I 131 tositumomab (e.g., BEXXAR), TPF, trametinib (e.g., MEKINIST), trastuzumab (e.g., HERCEPTIN), VAMP, vandetanib (e.g., CAPRELSA), VEIP, vemurafenib (e.g., ZELBORAF), vinblastine sulfate (e.g., VELBAN, VELSAR), vincristine sulfate (e.g., VINCASAR PFS), vincristine sulfate liposome (e.g., MARQIBO), vinorelbine tartrate (e.g., NAVELBINE), vismodegib (e.g., ERIVEDGE), vorinostat (e.g., ZOLINZA), XELIRI, XELOX, ziv-aflibercept (e.g., ZALTRAP), or zoledronic acid (e.g., ZOMETA), or a pharmaceutically acceptable salt thereof. In certain embodiments, at least one instance of the therapeutic agent is a bromodomain inhibitor. In certain embodiments, at least one instance of the therapeutic agent is a bromo and extra terminal protein (BET) inhibitor. In certain embodiments, at least one instance of the therapeutic agent is a bromodomain- containing protein 2 (BRD2) inhibitor, bromodomain-containing protein 3 (BRD3) inhibitor, bromodomain-containing protein 4 (BRD4) inhibitor, TBP (TATA box binding protein)- associated factor protein (TAF) (e.g., TAF1 or TAF1L) inhibitor, CREB-binding protein (CBP) inhibitor, or E1A binding protein p300 (EP300) inhibitor. In certain embodiments, at least one instance of the pharmaceutical agent is a PARP inhibitor, ALK inhibitor, or STING ligand. In certain embodiments, at least one of the pharmaceutical agents is a prophylactic agent. In certain embodiments, each instance of the pharmaceutical agent is a prophylactic agent. Prophylactic agents that can be included in the conjugates of the invention include, but are not limited to, antibiotics, nutritional supplements, and vaccines. Vaccines may comprise isolated proteins or peptides, inactivated organisms and viruses, dead organisms and viruses, genetically altered organisms or viruses, and cell extracts. Prophylactic agents may be combined with interleukins, interferon, cytokines, and adjuvants such as cholera toxin, alum, Freund's adjuvant. In certain embodiments, at least one of the pharmaceutical agents is a diagnostic agent. In certain embodiments, each instance of the pharmaceutical agent is a diagnostic agent. Exemplary diagnostic agents include, but are not limited to, fluorescent molecules; gases; metals; imaging agents, such as commercially available imaging agents used in positron emissions tomography (PET), computer assisted tomography (CAT), single photon emission computerized tomography, x-ray, fluoroscopy, and magnetic resonance imaging (MRI); and contrast agents. Examples of suitable materials for use as contrast agents in MRI include gadolinium chelates, as well as iron, magnesium, manganese, copper, and chromium. Examples of materials useful for CAT and x-ray imaging include iodine-based materials. In certain embodiments, the diagnostic agent is used in magnetic resonance imaging (MRI), such as iron oxide particles or gadolinium complexes. Gadolinium complexes that have been approved for clinical use include gadolinium chelates with DTPA, DTPA-BMA, DOTA and HP-DO3A which are reviewed in Aime, et al. (Chemical Society Reviews (1998), 27:19-29), the entire teachings of which are incorporated herein by reference. In certain embodiments, the diagnostic agent is a metal, inorganic compound, organometallic compound, organic compound, or salt thereof. In certain embodiments, the imaging agent contains a metal selected from the group consisting of scandium, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, yttrium, zirconium, niobium, molybdenum, technetium, ruthenium, rhodium, palladium, silver, cadmium, hafnium, tantalum, tungsten, rhenium, osmium, iridium, platinum, gold, mercury, rutherfordium, dubnium, seaborgium, bohrium, hassium, meitnerium, gadolinium, gallium, thallium, and barium. In certain embodiments, the diagnostic agent is an organic compound. In certain embodiments, the diagnostic agent is metal-free. In certain embodiments, the diagnostic agent is a metal-free organic compound. In certain embodiments, the imaging agent is a magnetic resonance imaging (MRI) agent. In certain embodiments, the MRI agent is gadolinium. In certain embodiments, the MRI agent is a nitroxide radical-containing compound. In certain embodiments, the imaging agent is a nuclear medicine imaging agent. In certain embodiments, the nuclear medicine imaging agent is selected from the group consisting of 64 Cu diacetyl-bis(N 4 -methylthiosemicarbazone) ( 64 Cu-ASTM), 18 F-fluorodeoxyglucose (FDG), 18 F- fluoride, 3'-deoxy-3'-[ 18 F]fluorothymidine (FLT), 18 F-fluoromisonidazole (FMISO), gallium, technetium-99m, and thallium. In certain embodiments, the imaging agent is radiographic imaging agent. In certain embodiments, the radiographic imaging agent is selected from the group consisting of barium, gastrografin, and iodine contrast agent. In certain embodiments, the imaging agent the diagnostic agent is a radical-containing compound. In certain embodiments, the imaging agent is a nitroxide radical-containing compound. In certain embodiments, the imaging agent the diagnostic agent is an organic compound. In certain embodiments, the imaging agent is a salt of an organic compound. In certain embodiments, the diagnostic agent may comprise a fluorescent molecule, a metal chelate, a contrast agent, a radionuclide, or a positron emission tomography (PET) imaging agent, an infrared imaging agent, a near-IR imaging agent, a computer assisted tomography (CAT) imaging agent, a photon emission computerized tomography imaging agent, an X-ray imaging agent, or a magnetic resonance imaging (MRI) agent. In some embodiments, the diagnostic agent is a fluorescent molecule. In some embodiments, the fluorescent molecule comprises an acridine dye, a cyanine dye, a rhodamine dye, a BODIPY dye, a fluorescein dye, a dansyl dye, an Alexa dye, an atto dye, a quantum dot, or a fluorescent protein. In some embodiments, the fluorescent molecule is a cyanine dye (e.g., Cy3, Cy 3.5, Cy5, Cy5.5, Cy7, or Cy7.5). In some embodiments, the diagnostic agent is an MRI agent (e.g., a contrast agent). Examples of suitable materials for use as MRI agents (e.g., contrast agents) include gadolinium chelates, as well as iron, magnesium, manganese, copper, and chromium. In some embodiments, the diagnostic agent is a CAT imaging agent or an X-ray imaging agent. Examples of materials useful for CAT and X-ray imaging include iodine-based materials. In some embodiments, the diagnostic agent is a PET imaging agent. Examples of suitable PET imaging agents include compounds and compositions comprising the positron emitting radioisotopoes 18 F, 15 O, 13 N, 11 C, 82 Rb, 64 Cu, and 68 Ga, e.g., fludeoxyglucose ( 18 F-FDG), 68 Ga- DOTA-psuedopeptides (e.g., 68 Ga-DOTA-TOC), 11 C-metomidate, 11 C-acetate, 11 C-methionine, 11 C-choline, 18 F-fluciclovine, 18 F-fluorocholine, 18 F-fluorodeoxysorbitol, 18 F-3’-fluoro-3’- deoxythymidine, 11 C-raclopride, and 18 F-desmethoxyfallypride. In some embodiments, the diagnostic agent is a near-IR imaging agent. Examples of near- IR imaging agents include Pz 247, DyLight 750, DyLight 800, cyanine dyes (e.g., Cy5, Cy5.5, Cy7), AlexaFluor 680, AlexaFluor 750, IRDye 680, IRDye 800CW, and Kodak X-SIGHT dyes. In some embodiments, the agent can be a radionuclide, e.g., for use as a therapeutic, diagnostic, or prognostic agents. Among the radionuclides used, gamma-emitters, positron- emitters, and X-ray emitters are suitable for diagnostic and/or therapy, while beta emitters and alpha-emitters may also be used for therapy. Suitable radionuclides for forming use with various embodiments of the present invention include, but are not limited to, 123 I, 125 I, 130 I, 131 I, 133 I, 135 I, 47 Sc, 72 As, 72 Sc, 90 Y, 88 Y, 97 Ru, 100 Pd, 101m Rh, 119 Sb, 128 Ba, 197 Hg, 211 At, 212 Bi, 212 Pb, 109 Pd, 111 In, 67 Ga, 68 Ga, 67 Cu, 75 Br, 77 Br, 99m Tc, 14 C, 13 N, 15 O, 32 P, 33 P, or 18 F. In certain embodiments, at least one instance of the diagnostic agent is a contrast agent. In certain embodiments, at least one instance of the contrast agent is a magnetic-resonance signal enhancing agent, X-ray attenuating agent, ultrasound scattering agent, or ultrasound frequency shifting agent. In certain embodiments, the pharmaceutical agent is a monovalent radical. In certain embodiments, the monovalent radical of the pharmaceutical agent is formed by removing a hydrogen atom from the moiety HV of the pharmaceutical agent. In certain embodiments, V is a carbon atom. In certain embodiments, V is a heteroatom. In certain embodiments, V is an oxygen atom. In certain embodiments, V is a sulfur atom. In certain embodiments, V is a nitrogen atom. In certain embodiments, the monovalent radical of the pharmaceutical agent is formed further by changing the atom V of the pharmaceutical agent to substituted or unsubstituted U, wherein each of V and U is a heteroatom, and V and U are different from each other. In another aspect, the present disclosure provides a composition comprising: the copolymer; and optionally an excipient. In certain embodiments, the composition is an adhesive composition. In certain embodiments, the composition is a coating composition. In certain embodiments, the composition comprises: the copolymer; and optionally a pharmaceutically acceptable excipient. In certain embodiments, the composition is a pharmaceutical composition. In certain embodiments, the pharmaceutical composition described herein comprises a copolymer described herein and a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition described herein comprises a conjugate described herein and a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical compositions are useful for delivering an agent (e.g., to a subject or cell). In certain embodiments, the pharmaceutical compositions are useful for treating a disease in a subject in need thereof. In certain embodiments, the pharmaceutical compositions are useful for preventing a disease in a subject. In certain embodiments, the copolymer or conjugate described herein is provided in an effective amount in the pharmaceutical composition. In certain embodiments, the effective amount is a therapeutically effective amount. In certain embodiments, the effective amount is a prophylactically effective amount. In certain embodiments, the effective amount is an amount effective for treating a proliferative disease in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for preventing a proliferative disease in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for treating a hematological disease in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for preventing a hematological disease in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for treating a neurological disease in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for preventing a neurological disease in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for treating a in a painful condition subject in need thereof. In certain embodiments, the effective amount is an amount effective for preventing a painful condition in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for treating a psychiatric disorder in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for preventing a psychiatric disorder in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for treating a metabolic disorder in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for preventing a metabolic disorder in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for reducing the risk of developing a disease (e.g., proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. In certain embodiments, the effective amount is an amount effective for inhibiting the activity (e.g., aberrant activity, such as increased activity) of a protein kinase in a subject or cell. In certain embodiments, the cell is in vitro. In certain embodiments, the cell is in vivo. Pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology. In general, such preparatory methods include bringing the copolymer or conjugate described herein (which may includes a therapeutic agent (the “active ingredient”)) into association with a carrier or excipient, and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping, and/or packaging the product into a desired single- or multi-dose unit. Pharmaceutical compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. A “unit dose” is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage, such as one- half or one-third of such a dosage. Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition described herein will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. The composition may comprise between 0.1% and 100% (w/w) active ingredient. Pharmaceutically acceptable excipients used in the manufacture of provided pharmaceutical compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the composition. Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof. Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose, and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof. Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate)), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g., carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate (Tween ® 20), polyoxyethylene sorbitan monostearate (Tween ® 60), polyoxyethylene sorbitan monooleate (Tween ® 80), sorbitan monopalmitate (Span ® 40), sorbitan monostearate (Span ® 60), sorbitan tristearate (Span ® 65), glyceryl monooleate, sorbitan monooleate (Span ® 80), polyoxyethylene esters (e.g., polyoxyethylene monostearate (Myrj ® 45), polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol ® ), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., Cremophor ® ), polyoxyethylene ethers, (e.g., polyoxyethylene lauryl ether (Brij ® 30)), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic ® F-68, poloxamer P-188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, and/or mixtures thereof. Exemplary binding agents include starch (e.g., cornstarch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum ® ), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, and/or mixtures thereof. Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoan preservatives, alcohol preservatives, acidic preservatives, and other preservatives. In certain embodiments, the preservative is an antioxidant. In other embodiments, the preservative is a chelating agent. Exemplary antioxidants include alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite. Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal. Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid. Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol. Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid. Other preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant ® Plus, Phenonip ® , methylparaben, Germall ® 115, Germaben ® II, Neolone ® , Kathon ® , and Euxyl ® . Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer’s solution, ethyl alcohol, and mixtures thereof. Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof. Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary synthetic oils include butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixtures thereof. Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredients, the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. In certain embodiments for parenteral administration, the conjugates described herein are mixed with solubilizing agents such as Cremophor ® , alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer’s solution, U.S.P., and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form may be accomplished by dissolving or suspending the drug in an oil vehicle. Compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing the conjugates described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient. Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, (h) absorbents such as kaolin and bentonite clay, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may include a buffering agent. Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the art of pharmacology. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of encapsulating compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like. The active ingredient can be in a micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings, and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active ingredient can be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may comprise buffering agents. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of encapsulating agents which can be used include polymeric substances and waxes. Dosage forms for topical and/or transdermal administration of a copolymer or conjugate described herein may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and/or patches. Generally, the active ingredient is admixed under sterile conditions with a pharmaceutically acceptable carrier or excipient and/or any needed preservatives and/or buffers as can be required. Additionally, the present disclosure contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of an active ingredient to the body. Such dosage forms can be prepared, for example, by dissolving and/or dispensing the active ingredient in the proper medium. Alternatively or additionally, the rate can be controlled by either providing a rate controlling membrane and/or by dispersing the active ingredient in a polymer matrix and/or gel. Suitable devices for use in delivering intradermal pharmaceutical compositions described herein include short needle devices. Intradermal compositions can be administered by devices which limit the effective penetration length of a needle into the skin. Alternatively or additionally, conventional syringes can be used in the classical mantoux method of intradermal administration. Jet injection devices which deliver liquid formulations to the dermis via a liquid jet injector and/or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are suitable. Ballistic powder/particle delivery devices which use compressed gas to accelerate the copolymer or conjugate in powder form through the outer layers of the skin to the dermis are suitable. Formulations suitable for topical administration include liquid and/or semi-liquid preparations such as liniments, lotions, oil-in-water and/or water-in-oil emulsions such as creams, ointments, and/or pastes, and/or solutions and/or suspensions. Topically administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient can be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the additional ingredients described herein. A pharmaceutical composition described herein can be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers, or from about 1 to about 6 nanometers. Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant can be directed to disperse the powder and/or using a self-propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container. Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers. Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form. Low boiling propellants generally include liquid propellants having a boiling point of below 65 °F at atmospheric pressure. Generally the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition. The propellant may further comprise additional ingredients such as a liquid non- ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient). Pharmaceutical compositions described herein formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and/or suspension. Such formulations can be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization and/or atomization device. Such formulations may further comprise one or more additional ingredients including a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative such as methylhydroxybenzoate. The droplets provided by this route of administration may have an average diameter in the range from about 0.1 to about 200 nanometers. Formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition described herein. Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered by rapid inhalation through the nasal passage from a container of the powder held close to the nares. Formulations for nasal administration may, for example, comprise from about as little as 0.1% (w/w) to as much as 100% (w/w) of the active ingredient, and may comprise one or more of the additional ingredients described herein. A pharmaceutical composition described herein can be prepared, packaged, and/or sold in a formulation for buccal administration. Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may contain, for example, 0.1 to 20% (w/w) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising the active ingredient. Such powdered, aerosolized, and/or aerosolized formulations, when dispersed, may have an average particle and/or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein. A pharmaceutical composition described herein can be prepared, packaged, and/or sold in a formulation for ophthalmic administration. Such formulations may, for example, be in the form of eye drops including, for example, a 0.1-1.0% (w/w) solution and/or suspension of the active ingredient in an aqueous or oily liquid carrier or excipient. Such drops may further comprise buffering agents, salts, and/or one or more other of the additional ingredients described herein. Other opthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form and/or in a liposomal preparation. Ear drops and/or eye drops are also contemplated as being within the scope of this disclosure. Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with ordinary experimentation. Copolymers provided herein are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions described herein will be decided by a physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; the age, body weight, general health, sex, and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts. The copolymers, conjugates, and compositions provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol. Specifically contemplated routes are oral administration, intravenous administration (e.g., systemic intravenous injection), regional administration via blood and/or lymph supply, and/or direct administration to an affected site. In general, the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), and/or the condition of the subject (e.g., whether the subject is able to tolerate oral administration). In certain embodiments, the copolymer, conjugate, or pharmaceutical composition described herein is suitable for topical administration to the eye of a subject. The exact amount of a copolymer or conjugate required to achieve an effective amount will vary from subject to subject, depending, for example, on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular copolymer or conjugate, mode of administration, and the like. An effective amount may be included in a single dose (e.g., single oral dose) or multiple doses (e.g., multiple oral doses). In certain embodiments, when multiple doses are administered to a subject or applied to a tissue or cell, any two doses of the multiple doses include different or substantially the same amounts of a copolymer or conjugate described herein. In certain embodiments, when multiple doses are administered to a subject or applied to a tissue or cell, the frequency of administering the multiple doses to the subject or applying the multiple doses to the tissue or cell is three doses a day, two doses a day, one dose a day, one dose every other day, one dose every third day, one dose every week, one dose every two weeks, one dose every three weeks, or one dose every four weeks. In certain embodiments, the frequency of administering the multiple doses to the subject or applying the multiple doses to the tissue or cell is one dose per day. In certain embodiments, the frequency of administering the multiple doses to the subject or applying the multiple doses to the tissue or cell is two doses per day. In certain embodiments, the frequency of administering the multiple doses to the subject or applying the multiple doses to the tissue or cell is three doses per day. In certain embodiments, when multiple doses are administered to a subject or applied to a tissue or cell, the duration between the first dose and last dose of the multiple doses is one day, two days, four days, one week, two weeks, three weeks, one month, two months, three months, four months, six months, nine months, one year, two years, three years, four years, five years, seven years, ten years, fifteen years, twenty years, or the lifetime of the subject, tissue, or cell. In certain embodiments, the duration between the first dose and last dose of the multiple doses is three months, six months, or one year. In certain embodiments, the duration between the first dose and last dose of the multiple doses is the lifetime of the subject, tissue, or cell. In certain embodiments, a dose (e.g., a single dose, or any dose of multiple doses) described herein includes independently between 0.1 µg and 1 µg, between 0.001 mg and 0.01 mg, between 0.01 mg and 0.1 mg, between 0.1 mg and 1 mg, between 1 mg and 3 mg, between 3 mg and 10 mg, between 10 mg and 30 mg, between 30 mg and 100 mg, between 100 mg and 300 mg, between 300 mg and 1,000 mg, or between 1 g and 10 g, inclusive, of a copolymer or conjugate described herein. In certain embodiments, a dose described herein includes independently between 1 mg and 3 mg, inclusive, of a copolymer or conjugate described herein. In certain embodiments, a dose described herein includes independently between 3 mg and 10 mg, inclusive, of a copolymer or conjugate described herein. In certain embodiments, a dose described herein includes independently between 10 mg and 30 mg, inclusive, of a copolymer or conjugate described herein. In certain embodiments, a dose described herein includes independently between 30 mg and 100 mg, inclusive, of a copolymer or conjugate described herein. Dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult. In certain embodiments, a dose described herein is a dose to an adult human whose body weight is 70 kg. A copolymer, conjugate, or composition, as described herein, can be administered in combination with one or more additional pharmaceutical agents (e.g., therapeutically and/or prophylactically active agents). The copolymers, conjugates, or compositions can be administered in combination with additional pharmaceutical agents that improve their activity (e.g., activity (e.g., potency and/or efficacy) in treating a disease in a subject in need thereof, in preventing a disease in a subject in need thereof, in reducing the risk to develop a disease in a subject in need thereof, and/or in inhibiting the activity of a protein kinase in a subject or cell), improve bioavailability, improve safety, reduce drug resistance, reduce and/or modify metabolism, inhibit excretion, and/or modify distribution in a subject or cell. It will also be appreciated that the therapy employed may achieve a desired effect for the same disorder, and/or it may achieve different effects. In certain embodiments, a pharmaceutical composition described herein including a copolymer or conjugate described herein and an additional pharmaceutical agent shows a synergistic effect that is absent in a pharmaceutical composition including one of the copolymer/conjugate and the additional pharmaceutical agent, but not both. The copolymer, conjugate, or composition can be administered concurrently with, prior to, or subsequent to one or more additional pharmaceutical agents, which are different from the copolymer, conjugate, or composition and may be useful as, e.g., combination therapies. Pharmaceutical agents include therapeutically active agents. Pharmaceutical agents also include prophylactically active agents. Pharmaceutical agents include small organic molecules such as drug compounds (e.g., compounds approved for human or veterinary use by the U.S. Food and Drug Administration as provided in the Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells. In certain embodiments, the additional pharmaceutical agent is a pharmaceutical agent useful for treating and/or preventing a disease (e.g., proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder). Each additional pharmaceutical agent may be administered at a dose and/or on a time schedule determined for that pharmaceutical agent. The additional pharmaceutical agents may also be administered together with each other and/or with the copolymer, conjugate, or composition described herein in a single dose or administered separately in different doses. The particular combination to employ in a regimen will take into account compatibility of the copolymer or conjugate described herein with the additional pharmaceutical agent(s) and/or the desired therapeutic and/or prophylactic effect to be achieved. In general, it is expected that the additional pharmaceutical agent(s) in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually. The additional pharmaceutical agents include anti-proliferative agents, anti-cancer agents, cytotoxic agents, anti-angiogenesis agents, anti-inflammatory agents, immunosuppressants, anti- bacterial agents, anti-viral agents, cardiovascular agents, cholesterol-lowering agents, anti- diabetic agents, anti-allergic agents, contraceptive agents, and pain-relieving agents. In certain embodiments, the additional pharmaceutical agent is an anti-proliferative agent. In certain embodiments, the additional pharmaceutical agent is an anti-cancer agent. In certain embodiments, the additional pharmaceutical agent is an anti-viral agent. In certain embodiments, the additional pharmaceutical agent is a binder or inhibitor of a protein kinase. In certain embodiments, the additional pharmaceutical agent is selected from the group consisting of epigenetic or transcriptional modulators (e.g., DNA methyltransferase inhibitors, histone deacetylase inhibitors (HDAC inhibitors), lysine methyltransferase inhibitors), antimitotic drugs (e.g., taxanes and vinca alkaloids), hormone receptor modulators (e.g., estrogen receptor modulators and androgen receptor modulators), cell signaling pathway inhibitors (e.g., tyrosine protein kinase inhibitors), modulators of protein stability (e.g., proteasome inhibitors), Hsp90 inhibitors, glucocorticoids, all-trans retinoic acids, and other agents that promote differentiation. In certain embodiments, the copolymers or conjugates described herein or pharmaceutical compositions can be administered in combination with an anti-cancer therapy including surgery, radiation therapy, transplantation (e.g., stem cell transplantation, bone marrow transplantation), immunotherapy, and chemotherapy. In another aspect, the present disclosure provides a kit comprising: the copolymer; and instructions for using the copolymer. In certain embodiments, the kits are useful for delivering a pharmaceutical agent (e.g., to a subject or cell). In certain embodiments, the kits are useful for treating a disease (e.g., proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. In certain embodiments, the kits are useful for preventing a disease (e.g., proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. In certain embodiments, the kits are useful for reducing the risk of developing a disease (e.g., proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. In certain embodiments, the kits are useful for inhibiting the activity (e.g., aberrant activity, such as increased activity) of a protein kinase in a subject or cell. In certain embodiments, a kit described herein further includes instructions for using the kit. A kit described herein may also include information as required by a regulatory agency such as the U.S. Food and Drug Administration (FDA). In certain embodiments, the information included in the kits is prescribing information. In certain embodiments, the kits and instructions provide for delivering a pharmaceutical agent. In certain embodiments, the kits and instructions provide for treating a disease (e.g., proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. In certain embodiments, the kits and instructions provide for preventing a disease (e.g., proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. In certain embodiments, the kits and instructions provide for reducing the risk of developing a disease (e.g., proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. In certain embodiments, the kits and instructions provide for inhibiting the activity (e.g., aberrant activity, such as increased activity) of a protein kinase in a subject or cell. A kit described herein may include one or more additional pharmaceutical agents described herein as a separate composition. In another aspect, the present disclosure provides a method of delivering a pharmaceutical agent to a subject in need thereof comprising administering to the subject in need thereof an effective amount of the copolymer. In another aspect, the present disclosure provides a method of treating a disease in a subject in need thereof comprising administering to or implanting in the subject in need thereof an effective amount of the copolymer. In another aspect, the present disclosure provides a method of preventing a disease in a subject in need thereof comprising administering to or implanting in the subject in need thereof an effective amount of the copolymer. In another aspect, the present disclosure provides a method of diagnosing a disease in a subject in need thereof comprising administering to or implanting in the subject in need thereof an effective amount of the copolymer. In certain embodiments, the disease is a proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder. In certain embodiments, the disease is a cancer. In certain embodiments, the disease is a solid tumor. In certain embodiments, the disease is a hematologic malignancy. In certain embodiments, lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer. In certain embodiments, the disease is benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, or autoimmune disease. In certain embodiments, the copolymers are useful for the treatment or prevention of the disease in part because at least one instance of the pharmaceutical agents included in the copolymers are useful for the treatment or prevention of the disease. For example, when the disease is cancer, at least one of the pharmaceutical agents is an anti-cancer agent. In certain embodiments, the copolymers are advantageous over the at least one instance of the pharmaceutical agents for the treatment or prevention of the disease in part because the copolymers improve (e.g., increase) the delivery of the at least one instance of the pharmaceutical agents to the subject (e.g., to the target organ, tissue, or cell of the subject). In certain embodiments, the copolymers are useful for diagnosing the disease in part because at least one instance of the pharmaceutical agents included in the copolymers are useful for diagnosing the disease. In certain embodiments, the copolymers are advantageous over the at least one instance of the pharmaceutical agents for diagnosing the disease in part because the copolymers improve (e.g., increase) the delivery of the at least one instance of the pharmaceutical agents to the subject (e.g., to the target organ, tissue, or cell of the subject). In certain embodiments, the subject is a human. In certain embodiments, the subject is a human aged 18 years or above. In some embodiments, the subject is a human aged <2 years. In some embodiments, the subject is a human aged 2-6 years, inclusive. In some embodiments, the subject is a human aged 6-18 years, inclusive. EXAMPLES In order that the present disclosure may be more fully understood, the following examples are set forth. The synthetic and biological examples described in this application are offered to illustrate the compounds, pharmaceutical compositions, and methods provided herein and are not to be construed in any way as limiting their scope. Example 1. In the small molecule form, a silyl ether containing an internal pentafluorophenyl (Si- PFP) was cleaved when exposed to a nucleophile (such as a thiol) in the presence of base (such as Cs 2 CO 3 ). Following reaction, gas chromatography-mass spectrometry (GC-MS) showed a disappearance of the Si-PFP and appearance of decomposition/cleavage product cis-butenediol. See Figure 3. Example 2. Degradation in pDCPD thermoset materials A control gel and a Nb-PFP-doped gel were prepared as described in Figures 4A and 4B. For degradation studies, THF was used as the solvent over N,N-dimethylformamide (DMF), as THF was better at swelling the gels, thus allowing the reagents access to the PFP sites. DBU was used as the base. Para-fluoro-thiol reaction (PFTR) has been shown to occur in THF with DBU (Cavalli et al., Chemistry – A European Journal, 2019, 25, 10049-10053). The samples were subjected to the degradation conditions shown in Figures 4A and 4B. After 3 h, the control gel showed degradation in only TBAF, leaving behind a thin skin layer of low mass, consistent with iPrSi-doped thermoset materials (Figure 4A). The Nb-PFP- doped gel, however, showed degradation in TBAF, and also in the presence of 1-dodecanethiol and DBU, but not in the presence of 1-dodecanethiol alone or DBU alone (Figure 4B). EQUIVALENTS AND SCOPE In the claims articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process. Furthermore, the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. It is also noted that the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. The entire contents of U.S. Patent Application Publication Number US-2020-0055879; U.S. Provisional Patent Application Numbers 63/144437 and 63/111608; and international PCT Application Number PCT/US2020/050927 are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the invention can be excluded from any claim, for any reason, whether or not related to the existence of prior art. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following claims.




 
Previous Patent: CANINE INSPECTION RECORDING

Next Patent: THERMAL MANAGEMENT CONTROL SYSTEM AND METHODS FOR HEATING A BED OF A HYBRID HAUL TRUCK